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Abstract
Helicobacter pylori is a globally important and genetically diverse gastric
pathogen that infects most people in developing countries. Earlier reports
indicated high prevalence of H. pylori colonization, but a low frequency of
H. pylori-associated diseases in Africa but recent reviews have shown that
gastroduodenal disease is actually common in Africa. Most detailed
analyses of H. pylori have used strains from non-African countries,
despite the high importance of Africa in the emergence and evolution of
humans and their pathogens. There have been far fewer critical studies
such as genotypes in association with gastric disease, population genetics
and antimicrobial resistance and susceptibility of H. pylori strains from
Africa.
It is with this background that the genotypes of H. pylori in association
with gastroduodenal diseases, antibiotic susceptibility to commonly used
drugs and population genetics from ethnic African adults and children in
The Gambia were investigated.
In this study, it was found that the prevalence of H. pylori is high in
dyspeptic patients in The Gambia and that many strains were of the
putatively more virulent cagA+, vacAsl and vacAml genotypes. There
was a high prevalence of cagA positive strains in patients with overt
gastric diseases than those with non-ulcerative dyspepsia; conversely, the
co-existence of both cagA+ and cagA- was found to be protective against
the development of gastroduodenal disease.
Analyses of the sequenced data with the STRUCTUREsoftware indicated
that Gambian H. pylori strains were closely related to hspWAfrica than to
strains from more distant African regions (hspSAfrica and hpNEAfrica)
indicating common ancestral origin. Essentially no traces of European or
North African ancestry were found despite Gambia's history of invasion
and colonisation by peoples from these regions during the last
millennium.
Antibiotic susceptibility tests have shown that Gambian strains were found
to be highly sensitive to clarithromycin, erythromycin, tetracycline and
amoxicillin but found that more than two-thirds of Gambian H. pylori
strains were metronidazole resistant. These data indicate caution in use of
metronidazole-based therapies in The Gambia.
This thesis provides a detailed initial description of a set of H. pylori
isolates directly related to a geographically defined West African
population. The data presented has answered some relevant questions on
H. pylori virulent genes in association with gastro-duodenal diseases and
antibiotic susceptibility providing a comprehensive basis for future
studies.
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Chapter 1.0 Literature Review
1.1 Introduction
This study was part of a Helicobacter pylori (H. pylori) project jointly
sponsored by the National Institute of Health (NIH) of USA and the
Medical Research Council (MRC) Unit, The Gambia, West Africa and was
conducted in The Gambia in a population with a high early childhood
incidence of H. pylori colonization. All subjects enrolled in this study were
Gambians of West African ethnicity.
This was a descriptive study aimed at providing the first data to evaluate
genotypes of H. pylori isolates obtained from study subjects living in The
Gambia, genotypes and clinical outcome and to compare the differences
with H. pylori genotypes from other countries and assess the population
structure of the strains from this study population and their relatedness
with strains from other geographically defined populations.
Taking part in this study was beneficial to the study subjects as it
influenced treatment if associated diseases, such as peptic ulceration,
gastric cancer or pre-cancerous lesions were detected. In these cases, H.
pylori eradication therapy was offered.
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1.2 The Gambia
The Gambia is a country in West Africa that has become a centre for
tropical medical research, largely due to the MRC unit providing scientific
and clinical facilities unique in West Africa. The country has some urban
and semi-urban communities, but no major cities. It is the smallest
country on mainland Africa, bordered to the north, east and south by
Senegal, with a short coastline on the Atlantic Ocean and shares historical
roots with many other West African nations.
Figure 1.1 Map of The Gambia showing the administrative regions
The country has an area of about 11 000 km>, less than 48Km wide at its
widest point and 338Km long. The country is divided into two halves by
the Gambia River which flows through the country's centre and empties
into the Atlantic Ocean. The Gambia is divided into five administrative
regions (West Coast, North Bank, Lower River, Central River and Upper
River regions) with 2 municipal areas -Banjul and Kanifing.
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An agriculturally fertile country, its economy is dominated by farming,
fishing, and tourism. About a third of the population lives below the
internationally poverty line of US$1.25 a day [1].
The climate of The Gambia is tropical. There is a hot and rainy season,
normally from June until October, but from then until May there are cooler
temperatures with less precipitation [2]. The Gambia is one of the most
densely populated countries in the world with an estimated population of
2 million most of whom are Muslims (90%) and live in the rural villages
(630/0).A wide variety of ethnic groups live in the Gambia, each
preserving its own language and traditions. The Mandinka tribe is the
largest, followed by the Fula, Wolof, Jola and Sarahule [2]. About 99% of
the population is African and 1% non-African. The non-African residents
include Europeans and families of Lebaneseorigin [2].
The Gambia's first contact with Arabians was about the 9thcentury AD
during the trans-Saharan trade, when Arab merchants and scholars
established trade routes in West Africa to trade in slaves, gold and ivory.
Contacts with Europeans, which was mainly in trade, began in the 15th
century with the Portuguese and French, which turned into predominantly
slave trade. In the 17thCentury, The Gambia was colonised by the British
and gained full independence from Britain in 1965.
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1.3 Human gut Microbiota
The human body is inhabited by a large number of micro-organisms
including bacteria which evolve throughout the life of the individual and
play crucial roles in the maintenance of health but also contribute to the
development of disease. The human gut of an average healthy adult
individual contains about 100 trillion bacterial cells and outnumbers the
human cells by 10 to 1 [3] and it is estimated that 500 to 1000 species of
bacteria live in the human gut as normal gut microbiota [4].
Colonisation and composition of the human gut begins during birth upon
passage through the birth canal [4] and thereafter influenced by other
factors such as environment, infant diet, hospitalization, antibiotics and
kinship [4-7]. In addition, host genetic factors also play an important role
in the composition of the gut microbiota [4,5]. The normal gut microbiota
in healthy individuals helps maintain the health of the host. However, the
overgrowth of these micro-organisms which can lead to disease state is
continuously checked and a balance maintained by the host immune
system. The gut macrophages, T cells, B cells and secretory IgA maintain
a proper immune response to the gut resident microbiota and invading
pathogens [4,6] to prevent or control disease. In addition, the integrity of
the gut mucosal barrier, gastric acidity and peristalsis normally control
bacterial colonization of the human stomach thereby prevent disease.
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1.4 Imbalances of the Gut and disease
Studies have revealed that deviations from the "normal gut microbiota"
due to intrusion by antibiotics or invading pathogens leads to disruption of
the fine balance between host and resident microbiota which may lead to
disease states [8]. The consequent immune response of the host towards
the invading pathogen may decrease the viability of resident microbiota
allowing the invading pathogen to occupy the vacated niche and establish
itself [9-11]. The proteobacteria which includes H. pylori have utilized
these hosts' responses effectively to successfully colonize the human gut
and initiate disease processes [4].
1.S Historical background
Contemporary scientific research has shown that the bacterium now
known as H. pylori was recently rediscovered in 1982 [12]. This
bacterium was originally referred to as Campylobacter pvtoridts because
of its similarity to Campylobacter. However, in 1989, flagellum
morphology, fatty acid content and phylogenetiC analysis using the 165
rRNA gene led to new evidence that this bacterium does not belong to
Campylobacter [13] but rather in a different group within the Gram
negative bacteria. Thus, the bacterium was placed in its own genus
Helicobacter [13].
The first description of H. pylori dates back to the 19th century, when two
German scientists called Bottcher and Letulle found spiral bacteria in the
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lining of the human stomach [14]. In 1889, Jaworski found spiral-shaped
bacteria, which he called Vibrio rugula, in gastric washings [14] and in
1892, the Italian researcher Giulio Bizzozero identified spiral-shaped
bacteria in the gastric mucosa of dogs [14]. The identified spiral-shaped
bacteria could not be grown in conventional culture media and so these
early studies did not have much impact and were eventually forgotten. In
the 20th century, however, interest in this bacterium was reactivated
when in 1982; Warren inoculated gastric biopsies on a non-selective
chocolate agar. After two days incubation in micro-aerobic atmosphere,
there was no visible colonial growth on the media plates. The plates were
however unintentionally left for six days, and fortuitously there was
visible bacterial growth of what is now known as H. pylori on the plates
[13]. Robin Warren and Barry Marshall established the relationship of H.
pylori with gastritis after they performed self inoculation with H. pylori
and consequently developed symptomatic gastritis shortly after ingestion
of the bacteria.
To date about twenty species have been identified infecting a varying
number of hosts ranging from human to poultry [15]. The ecological niche
of the species H. pylori in man is the gastroduodenal mucosa. However,
H. pylori has been isolated from dental plaque, faeces and blood [16-19].
There is also evidence that H. pylori is found in water and the
environment, although this has only been confirmed by molecular
methods such as peR and not by culture [20].
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1.6 Detection of Helicobacter pylori
There are several methods that are available for the detection of
infections caused by H. pylori. These methods can be grouped into
invasive, semi-invasive and non-invasive and the choice of test largely
depends on clinical status, availability and affordability. The objective for
all the methods employed for diagnosis is to demonstrate that the H.
pylori bacterium is present in the upper gastro-intestinal tract. In recent
times, because H. pylori is a fastidious organism and difficult to culture,
the approach has focused on detection of specific DNA sequences instead
of culturing the bacterium and this has increased sensitivity.
1.6.1 Invasive methods
1.6.1.1 Upper gastric endoscopy
Upper gastric endoscopy is regarded as the gold standard and reference
method used for the detection of H. pylori and diagnosing problems and
diseases in the upper gastric tract associated with H. pylori infection such
as gastric and duodenal ulcers, stomach cancers and gastritis. The
procedure involves the examination of the oesophagus (gullet), stomach
and duodenum (the first section of the small intestine) with a long flexible
tube with a light source and a video camera attached. The images
captured are viewed on a television (TV) monitor.
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1.6.1.2 Biopsies for culture and Rapid Urease Test (RUT)
Gastric tissue is removed from the gastric mucosa by employing forceps
passed through the operating tube of the endoscope to the gastric wall.
Biopsies are taken either from the body and/or antral part of the
stomach.
1.6.1.3 Culture
The biopsies collected during endoscopy are directly inoculated on
appropriate media which is incubated at 37°C in micro-aerobic
atmosphere and examined for growth between 4-7 days [21]. The
method is specific but sensitivity is low due to the fastidious nature of the
organism [22].
1.6.1.4 Rapid Urease Test (RUT)
This test, also known as Campylobacter-Like Organism (CLO) test, utilizes
the ability of H. pylori to produce large quantities of urease [23]. The
biopsy obtained during endoscopy is inoculated into a medium that
contains urea and phenol red indicator. If H. pylori is present in the
tissue, the urease produced by the organism hydrolyzes urea to form
carbon dioxide and ammonia thereby creating an alkali environment
turning the medium from yellow to pink within one minute [24,25]. The
sensitivity and specificity of the test is high [25,26]. The test is now
commercially available; it is accurate and relatively cheap [26].
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1.6.1.5 Histology
This method requires endoscopy and the collection of gastric biopsies. The
formalin fixed or frozen biopsy samples are stained using Haematoxylin-
Eosin, Giemsa, Silver stain or antibody-immuno stain and examined for
the presence of H. pylori [27-30]. Although some staining techniques may
be unreliable [31], sensitivities of up to 98% have been reported [30].
This technique requires expertise, and may take up to five days or more
after sampling to obtain a result. However, a marked advantage of this
method is that gastritis, intestinal metaplasia and atrophy can be
accurately [32] assessed and confirmed.
Upper gastric endoscopy is an invasive and costly technique that causes
discomfort to patients. In addition, although sterilization techniques of
scopes have improved greatly, the risk of contamination by HIV and
Hepatitis C viruses still remain [29]. Other disadvantages of this
technique are that it only explores a small part of the stomach which can
lead to sampling errors and only available in specialist endoscopy units
which limits its use in developing countries and field studies. Thus,
numerous non-invasive methods have been developed and evaluated over
the years.
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1.6.2 Semi-Invasive methods
1.6.2.1 Serological test
The method involves the use of venous or peripheral blood to measure
IgG antibodies in response to H. pylori infection. Several methods have
been described including the Enzyme-Linked Immunosorbent Assay
(ELISA) [33,34] and commercially available Latex test kits. The tests are
generally simple to perform, reproducible and cheap [35] but the
sensitivity is low. The serological methods are very useful for
epidemiological [36] and retrospective studies but cannot be used for the
confirmation of successful treatment [37].
1.6.3 Non-Invasive methods
1.6.3.1 Urea Breath Test (UBT)
The UBT is based on the ability of H. pylori to breakdown urea into
ammonia and carbon dioxide. A radioactive labelled carbon capsule
containing urea (14C) or a non-radioactive isotope (l3C) is swallowed by
the patient. If H. pylori is present in the stomach, the urea is hydrolyzed
into radioactive labelled carbon dioxide (C02) and ammonia. The CO2 is
absorbed in the blood and released in the lungs where it is exhaled in the
breath. The extracted air is collected and measured. 14C is a beta-emitting
radioisotope and can be detected using liquid scintillation counting whilst
13C is a stable, non-radioactive isotope that is measured using a mass
spectrometer. The test is highly accurate, specific, sensitive and painless
[23,38-40] and suitable for use in epidemiological studies including
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children. However false negative results have been reported in cases
where the patient is receiving acid suppression medications and/or is
suffering from active bleeding [41-43] and also requires equipment which
is routinely unavailable in most laboratories especially in resource poor
countries. However, the test can be used to demonstrate that H. pylori
has been eradicated after successful treatment with antibiotics [44].
1.6.3.2 Stool culture
There is continued evidence that H. pylori are transmitted through the
oral-faecal route [45]. Although, this remains largely speculative due to
the difficulty of successfully culturing the organism from stool. Several
studies [17,46,47] have successfully isolated H. pylori from faeces albeit
with great difficulty largely due to the presence of gut microbiota,
susceptibility of the bacterium to bile salts and the fastidious nature of the
organism [29]. These difficulties have resulted in the development of
molecular and antigen based methods for the detection of H. pylori in
stool.
1.6.3.3 Stool Antigen test
Several commercial methods are now available for the detection of H.
pylori antigen in stool [48-50]. These antigen-based tests are highly
sensitive and specific [51,52], simple to perform, cheap and do not
require specialized equipment and/or personnel. They are also very useful
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in large scale epidemiological studies especially in children and can also
be used to evaluate success in H. pylori eradication therapy [53].
1.6.3.4 Urine antibody test
A rapid urine test (RAPIRUNR) is a commercial method used to detect
anti-H. pylori IgG. The test was found to be highly specific and sensitive
and is useful for H. pylori screening [54]. However most of these studies
have been done on Asian strains and therefore the test kits should be
evaluated with local strains.
1.6.3.5 peR of stool
In recent times, because H. pylori is a fastidious organism and difficult to
culture, the approach has focused on detection of specific DNA sequences
instead of culturing the bacterium and this has increased sensitivity.
These DNA based methods (peR) have been successfully used to detect
H. pylori from stool and has shown acceptable sensitivity and specificity
[55] despite the presence of inhibitors [56,57] and also H. pylori
degradation in the intestine [58].
1.7 Epidemiology
H. pylori is endemic in human populations colonizing the human gastric
mucosa leading to the development of gastro-duodenal diseases in adult
life, usually after years of chronic infection [59,60]. Prevalence of about
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20% has been reported in developed countries and over 80% in
developing countries including Africa [19,61-67].
Once established, colonization usually persists for a very long time unless
treated by antibiotics [68]. Chronic H. pylori infection is one of the
strongest key factors in the etiology of various gastrointestinal diseases,
ranging from chronic active gastritis without clinical symptoms to gastric
and duodenal ulceration and gastric adenocarcinoma [69-74].
The high prevalence in developing countries do not parallel the
development of H. pylori-associated diseases as peptic ulcers and gastric
carcinomas were reportedly rare in individuals from these countries
particularly in Africa [19,62,67,75] compared to those from Europe and
USA [76-78]. This observation, which has been termed "The African
Enigma", remains largely unexplained. It is however, believed that
geographical variations in pathogenic determinants between isolates of H.
pylori and variations in stomach ecology, host immune mechanisms and
physiology between human populations may be very important factors
[47].
However, recent reviews and studies have shown that, the prevalence of
gastric diseases such as gastric cancers, gastric and duodenal diseases in
Africa are indeed comparable with those in Europe [79,80]. The "Africa
Enigma" may have been due to poor maintenance of cancer registries,
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shorter life expectancy compared to developed countries, inaccessibility to
competent health facilities to accurately diagnose these diseases and poor
study designs.
1.7.1 H. pylori genotypes in children
H. pylori are acquired very early in life particularly in Africa where up to
960/0of children are infected by the age of five years [19,65]. The studies
that have so far characterized child isolates have also shown marked
geographical differences of genotypes. For example, studies in Brazil,
Slovenia, Colombia, North America, Korea and Japan [81-86] have shown
that between 64-75% of all child isolates carried the virulent 51 allele of
vacA gene. 82% and 94 % of Korean isolates [84] carried the m1 allele of
vacA gene and cagA gene respectively which is similar to figures reported
in Japan [81]. Similarly in Brazil [82], the majority of child isolates were
m1 allele positive. This may be a contributing factor to the high risk of
gastric carcinoma in adult life in these populations [39,86]. In contrast, a
significant number of children carried the less virulent genes of cagA and
vacA in Portugal [87] than isolates from adults. This is similar to figures
reported in Israel [88] where only about 25% of children carried the
virulent cagA gene and 65% of the avirulent vacA alleles of 52m2.
1.7.2 Transmission
The transmission of H. pylori is poorly understood because of the
difficulties of obtaining samples for large epidemiological transmission
14
studies. It is believed that transmission of H. pylori occurs mainly at an
early stage in life and mainly between siblings [89]. Several studies have
considered close contact between individuals through vomitus, saliva
[90,91] and also direct contact [92] as important routes for transmission.
Individuals can also be infected through the faecal-oral route by ingesting
contaminated water and food [90,92]. In recent studies in China and Iran,
similar H. pylori genotypes were found in both the saliva and stomach of
patients indicating that saliva can be both a transmitting and re-infecting
vector [93,94]. However, a study in Europe found that oropharygeal
infection seem to be independent to gastric infection [95]. It has been
observed in some studies [96] that the house fly is a vector for the
transmission of H. pylori. However, in Gambian villages where there is a
high prevalence of H. pylori, the house fly is neither an important
reservoir of infection nor a major route of transmission [97].
The only proven route of transmission is the hospital acquired infection
during endoscopy. This iatrogenic transmission can occur when the
endoscopy is not adequately disinfected [98,99]. Generally low sanitation,
low social class and overcrowding are important risk factors for the
transmission of this organism particularly in developing countries.
The prevalence of H. pylori infection in industrialized countries has
declined dramatically during the last century [100], probably due to
improvements in hygiene and sanitation. In these societies, the pattern of
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transmission is predominantly intrafamilial [89,101] (although community
transmission is frequent in developing countries), and there is also
generally low risk of infection in adulthood.
1.8 H. pylori pathogenesis
H. pylori is one of the most successful human pathogens and over half of
the world's population is colonized with this Gram-negative bacterium with
prevalence of over 80% in many developing countries including The
Gambia [19,62,63,102], typically starting in infancy [19,102,103] and
lasting for life [104]. H. pylori isolates possess substantial genotypic
diversity, which engenders differential host inflammatory responses that
influence pathologic outcome. The majority of people infected with H.
pylori remain asymptomatic; only about 20% eventually proceed to
develop severe H. pylori associated diseases. Distinct H. pylori genotypes
have been linked to the risk of gastroduodenal diseases. These include
the vacA, cagA and iceA genes. The vacA mid region shows a marked
geographic variation. For example, the majority of European H. pylori
strains carry the mla allele, whereas, Asian and Indian H. pylori strains
carry the mlb and mlc alleles respectively [21].
Most H. pylori strains from patients with gastro-duodenal disease from
industrialized countries carry the cagPAI, whilst the majority of strains
from subjects with H. pylori colonization lack cagPAI [lOS]. For example,
600/0 of H. pylori strains isolated from patients with gastric disease in
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industrialized countries carry the cagPAI [106]. However, almost all Asian
H. pylori strains carry the cagPAI and the toxigenic "sl"-type alleles of
vacA independent of disease [21]. The majority of cag-positive strains
also carry the sl allele of vacA [107-109], whereas majority of cag-
negative strains contain the non-toxigenic s2 allele.
The iceA gene which consists of two alleles; iceA1 and iceA2 [105] have
been associated with disease outcome. For example, iceA1 isolates have
been seen significantly more often in patients with peptic ulcer diseases in
Turkey [110,111] and gastric carcinoma in South African patients [112]
whereas the iceA2 genotype was mostly reported in patients with gastritis
[110,112] in a study in South Africa.
Most studies [21,105,113] that investigate this diversity focused on
bacterial factors such as cagA and vacA genes. There have been
conflicting and inconsistent reports as some countries with high
prevalence of H. pylori carrying the cagA and vacA genes do not parallel
disease outcome [21,114-116]. Further, a study in Colombia [117] has
found that there is a 25-fold increase in gastric cancer rate in the
mountain regions as compared to coastal areas despite similarities
(",900/0) in H. pylori prevalences. This therefore suggests that apart from
bacterial factors, there are other important determinants of the risk of
overt disease such as human genetic and physiology, nutrition and
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environmental factors which significantly contribute to H. pylori associated
disease outcome [118,119].
It has not been clearly established as to how the presence of H. pylori
leads to gastric and duodenal ulcers, but disruption of gastric and
duodenal mucosal integrity seems to involve a complex interaction
between the host and pathogen. The complex interaction between
bacterial, host genetic and environmental factors lead to different clinical
outcomes of H. pylori infection in different geographic regions of the
world. H. pylori have developed effective ways of evading the host
immune response during colonisation and establish persistent infection
[120,121] .
1.8.1 Urease gene
A thick layer of mucus that covers the stomach lining protects the
stomach from its own gastric juice. H. pylori take advantage of this by
living in the mucus lining. Once H. pylori is in the mucus layer, it is able
to fight the harsh condition of the stomach with copious production of the
enzyme urease. The urease which has two subunits (ureaseA -3KDA- and
ureaseB -62KDA) [122] is found in both the cytoplasm and cell membrane
of the organism and is produced in large quantities both in vivo and in
vitro [99]. The urease gene plays a key role in the colonization,
pathogenicity, motility and survival of this organism. The urease genes
are conserved in most strains of H. pylori and are used for the detection
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of H. pylori in biological specimens [123]. After being ingested, H. pylori
produce copious amounts of urease which neutralises the acidic contents
of the stomach to an optimal pH for survival [120,124]. The urease
hydrolyzes urea to form carbon dioxide and ammonia as a by-product
thereby neutralizing the excess acid found in the stomach, creating a
more basic pH between 5.5 to 8.5 (figure 1.2) and conducive environment
for survival [125]. The strong bases protect H. pylori from the acid in the
stomach [126J. The large quantities of ammonia and ammonia by-
products produced such as protease and phopholipases (enzymes that
break down proteins and hydrolyze phospholipids into fatty acids and
other lipophilic substances respectively) chloramine [127] have also been
shown to have cytotoxic effects [127J.
Figure 1.2 Schematic representation of urease production and
hydrolysis in the stomach.
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S= in the presence of H. pylori, the urease produced by the organism hydrolyzes
urea to form carbon dioxide, ammonia and proteolytic enzymes that damage
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Further, the urease activity that reduces gastric acidity, the shape,
mobility, the action of the bacterium's polar flagella that counteracts
peristalsis [128], and mucus degrading ability [129] of H. pylori assist the
bacteria to invade the mucus layer of the stomach and bind to the inner
surface of the gastric epithelial cells with the help of many adhesions
including BabA, OipA, SabA etc [120].
1.8.2 Host Factors
Several studies have shown that apart from bacterial factors, host genetic
polymorphisms are also very important in determining H. pylori
associated diseases. In general the over expression of the pro-
inflammatory cytokines such as IL-1f3, IL-8, increased TNF-a and gastrin
were shown to be associated with the development gastritis and gastric
cancer [118].
The presence of H. pylori in the gastric mucosa induces both active and
chronic inflammation via the release of cytokines such as interleukin-8,
tumour-necrosis factors-a (TNF- a) and interleukin-1f3 [130]. Studies
have shown that the resultant gastric inflammation can lead to H. pylori
eradication by affecting the ability of the bacteria to survive [131].
H. pylori colonization of the mucus layer induces an inflammatory
response. Host immune gene polymorphisms and gastric acid secretion
largely determine the bacterium's ability to colonize a specific gastric
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niche. The severity of this inflammation underlies the type of gastritis
(type B or type AB) [130,132] and H. pylori clinical diseases such as
duodenal and gastric ulcers [133]. It has been shown that the amount of
acid produced in the stomach correlates with the type of ulcer [132]. The
large amount of acid produced by some people may confine H. pylori in
the antrum and the subsequent inflammatory response may induce the
production of gastric juice which stimulates the corpus to secrete more
acid [134,135]. The increased acid load damages the duodenum leading
to duodenal ulcers. In contrast, normal or low acid production in some
people allows H. pylori to survive in the body of the stomach. The chronic
infection leads to further reduction of acid production which leads to
atrophy of the stomach lining, gastric ulcer and gastric cancer as
illustrated in figure 1.3 which shows that disease development takes
decades after colonisation [124].
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Figure 1.3 Development of disease following H. pylori infection
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This observation is consistent with findings in humans [132] and also in
mouse models [136,137] which suggest that susceptibility to H. pylori
infection and disease development may partly be dependent on host
genetiC factors.
1.8.3 Cellular responses
H. pylori infection provokes an acquired immune response with the
production of antibodies and either a Th 1 or Th2 response [138]. During
active disease, H. pylori induces a Th1-mediated pro-inflammatory
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response that recruits CD4+ T cells resulting in the increased local
production of cytokines such as IFN-y and interleukin-12 [139].
In experiments using animals [138], mice with a predominant Th1
response developed more gastric inflammation during H. pylori
colonization than those with a Th2 response. These data suggest that a
Th2 response may protect against symptomatic H. pylori infection.
Endemic helminth infection can also modulate the immune response in
favour of a Th2 response. This observation in mice [140] may also explain
the relative low prevalence of H. pylori-associated disease in Africa
despite high H. pylori prevalence.
1.8.4 H. pylori and non-gastroduodenal disease
H. pylori colonisation also increases the risk of infection by diarrheal
pathogens [141], iron deficiency [142] infant malnutrition and growth
faltering in low income societies [143,144].
1.8.4.1 Iron-deficient anaemia
Iron deficiency anaemia (IDA), which is one of the most common
nutritional deficiencies in the world, has been associated with H. pylori
infection. Almost all pathogenic bacteria including H. pylori require iron
(Fe) for metabolism and growth. H. pylori could cause iron deficiency
indirectly by suppressing gastric acid secretion, thereby reducing solubility
and uptake of dietary iron. There is also evidence obtained with a mouse
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infection model suggesting that H. pylori successfully competes for dietary
iron when the diet is iron poor [145]. Other potential explanations for an
association between iron deficiency and H. pylori include occult blood loss
from gastric erosion. Thus, in addition to host and environmental factors,
colonisation of the stomach by H. pylori may be involved in the
development of IDA [146]. Several studies have shown a strong
association between H. pylori infection and IDA [142,147,148] regardless
of the presence or absence of peptic ulcer disease [149].
1.8.4.2 Diarrheal diseases
It is believed that low acid secretion (hypochlorhydria) as has been seen
in Gambian children [150] and the loss of gastric acid barrier could
increase susceptibility to gastric pathogens thereby increasing the risk of
diarrhoea in H. pylori infected individuals. In a study in Peru [141],
children infected with H. pylori had twice the risk of diarrhoeal disease in
a year than uninfected children.
1.8.4.3 Malnutrition and growth faltering
Lossof gastric acid barrier and injury of the lining of the small intestine
due to H. pylori infections may lead to damage to the intestinal mucosal
barrier and poor absorption of nutrients which leads to malnutrition and
growth faltering. In The Gambia where H. pylori colonisation in infancy is
high [19,62], significant growth faltering and malnutrition was found in
children with early H. pylori colonisation.
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1.8.4.4 Diet and gastroduodenal disease
H. pylori infection is an established risk factor for the development of
gastro-duodenal disease but the development of gastroduodenal disease
is influenced by other factors. The incidence of gastric disease varies in
different ethnic groups and geographic locations [75,151,152]. Among the
factors implicated in this difference is diet, which is an important factor in
the development of gastroduodenal disease. Animal and case-controlled
studies in humans [153] have shown that the risk of gastric cancer may
be increased with a high intake of salt, preserved foods and foods high in
fat and low intake of fruits and vegetables. Diet high in fruit and
vegetables was shown to be protective against gastriC cancer in an urban
Portuguese population and also in USA [154,155]. Further, a 25-fold
increase in gastriC cancer was observed in a population in South America
[117] whose diet was predominantly starch-based when compared to
those with sea food based diet. Studies have shown that Nickel is
important in H. pylori survival. Nickel free diet has been shown to reduce
urease activity and expose the bacterium to the gastriC acid with a
decrease of survival [156]. Similarly in Korea [157,158], a Korean pickled
dish was shown to contain a strain of bacteria called Lactobacilli plantarun
NOl. This bacterial strain was found to reduce the activity of urease found
in H. pylori by 40-60% and consequently antagonised the ability of H.
pylori to bind to human gastric cell lines [158]. Red ginseng from Korea, a
natural herb and an extract of lichochalcone A were shown to have
properties that stops inflammatory carcinogenesis associated with H.
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pylori infection thereby blocking the progression of H. pylori associated
precancerous lesion respectively [157].
1.8.4.5 Benefits of H. pylori colonisation
Studies have shown that H. pylori have co-evolved with human kind
[159,160] for more than 60 0000 years. There have been suggestions
that since H. pylori has been with man for thousands of years, it must
have possible benefits to mankind [161]. It has been reported in some
studies that H. pylori colonisation may be beneficial [162,163] as
disorders such as esophageal diseases, childhood-onset asthma and
tuberculosis are less likely to occur in patients infected with H. pylori
[162-164]
Several studies have reported an inverse relationship between H. pylori
and Gastro esophageal reflux disease (GERD) [165]. GERD is a condition
in which the stomach contents leak backwards from the stomach into the
oesophagus. This action can irritate the oesophagus, causing heart burn
and other symptoms. Despite the benefits shown in above studies,
systemic studies at least in Western societies showed that there is no
relationship between H. pylori colonisation and GERD [166].
1.9 Characteristics of H. pylori
H. pylori belonged to the family Helicobacteriaceae and it is spirally
shaped as shown in figure 1.4. The genus Helicobacter is derived from
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two Greek words "helix" which means "spiral" or "coil" and "bakterion"
which means "small staff" [167]. The species name "pylori" also came
from two Greek words such as "pyle" which means "gate" and "ourus"
which means "keeper" [167], referring to the pylorus region of the
stomach where H. pylori mainly resides.
Figure 1.4 3-~ image of H. pylori
www.righthealth.com
1.9.1 Laboratory diagnoses
1.9.1.1 Cultural characteristics and growth requirements
H. pylori is a motile, non-spore forming bacteria. It is a fastidious
organism and technically very difficult to grow and maintain as repeated
culture leads to loss of viability [168]. Its successful growth on culture
media is dependent on several factors such as temperature, oxygen
stress, availability of nutrients [168], and pH between 5.5-8.5. There are
several basal media such as Columbia agar [21], Brain Heart infusion
agar [169,170], Brucella [22] and Mueller-Hinton agar [26] enriched with
blood or blood products which have been described and used for the
isolation of H. pylori. H. pylori grows well on Columbia agar supplemented
with 10% laked or lysed horse blood and 1% vitox (Oxoid, Basingstoke,
UK) which contains micro-nutrients such as vitamin B12, adenine, L-
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cystine, cysteine, Nicotinamide adenine dinucleotide (NAD). It is a micro-
aerophile and requires an atmosphere composed of 86% Nitrogen, 4%
oxygen, 5% carbon dioxide and 5% hydrogen [171] to grow. After 3-7
days incubation at 3s-37°C, on 10% Columbia-Blood agar, H. pylori
colonies are grey, convex and translucent colonies of 1-2mm diameter.
The morphology of this organism changes from a typical spiral or rod-
shaped to coccoidal forms after 10 days of storage [168]. These changes
are attributed to reduction in DNA, RNA and ATP quantities [168] as a
result of unfavourable conditions such as nutrient starvation during
prolonged incubation, exposure to antibiotics and extreme temperature
and pH. These coccoidal forms are generally unculturable [15] but may be
involved in transmission [172].
1.9.1.2 The use of gas generating kit
The atmosphere in which H. pylori is incubated is a critically important
factor in the successful growth and isolation of the bacteria from clinical
specimens. Micro-aerobic incubators are used primarily in the study and
isolation of micro-aerophilic organisms such as Campylobaeter species
and H. pylori and other similar organisms. Here up to four gases -
nitrogen, carbon dioxide, air and a 10% hydrogen/nitrogen mix - can be
combined within safe and varying ratios to provide a specific atmosphere.
These incubators however are expensive and not within reach of most
laboratories in the developing world. Therefore, gas generating kits
(GasPaks) have been used as a cheaper and more convenient alternative.
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However, these GasPakshave been shown to provide a variable micro-
aerobic atmosphere [29,173]. The generation of a suitable micro-aerobic
atmosphere using GasPakscan take up to thirty minutes, during which
time the stressed H. pylori becomes non-culturable as a result of the
toxicity of high levels of oxygen.
1.9.1.3 Gram Stain appearance
The Gram reaction of H. pylori exhibits a marked degree of
pleomorphism. It is helical, coma-shaped and sometimes straight Gram-
Negative bacilli measuring between O.5-1.0~m in diameter and 1.5-101-lm
in length [171].
1.9.1.4 Extracellular enzyme activities
H. pylori is mostly inactive in conventional biochemical reactions as it
neither oxidize nor ferments carbohydrates. However, it is catalase and
oxidase positive. H. pylori is also urease positive and this ureolytic activity
is usually very rapid and strong.
1.10 Genomic features and genetic diversity of H. pylori
In recent years, the complete genome sequences of several H. pylori
isolates have been published [174-177]. The genome (a circular DNA) is
about 1.6 to 1.7 mega bases [177] with a low G+C content of about 32-
44% and is relatively small when compared with other bacteria such as
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Staphylococcus aureus [178] and Neisseria gonorrhoeae [179]. The
genome contains some predicted genes that encode surface exposed and
secreted proteins that are likely to be important in host-pathogen
interactions [180].
A most striking feature of H. pylori as a species is its high genetic
diversity: any 2 independent clinical isolates even from the same
community differ on average by some 3% or more in base substitutions in
essential housekeeping genes and 5% or more in gene content [181].
Individual isolates are almost always distinguishable from one another by
random amplification of polymorphic DNA (RAPD)-PCR typing or focused
DNA sequencing of 1 or 2 housekeeping genes [182]. This diversity has
been ascribed to multiple factors: (i) frequent mutation throughout the
genome [183]; (ii) ON-OFF switching of certain contingency genes due to
frame shift mutations in repetitive sequence tracts [184]; (iii) extensive
recombination between H. pylori lineages [185]; (iv) selection stemming
from differences among humans in traits important to individual strains,
which may be strongest immediately after colonization of a new host and
again later, as host immune and inflammatory responses develop; (v) H.
pylori's preferential transmission within a family or local community
[89,186], and (vi) the extraordinary chronicity of infection (frequently for
decades), which creates a highly fragmented population structure,
equivalent to island populations of classical higher organism population
genetiCS [187]. Collectively, these features diminish the chance that few
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genotypes might emerge ideally adapted for all human hosts. Rather
many evolutionary trajectories may develop, a situation likened to "a
rugged evolutionary landscape" [188].
1.10.1 H. pylori virulence genes
Amongst the genes known to playa role in disease causation are cagA,
encoded within the cag pathogenicity island (cagPAI), the vacuolating
cytotoxin, vacA and iceA gene (induced by contact with epithelium).
1.10.1.1 cagA
The cagA protein is produced by a majority of H. pylori strains [189].
OnceH. pylori comes in contact with the stomach gastric epithelial cells,
this toxin is injected into the cells of the stomach lining thereby altering
the structure of the stomach cells and allowing the bacteria to attach
themselves more readily leading to chronic inflammation. The cells
undergo tyrosine phosphorylation [190,191] which eventually leads to
morphological transformation [191]. Long-term exposure to the toxin
causes chronic inflammation. However, not all strains of H. pylori carry
the cagA gene; those that do are classified as cagA-positive.
The strains that do not produce this toxin (cagA negative) are believed to
be less virulent. Most isolates from patients with gastro-duodenal
diseases from industrialized countries carry cagPAI, whilst many strains
from subjects with more benign colonization do not.
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1.10.1.2 3' repeat sequence of cagA
Sequence analysis of the cagA gene reveals that this protein is
heterogeneous and varies in size due to the variable repeat sequences of
the 3' region of the gene [191,192]. At least four subtypes (A-D) have
been described based on their sizes [115,193].
The function of this heterogeneity is not well understood. However it is
believed that this variability influences pathogenicity and is also used by
the organism to evade the immune system by presenting antigenic
diversity or immune dominant non-protective epitopes [59].
1.10.1.3 vacA
The vacA gene is present in all H. pylori strains but only about 50% of the
strains have detectable cytotoxin activity [113]. This cytotoxin, which is
an important virulence determinant, induces vacuolation of mammalian
epithelial cells [194] and also suppresses Band T cell-immunity
[195,196].
1.10.1.4 Signal and mid region of vacA
The vacA gene comprises of two variable parts, namely the signal peptide
coding signal region (s) and the mid (m) region [197]. The "s" region also
comprises of two alleles sl and s2, and the sl allele has several subtypes
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such as sla, slb, slc. The "mil region also has two main alleles namely
ml and m2 with the ml comprising of the three subtypes mla, mlb, mlc
[21,198]. The presence of various subtypes of signal and mid region leads
to a mosaic organization of the vacA gene [198]. Certain combinations
correlate with the different levels of cytotoxic activity demonstrated by
this organization, and correlate with pathogenicity of the organism [198].
The amount of cytotoxin produced is highest with H. pylori strains
exhibiting the st/m: allele, followed by the 511m2 allele. H. pylori strains
exhibiting the s21ml or 521m2 allele show little or no evidence of
cytotoxin activity [105].
1.10.1.5 iceA gene (induced by contact with epithelium)
The iceA gene, which has been identified recently, encodes a homolog of
a type II restriction endonuclease [111,199] and has two alleles
designated iceAl and iceA2. The two allelic variants yield either 297bp
(iceAl) or 229 and 334bp (iceA2) products by PCR [197] according to the
presence of repeated sequences of 105 nucleotides. These genes have
been associated with gastric disease [110,112,199]. In a meta-analysis
from articles published through 2011 [200], iceAl was significantly
associated with peptic ulcer (PU) disease where as iceA2 was inversely
associated with PU.
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Besides cagA, vacA and iceA, the duodenal ulcer-promoting gene A
(dupA) which encodes a VirB4 ATPase homolog, is also associated with an
increased risk of developing duodenal ulcer but a reduced risk of gastric
atrophy and gastric cancer [120]. Recent studies have indicated that this
could be due to secretion of pro-inflammatory cytokine by mononuclear
cells induced by an active dupA [201].
1.10.1.6 Extra-chromosomal DNA-plasmid
About 50% of all H. pylori carry plasmids [202]; the sizes of these
plasm ids vary from 1.8-100 kilo bases [203] and are generally cryptic
with unknown roles and functions. However, there are some indications
that these plasm ids might contribute to the genetic diversity of H. pylori
through multiple recombination events [204].
1.11 Phylogeny
Phylogenetic analyses of both virulent and housekeeping gene sequences
from different parts of the world have revealed distinct H. pylori gene
pools in geographically defined human populations in regions of Asia,
Europe, and Africa [81,159,170,205]. Studies have revealed that genetic
recombination of H. pylori between isolates from different continents is
rare [206,207]. This relative segregation of H. pylori serves as a useful
genetic marker tracking human descent in which an individual spent
his/her childhood and also helps track human migration. These analyses
have also shown that H. pylori followed human migration out of Africa
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[159,160] and identified seven H. pylori populations which are designated
hpAfrica1, hpAfrica2, hpNEastAfrica, hpEurope, hpSahul, hpAsia2,
hpEastAsia [89,159,208]. Detailed analyses have further subdivided the
hpEAsia population into three subpopulations - hspEAsia (common in East
Asia, hspmaori (common in Polynesians) and hspAmerind (common in
Americas). HpAfrica1 also has two sub-populations - hspWAfrica
(common in West Africa) and similar sub-population called hspSAfrica
which is common in South Africa.
The African strains (hspWAfrica (West), hspSAfrica (South) and
hpNEAfrica (North East), form distinct phylogenetic populations but
closely related to one another than to those from elsewhere and the very
divergent hpAfrica2 found in South Africa. These phylogenetic analyses
have led to a proposal that historical patterns of human migration and of
racial admixture can be predicted from DNA sequences of H. pylori
housekeeping genes [159,160,186,209]. For example, in a study in a
shanty town, Peru, the population admixture of Amerindj Asian strains
found in this area is a reflection of human migration from Asia to the
America about 15000 years ago [210]. However, the H. pylori strains
found in South America were predominantly hpEurope which suggest that
the ancestral H. pylori strains (hspAmerind) may have been lost or
displaced by the much fitter European strain with more competitive
advantage [117,210]. Further, in ethnic groups in Malaysia, four different
H. pylori sub-populations (hpAsia2, hpEasia, hpEurope and hpAfrica1),
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were found probably reflecting the migration of Chinese and Indians into
Malaysia about 3000 years ago. The presence of hpEurope may have
been due to importation by the Indians who have been colonized by
portugal and Britain [207,211].
The clustering of the discrete hspWAfrica, hspSAfrica and hpNEAfrica
popultations may reflect the expansion of the Bantu people throughout
the African continent from an ancestral homeland in or near present day
Benin, Cameroon and Nigeria over the last 4000 years. The frequent
isolations of hpAfrica1 and hpEurope in the Americas may reflect the
transfer of slaves from Africa about three centuries ago and also
European colonization. Phylogenetic analysis have shown that in a study
in Colombia [117], subjects living in coastal regions who are
predominantly "Mulatoes" of African and European descent carried strains
that were mainly hpAfrica1 (66%) and hpEurope (340/0).
An ability to discern H. pylori lineages from distinct human populations
should also have medical relevance, because disease outcomes associated
with H. pylori infection vary geographically [80,212], and some of this
variation might stem from genetic differences between H. pylori
populations [213,214]. A study in Colombia with a high prevalence of H.
pylori infection, showed a 25-fold increase in gastric cancer risk in one
area (high mountain) when compared to coastal regions. Phylogenetic
analysis, revealed that all isolates from the gastric cancer high risk area
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where all hpEurope whereas those from the coastal region were
predominantly hpAfrica1 (66%). Further analyses showed that hpAfrica
strains were associated with reduced severity of gastric lesions [117] as
compared to those that carried hpEurope strains with more severe pre-
malignant histological lesions. Phylogenetic analysis can therefore be a
useful tool for clinical management and for enhanced disease surveillance
in high risk areas. Further, phylogenetic analysis of several strains from
Africa, Europe, Asia and China showed that the phylogenetic origin of H.
pylori can be a determinant of gastric cancer risk [212].
1.12 Treatment of H. pylori infection
When H. pylori is detected in patients showing clinical signs of H. pylori
associated diseases, the normal procedure is to eradicate the bacteria
with antibiotics allowing the disease to heal. Over the past two decades,
different treatment regimes using a proton pump inhibitor and various
antibiotic combinations such as clarithromycin, tetracycline,
metronidazole, amoxicillin and fluoroquinolones
[215,216] have been recommended and used for the successful
treatment of H. pylori infection to heal ulcers and prevent relapses. In The
Gambia, where H. pylori infection is high and H. pylori associated disease
occur [19], several antibiotics and a proton pump (clarithromycin,
amoxicillin, tetracycline, ampicillin, metronidazole and omeprazole) in
various combinations depending on availability and affordability are used
for the eradication of H. pylori (clinical communication). However, all the
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recommended regimes can only cure up to about 90% of people [217].
This is of course a great concern particularly to the developing world
where the current cost of treatment is often beyond the reach of the
ordinary citizen.
In most cases, the diagnosis of H. pylori is based on non-culture
investigations such as Urea-Breath test, stool antigen or Rapid urease and
so routine antibiotic susceptibility is rarely undertaken before antibiotic
prescription [218]. This empirical treatment together with other factors
including non-compliance of treatment [219], has contributed to
treatment and/or eradication failures.
1.12.1 Antibiotic susceptibility
Infection of this bacterium causes a very high rate of morbidity in both
developed and developing countries which directly impacts on the burden
of health care systems worldwide particularly in resource-poor countries.
Therefore local knowledge of antibiotic susceptibility and resistance is
important to plan locally appropriate effective treatment.
1.12.2 Metronidazole resistance
In Europe and USA between 12-40% of H. pylori strains were reported
resistant to metronidazole (Mtz) [216]. The figures are much higher in
developing countries especially in Africa where resistance of up to 100%
has been reported [169,220,221]. In the strains studied to date, mostly
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from industrialized societies, modest level Mtz resistance (e.g. to 8 or
161-1gMtz/ml) was often associated with inactivation of the gene rdxA,
which encodes a non-essential oxygen-insensitive NAPDHnitroreductase
that chemically reduces metronidazole in vitro [222]. Higher level
resistance in rdxA mutant strains, e.g., to 32 I-IgMtz/rnl, results from
inactivation of frxA, a related but generally less strongly transcribed
nitroreductase gene. However, according to Jeong et ai, the inactivation
of frxa enhances resistance to metronidazole [222] and that genes
conferring resistance to metronidazole without rdxA inactivation are rare
or non-existent in H. pylori populations; yet higher resistance can result
from mutations in any of several additional genes that likely also affect
intracellular redox potential [222-224]. It is also important that Mtz's
hydroxylamine-type derivatives are mutagenic, that exposure to sub-
lethal Mtz concentrations [225] both induces and selects for mutations to
Mtz resistance.
1.12.3 Clarithromycin resistance
Clarithromycin is a macrolide that is used in combination with other
antibiotics to treat gastric diseases associated with H. pylori [226].
However, we have seen an increase in the prevalence of H. pylori
resistance to this macrolide both in developed and developing countries
which has been attributed mainly to its increasing use to treat respiratory
infections especially in children at least in Europe and USA [216,227].
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Between 2-22% H. pylori resistance to clarithromycin have been reported
in Europe and USA [216]. Studies in Africa have also shown increase in
prevalence of clarithromycin and between 4-55% have been reported in
various countries [169,228,229].
Most of the resistance to clarithromycin results from two point mutation-
A2142G and A2143G- in 235 rRNA gene of H. pylori, the latter being more
predominant [230]. However, there are reports that other mutations in
the 235 rRNA genes such as T2182C and T2190C were implicated in H.
pylori resistance to clarithromycin [231].
1.12.4 Amoxicillin and tetracycline resistance
Resistance to amoxicillin and tetracycline is uncommon among H. pylori
clinical isolates especially in USA and Europe [232,233] accounting for
less than 1% and so treatment failures due to resistance to amoxicillin
and/or tetracycline is not of great concern. Resistance to amoxicillin is
usually mediated by mutations of the genes encoding penicillin-binding
proteins [234,235]. For tetracycline, the resistance mechanism is caused
by a triple mutation in the 165 rRNA gene exhibiting AGA926-928TTC
[236,237]. The rarity of tetracycline resistance in clinical isolates may be
due to the need for this triple mutation. Thus, the near or universal
resistance to amoxicillin and/or tetracycline reported in some studies in
Africa [169,221] must therefore be interpreted with caution.
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1.12.5 Antibiotic resistance in Africa
In Africa, the pattern of resistance is variable. These differences might be
due to the variations in local antibiotic prescription and community
availability. For example, in Cameroon [169], resistant rates of 43.9%,
44.70/0, 86.4% and 84.4% have been reported for tetracycline,
clarithromycin, amoxicillin and metronidazole respectively. In a similar
study in Western Nigeria, 100% resistance was reported to amoxicillin,
tetracycline and metronidazole [221] whereas in Kenya [220], all strains
were resistant to metronidazole but sensitive to clarithromycin, amoxicillin
and tetracycline. In Egypt, although there was universal resistance to
metronidazole in child isolates [228], resistant against clarithromycin,
erythromycin, azithromycin, ciprofloxacin and ampicillin varied between
2-4%.
The steady increase in the rate of resistance to antibiotics used for the
treatment of H. pylori is a great public health concern especially to the
developing countries where the cost of the first line drugs is often beyond
the reach of the average citizen. It is therefore important that antibiotic
resistant levels are continuously monitored to help clinicians effectively
manage patients and effectively deal with the ever increasing high rate of
treatment failures. It is also important that cheaper drugs such as
erythromycin are tested as a suitable alternative to the already high cost
of H. pylori eradication antibiotics.
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1.13 Prevention of H. pylori infection
The ability of H. pylori to survive, evolve and re-emerge for almost a
decade after treatment [238] has also contributed to treatment failures.
The increase in treatment failures has heightened the need for effective
prevention strategies [239]. It has been shown that transmission occurs
mainly in childhood [186], seems to run in families [89] and is more
common in crowded and unclean conditions [240] which suggests that H.
pylori infection may be contagious. As there are currently very little or no
defined guidelines to prevent transmission, it's always important to
observe simple and effected hygiene such as washing of hands, drinking
clean and safe water and eating food that is properly cooked.
1.13.1 Vaccines
Prevention of H. pylori by improving personal hygiene and sanitation in
resource poor countries will continue to be a challenge as clean drinking
water and proper drainage systems are almost non-existent in some
communities. Therefore, to achieve a global eradication of H. pylori, a
safe, effective and cost-effective vaccine seems to be the ultimate
approach. There have been extensive researches in the past two decades
to find a suitable candidate vaccine with varying degree of success [241-
243]. However, some studies have shown promising results [244],
suggesting that the stimulation of a Th2 response may be a key to
immunity against H. pylori infection [139]. Vaccination with a wide range
of antigens, adjuvants, and delivery routes produced statistically
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significant reductions in H. pylori colonization levels in mice [245]. These
have not been tested in humans and it is unclear whether similar
reductions in bacterial load can be achieved. In addition, a multiepitope
DNA vaccine containing eight proteins namely FlaA, UreaA, CagA, VacA,
HpaA, KatA, NapA and TsaA [246] and another containing the chaperonin
GroEL; the external membrane protein HomS; and the highly virulent
marker VacA protein are being evaluated [247]. DNA vaccines are live
attenuated vaccines and provide important advantages as they mimic the
effects of natural infection in their ability to endogenously express foreign
protein and also induce humoral as well as cellular immune responses
[247].
However, the development of a suitable vaccine has been affected by the
lack of understanding of the molecular basis of protection that can lead to
complete eradication of the bacterium [248], relative lack of good
understanding of the complex gastric immune response and the
heterogeneity of H. pylori. In addition to this, finding the best efficacious
method of vaccine delivery has also been a challenge. Although several
methods such as oral, nasal, rectal and systemic immunization have been
shown to confer protection in mice [249], the availability of a suitable
adjuvant and generation of adequate immunologic response in the
stomach continue to pose problems. Recent advances in H. pylori
genomics and an increase understanding of the gastric immune response
provide opportunity to accelerate progress in H. pylori vaccine
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development [250]. There is evidence of passive immunity against H.
pylori. A study in The Gambia has shown that specific antibodies in milk
directed against known bacterial colonization factors, such as urease,
appear to protect against H. pylori colonization in infants [251].
The increase in antibiotic resistance, poor compliance, inaccessibility and
unavailability of effective antibiotics especially in resource poor countries
makes the need for the development of a suitable vaccine more urgent.
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Chapter 2 Hypotheses, aims and objectives
This study of Gambian H. pylori strains was motivated by considering that
H. pylori is a genetically diverse bacterial species, with different
genotypes predominating in different well separated geographic regions.
However, most of the detailed studies and analyses of H. pylori have been
conducted in strains from industrialized countries. There have been far
fewer robust studies of H. pylori strains from Africa, especially those from
West Africa. It is therefore important that a detailed genetic study of the
H. pylori isolates in The Gambia is carried out in order to explore H. pylori
strains from a relatively unstudied population, to understand the
development of H. pylori associated diseases in The Gambia, West Africa
and to compare them with strains from other geographically defined
populations to help address important questions in this area.
2.1 Hypotheses
1. Putative virulence factors such as cagA and vacA influence
disease outcome in The Gambia.
2. Mixed colonization with different genotypes influences the
development of gastroduodenal disease
3. Children and adults in the Gambia are colonized by different
strains of H. pylori, which therefore circulate amongst different
age groups
4. Gambian isolates of H. pylori form a distinct phylogenetic family
within the grouping of African derived strains.
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2.2 Aims and objectives
The primary aim of this study is to characterise and evaluate the
putative virulent H. pylori genotypes in The Gambia in relation to
clinical outcome.
2.3 Objectives
1. Determine the prevalence of H. pylori genotypes in The Gambia
in relation to disease expression.
2. Determine the genotypes of child strains and compare with adult
strains.
3. Investigate the phylogenetic relationship between strains in The
Gambia, and those from other geographically defined
populations.
4. Determine the genetic relatedness and phylogenetic of isolates in
a single stomach.
5. Determine the prevalence of antibiotic susceptibility and
resistance to amoxicillin, clarithromycin, erythromycin,
metronidazole and tetracycline.
6. Investigate the usefulness of peR in the diagnosis of H. pylori in
The Gambia.
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Chapter 3.0 Materials and methods
3.1 Clinical settings at the MRC endoscopy unit
The MRChas an endoscopy unit which is the only facility that offers upper
gastric endoscopy in The Gambia and serves as the national endoscopy
referral centre. Patients were referred to the unit from throughout The
Gambia, principally directly from the MRCOut-patient Clinic or the Royal
Victoria Teaching Hospital (RVTH) in Banjul and other privately owned
clinics. The principle presentation was dyspepsia, but dysphagia and
gastrointestinal haemorrhage were also investigated by upper gastric
endoscopy.
3.2 Study population
The study population comprised subjects who attended the MRCOut-
patient department (OPD) and were sent to the endoscopy unit as part of
the routine clinical investigations or referred from the main hospital in
Banjul (RVTH) or from other private clinics. Adult subjects who consented
to join the study were recruited from among these out patients
undergoing diagnostic upper gastric endoscopy primarily for symptoms of
dyspepsia. The small group of young children comprised patients with
significant growth faltering associated with enteropathy undergoing
endoscopy in order to obtain small bowel biopsies as part of an
investigation into the underlying nature of their condition.
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3.3 Subject inclusion and exclusion criteria
3.3.1 Inclusion criteria
All patients referred for diagnostic endoscopy to the MRCUnit were
eligible for inclusion.
3.3.2 Exclusion criteria
Any contraindication to endoscopy and biopsy, such as liver dysfunction,
history of bleeding, history of other serious organ disease (for example,
kidney, heart, lung), bleeding time prolonged to over 10 minutes, or
unexpected findings such as oesophageal or gastric stricture that limits
endoscopic examination excluded subjects from the study, as did the use
of antibiotics during the previous two weeks. Patients with severe
oesophago-gastroduodenal disease, including those with gastro-
oesophageal varices and a small number with advanced gastric cancer
were also excluded from the study. In addition, if the endoscopist felt that
prolonging the procedure by 2 or 3 minutes in order to take the research
biopsies would not be advisable for any reason, the subject was also
excluded from the study.
3.4 Good Clinical Practice (GCP)
This study was conducted according to GCPand conformed to the
International Conference on Harmonisation Good Clinical Practice E6 (Rl)
(ICH-GCP) and the following specific regulatory requirements:
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• United States (US) Code of Federal Regulations (CFR) applicable to
clinical studies (45 CFR46 and 21 CFRincluding Parts 50 and 56
concerning informed consent and Institutional Review Board [IRB]
regulations) which regulates the protection of human subjects in
research supported or conducted by the Department of Health and
Human Services.
• Completion of Human Subjects Protection Training
The endoscopy team of MRCcomprised of three Medical doctors assisted
by two SRN nurses and four SEN nurses. As part of GCPrequirements,
the principal investigators of this study completed a "Human Participant
Protection Education for Research Team" on-line course sponsored by the
NIH. The whole endoscopy team also completed a Family Health
International Certificate course on Research Ethics Training curriculum
and also on the Protection of Human subjects in Clinical Research. In
addition, the lead endoscopist and I, as study coordinator, completed a
computer based Clinical Research Training course. Furthermore, all nurses
and laboratory technicians involved in this study completed a locally
organized introductory training on Good Clinical Practice (GCP). Standard
endoscopy procedures (SOP-CLS-001) were followed; using clean
endoscopes sterilized with Cidex (Johnson and Johnson Co) and rinsed
with clean water between cases, according to standard care at MRCUnit,
The Gambia.
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3.5 Study monitoring
Following ethical review, NIH monitors under took annual audits to
ascertain record keeping, data management, clinical and laboratory
processes to GCPand GCLPstandards. The local Clinical Trial Support
Team also undertook annual audits to review progress and study conduct.
In addition, an onsite Independent Safety Monitor [ISM (who was not
involved in the trial)] was selected by the Principal Investigator (PI) and
approved by DMID based on relevant study related experience and lack of
conflict of interest to independently and thoroughly review all serious
adverse events and to communicate in writing his/her findings, concerns
and recommendations to DMID and the study principal investigator.
3.6 Study approvals
This study was carried out under the supervision and approval of The
Gambia Government/MRC joint ethics committee (appendix A-ethics
letter) and Division of Microbiology Infectious Diseases (DMID)
International Review Board of USAwith a protocol number of DMID 06-
0053 and an MRCUnit, The Gambia IRB registration number:
IRB00003943 and a Federal Wide Assurance number: FWA 00006873.
FWA is the number indicating that all documents relevant to human
subject protection has been submitted to the office of Human Research
Protection.
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3.7 Subject enrollment and consent procedure
3.7.1 Adult subjects
Adult subjects who were referred to the endoscopy unit for upper
gastrointestinal endoscopy had the study described to them in English or
a local language that they can understand. The study information sheet
(appendix A- adult information sheet) was also given to them to read or
interpreted to them in a local language that they can understand and they
were asked if they would consent to additional biopsies (approximately 10
to 14mg) being collected from the gastric antrum, corpus, and cardia for
research purposes during the procedure (appendix A- adult consent
form). A signed consent was obtained at this stage. The study subjects
were not compensated for study participation. Those who declined (259)
went on to have their procedure as planned but without the collection of
additional biopsies.
3.7.2 Young Children
Young children who were referred to the endoscopy unit because of
persistent diarrhoea, malnutrition and suspected enteropathy had the
procedure described to the mothers or guardian at length before hand,
which included showing the mother or guardian the endoscope and biopsy
forceps prior to the child being prepared for the procedure. This study was
then explained to the mothers/guardians, who were asked if they would
consent to additional biopsies (approximately 5 to 7mg) being collected
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for the purposes of research. No compensation for participation was
offered to the parents or guardians who consented for their children to
join the study. A signed consent was obtained at this stage (appendix A-
child consent form). The mothers/guardians were encouraged to be
present during the procedure if they wished; several stayed with their
children, and a "running commentary" was provided in their language by
one of the team who speaks a local language that the mother or guardian
understands and to confirm at the appropriate juncture that the
parent/guardian was still happy for research biopsies to be taken once
they had a complete understanding of the processes involved. If parents
consented, and the endoscopist considered it appropriate, additional
biopsies were collected from the gastric antrum before the endoscope was
withdrawn. Those children whose guardians or parents declined (12) went
on to have their procedure as planned but without the collection of
additional biopsies.
3.7.3 Consent supervision
The study information and consenting processes were supervised by the
endoscopist who was present through out to answer any question from
the study subjects. There was always an independent witness to the
consenting process who was required to sign the consent form.
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3.7.4 Data management and security
Each subject was assigned a study number, and this was used to identify
all biopsy samples, H. pylori isolates and DNA extracts obtained from
individual subjects. All records are kept at the MRC Unit in Fajara, The
Gambia and data processes and record keeping were annually monitored
by NIH agents. H. pylori isolates and DNA extracts transported to
Washington University in St. Louis, Missouri, USA for antibiotic
susceptibility tests were identified by a study number alone. Only senior
MRC laboratory staff and the principal investigator were able to match
isolates with individual clinical records at the MRC Unit, The Gambia.
3.8 Patients referred for endoscopy
A total of 428 patients between 2003 to 2008 were investigated by upper
gastric endoscopy for routine clinical diagnoses in the MRC endoscopy
unit. These were patients either seen at the MRC-OPD and referred to the
MRC endoscopy unit as part of clinical investigations for dyspepsia or
patients referred from other hospitals or clinics from around the country.
In addition, there were 33 young children between the ages 18-33
months who were referred to the unit for endoscopy because of
enteropathy and malnutrition (figure 3.1).
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Figure 3.1 Flow chart of study samples
428 (9-87 years)
investigated for
suspected
dyspepsia/ dysphag ia
Study populations
259
declined
169 enrolled after
obtaining consent and
gastric
biopsy/biopsies
collected
169 samples cultured
for H. pylori and DNA
extracted directly
from biopsy materials
89 samples were
culture positive; 63
cultures purified
and maintained
58 isolates (38 from
antral and 20 from
body biopsies) used
for antibiotic
susceptibility studies
41 single colonies
(25 from antral and
16 from body
biopsies) used for
MLST studies
DNAs from
121 antral
samples used
for virulent
gene study
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21 enrolled after
obtaining
parental/guardian
consent and antral
biopsies collected
21 samples cultured for
H. pylori and DNA
extracted directly from
biopsy materials
6 samples were
culture positive; 6
cultures purified
and maintained
6 isolates used
for antibiotic
susceptibility
studies
5 single
colonies used
for MLST
studies
3.8.1 Study participants
One hundred and sixty nine subjects who were routinely investigated by
upper gastriointestinal endoscopy for clinical management and provided
written consent. were involved in this study (figure 3.1). The mean age of
these subjects was 38 with a median age of 33 years ranging from 9 to
87 years; 89 were female and 80 were male. All the subjects were
Gambians and most of them (111) came from the Greater Banjul (urban)
Area (GBA), 42 from the West Coast Region (WCR), 9 from Lower River
Region (LRR) and 7 from North Bank Region (NBR) of The Gambia (figure
1.1).
Of the 121 patients (figure 3.1) from whose biopsies we successfully
amplified virulence genes for analysis, the mean age of these subjects
was 35, ranging from 9 to 80 years. All the subjects were Gambians and
most of them (75) came from the GBA, 38 from the WCR, 5 from LRRand
3 from NBR of The Gambia.
3.8.2 Young children
Twenty one young children between the ages 18 to 31 months (figure
3.1) whose parents or guardians provided written informed consent were
also included in this study. Children subjects were all Gambians; 3 from
GBA, 6 from WCR, 10 from LRR, 2 from NBR. We succeeded in amplifying
virulence gene sequences only from the 6 culture positive children and
these were the ones included in the final analyses.
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3.8.3 Specimens
3.8.3.1 Gastric biopsies
Gastric biopsies were collected from subjects who consented to join the
study and underwent diagnostic endoscopy because of dyspeptic
symptoms or suspected enteropathy as part of routine investigation into
the underlying nature of their condition. The gastric biopsies collected
were immediately stored in ice and transported to the laboratory for
culture and/or DNA extraction.
3.9 Good Clinical Laboratory Practice (GCLP)
The gastric biopsies collected were stored in Brain Heart Infusion (BHI)
broth containing 20% glycerol immediately after collection and
transported on ice from the site of collection to the laboratory for
processing or stored at -70°C until used. Pipettes used in all experiments
were verified and calibrated according to standard protocol. All media
used for the culture of H. pylori were sterilized using an autoclave and
poured on Petri-dishes in a lamina flow cabinet to minimise
contamination. Sterile disposable loops were used for culturing and
spreading of biopsy samples and cultures. Despite the use of antibiotics
and antifungal in culture media, the cultures were sometimes overgrown
with contaminants. To minimize the level of contamination, a ClassII
safety cabinet was used during the laboratory processing of samples. The
gas chamber was disinfected with 2% Virkon and carbon catalysts
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sterilized by autoclaving each week. All biohazard materials were disposed
off according to the local Health and Safety regulations (SOP-H&S-OOl).
3.10 Detection of H. pylori
In this study, the detection of H. pylori was by culturing the bacterium on
solid selective media and isolating suspect colonies and identifying them
using standard microbiological techniques and also by PCRusing H. pylori
specific primer (Hp16s rRNA).
3.10.1 Bacteriology
3.10.1.1 Culture of H. pylori
Endoscopic biopsies were spread over the surface of a Columbia-blood
agar (Unipath Ltd, Basingstoke, UK) media plate supplemented with 10%
horse blood (TCS Biosciences, UK) and 2% vitox (Unipath Ltd,
Basingstoke, UK). To minimize contamination, trimethoprim (Sllg/ml),
vancomycin (6Ilg/ml), polymixin B (lOllg/ml), bacitracin (200llg/ml),
nalidixic acid (lOllg/ml) and amphotericin B (8Ilg/ml) were added to the
Columbia-blood agar and inoculated plates were immediately put in a gas
chamber under micro-aerobic atmosphere composed of 86% Nitrogen,
4% Oxygen, 5% Carbon dioxide and 5% Hydrogen. This atmosphere was
generated by the use of Campylobacter Gas generating kit (Oxoid, UK) in
the presence of a carbon catalyst and the plates were then incubated at
37°C for 4-7 days.
57
Figure 3.2 Gas generating system using GasPaks.
Culture plates
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Gas generating kit
(GasPak)
3.10.1.2 Isolation and identification
Identification of H. pylori was by standard methods including colony
morphology, Gram stain appearance, urease, oxidase and catalase
activities. On 100/0 Columbia-Blood agar, H. pylori colonies were grey,
convex and translucent colonies of 1-2mm diameter (figure 3.3). They
were urease, oxidase and catalase positive and Gram-negative bacilli
showing different shapes and sizes (figures 3.3-3.7).
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Figure 3.3 Bacterial culture of H.
pylori
H. pylori colonies after 4
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Figure 3.5 Oxidase reaction
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Figure 3.6 Urease test
Urease -ve
During preliminary studies and also during the study, this technique of
culturing H. pylori became challenging with cultures overgrown with
fungal as well as other bacterial contaminants despite the use of a
selective media. Thus, it was necessary to find an optimal method such as
polymerase chain reaction (PCR) to detect H. pylori in this challenging
environment and also to accurately evaluate the prevalence of mixed H.
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pylori infections in a host. The method of picking several colonies as
pooled cultures may not reflect the true picture as some H. pylori might
be un-culturable, die during culture or overgrown with contaminants.
3.10.2 Molecular detection of H. pylori using Hp16srRNA
3.10.2.1 Genomic DNA extraction from cultures
Genomic DNA was prepared by harvesting a 24 hour confluent growth of
H. pylori culture and extracted using a commercial kit (Qiagen DNA Mini
Kit, UK) as per manufacturers' guidelines described below:
Method
1. 1801-11of ATL buffer was added into 1.5ml eppendorf tube.
2. Fresh 24 hour culture was harvested from a whole media plate and
suspended in tube above and vortexed vigorously to obtain a
homogeneous suspension
3. 101-11of proteinase K was added, mixed for 15 seconds and
incubated at 56°C water bath for 1 hour, mixing at 15 minutes
intervals
4. 2001-11of AL buffer was added, mixed for 15 seconds and incubated
at 70°C for 10 minutes
5. 2001-11of 96-100% ethanol was added, mixed for 15 seconds,
transferred fluid into a spin column provided in Kit and centrifuged at
8000rpm for 1 minute and flow-through discarded
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6. The spin column was put into a new collection column and 500IJI of
AWl buffer added, mixed for 15 seconds, centrifuged at SOOOrpmfor
1 minute and flow-through discarded
7. The spin column was put into another collection column, 500IJI of
AW2 buffer added, centrifuged at 14000rpm for 3 minutes and flow-
through discarded.
S. The column was put in a clean 1.5 eppendorf tube, 200IJI of AE buffer
(elution buffer) added and incubated at room temperature for 5
minutes to increase DNA yield.
9. The tubes were centrifuged at 7000rpm for 1 minute and column
discarded.
10. Fluid in eppendorf about 200IJI was the extracted total DNA
11. The DNA was stored at -20°C until used.
3.10.2.2 Genomic DNA extraction directly from biopsies
Total genomic DNA was extracted from the biopsy samples by using a
combination of the QIAamp DNA isolation kit (Qiagen) and a bead-beater
method as described below:-
1. The biopsy samples were removed from the transport media and
transferred in a sterile 1.5ml eppendorf tube and lS0IJI of ATL
buffer added into the 1.5ml eppendorf tube.
2. 20IJI of proteinase K was added mixed and vortexed vigorously to
lyse the biopsies.
3. The suspension in the tubes were incubated at 56°C water bath for
1 hour, mixing at 15 minutes intervals.
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4. Glass beads of different diameters (O.lmm, 0.5mm and lmm,
Sigma, USA) were added to maximize contact and optimize
homocentsatton.
5. Samples were then homogenized in a FastPrep FP120 bead beater
(Biol0l, Savant Instruments) for 30 sec at 4 m/s and incubated for
an additional hour at 56°C mixing at 15 minutes intervals.
6. 2001J1of AL buffer was added, mixed for 15 seconds and incubated
at 70°C for 30 minutes.
7. 2001J1of 96-100% ethanol was added, mixed for 15 seconds, fluid
transferred into a spin column provided in Kit and centrifuged at
SOOOrpmfor 1 minute and flow-through discarded.
S. The spin column was put into a new collection column and 500IJI of
AWl buffer added, mixed for 15 seconds, centrifuged at SOOOrpm
for 1 minute and flow-through discarded.
9. The spin column was put into another collection column, 500IJI of
AW2 buffer added, centrifuged at 14000rpm for 3 minutes and flow-
through discarded.
10. The column was put in a clean 1.5 eppendorf tube, 200IJI of AE
buffer (elution buffer) added and incubated at room temperature for
5 minutes to increase DNA yield.
11. The tubes were centrifuged at 7000rpm for 1 minute and column
discarded.
12. Fluid in eppendorf about 2001J1was the extracted total DNA.
13. The DNA was stored at -20°C until used.
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3.10.2.3 Molecular detection of H. pylori 16srRNA gene
PCRwas performed to detect H. pylori 16srRNA gene as previously
described [252] ustnq the primers listed in table 3.1 and the following
cycling conditions: 30 cycles of 30 seconds at 95°C, 30 seconds at 55 or
60°C, and 30 seconds at 72°C. The amplified genes were detected by
electrophoresis in a 1.5% gel with ethidium bromide (500ng/ml) and
bands visualized using Gel Doc 2000 (Blo-Rad laboratories, Milan, Italy).
The presence of H. pylori was inferred when a product of the expected
size (109bp) was obtained using appropriate primers (table 3.1). A 100bp
DNA ladder (Biolabs, UK) was used as a size marker in all gels. To
determine the specificity of the Hp16srRNA primers, DNA was extracted
from faecal material, E. coli, Staphylococcus aureus, Salmonella and
Strep to cococcus pneumoniae and amplified with Hp1 and Hp2 primers.
These DNAs all tested negative.
3.11 Antibiotic susceptibility to H. pylori
3.11.1 Minimum Inhibitory Concentration (MIC) by agar dilution
Methods:
1. H. pylori strains were grown on selective media as described before
(section 3.10.1.1).
2. The test media were prepared with the following antibiotic
concentrations:
-amoxicillin 2lJg/ml
-clarithromycin 2lJg/ml
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-erythromycin 2lJg/ml
-metronidazole 8IJg/ml, or 16, 32, 64, 128, 2641Jg/ml
-tetracvcllne 2lJg/ml
-ordinary plate without these antibiotics but always contains the
three antibiotics -trimethroprim, vancomycin and amphotericin-
[253] that do not act against H. pylori to suppress possible
contaminating bacteria and moulds.
3. Plates were pre-warmed to room temperature
-NB: tetracycline is photosensitive, therefore plates were wrapped
up in foil and stored in a brown box prior to use.
4. Fresh 24 hour H. pylori cultures were harvested for this task.
5. 5001J1of sterile phosphate buffered saline pH7.2 (PBS, GIBCD,
invitrogen, USA) was dispensed into 1.5ml sterile eppendorf tubes
6. H. pylori cells were suspended to 105 McFarland standard and
vortexed to obtain a homogeneous suspension.
7. 901J1of sterile PBSwas dispensed into micro-titre wells A to H (figure
3.8).
8. Into well A, 101J1of suspended cells was added (step 6) and mixed
thoroughly.
9. Series of 10 fold dilutions A to H were made by transferring 101J1of
dilution from well A to B, then B to C, etc to the last well, changing
pipette tips in between.
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Figure 3.8 Micro-titre plate showing dilution of cells
Microtitre plate showing bacterial cell dilution
Suspended
cells
10. From each dilution, 101-l1was spotted on appropriate plate starting
with the lowest dilution (well H).
NB: an ordinary plate with each test strain was included for
comparison, to estimate number of bacteria in the original
suspension, and thereby the frequency of cells in the population
resistant to the tested antibiotics.
11. Two cultures were tested per plate as indicated in figure 3.9:
65
Figure 3.9 Culture plate showing spot inoculums of cell
suspension
C B A Sample 1
0 0 0 0
H G F E
0 0 0 0
0 0 0 0
H G F E Sample 2
0 0 0 0
C B
Keyo = 10j..LIspots
A-H = 10 fold dilutions 101 to 108
12. Inoculums were allowed to air dry and plates incubated in a micro-
aerobic atmosphere at 37°C for 5 days.
13. Colony count was recorded.
Results = A strain was considered to be susceptible to
concentrations of antibiotics that caused at least a 10-fold decrease
in the efficiency of colony formation by individual cells (efficiency of
plating, or EOP).
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3.11.2 rdxA (nitroreductase) gene transformation analysis
Resistance of H. pylori from other (non-West African) populations to
metronidazole is,mainly due to inactivation of rdxA or both rdxA and frxA
nitroreductase genes, depending on the strain (and whether frxA is highly
expressed or not). Metronidazole sensitive (Mtzs) strains generally have
functional alleles of these two genes. Given that MtzS H. pylori strains are
relatively uncommon in The Gambia; we elected to test if those that had
remained MtzS were very different from metronidazole resistant MtzR
strains in terms of ease of development of resistance or if they had simply
not been sufficiently exposed to the antibiotic to have selected for
emergence of resistance.
Method
1. MtzS H. pylori strains were sub-cultured on antibiotic free agar
plate.
2. The cells were harvested and sub-cultured again for 24hours to
obtain an exponential growth.
3. 24 hour cultures were transferred in a fresh antibiotic free agar
plate.
4. 5J.J1of genomic DNA (ordinary Qiagen prep) from strain that
contains a chloramphenicol resistance (CamR) cassette inserted at
the rdxA locus (rdxA-null mutant) was added to the freshly cultured
bacterial cells and incubated over night at 37°C.
5. Some bacterial cells would have taken the DNA.
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6. The cells were then harvested and subcultured on an agar plate
with chloramphenicol to select out CamR strains.
7. The cells of CamR colonies were scraped with sterile toothpick and
streaked on agar plate with 8J.lg/ml of Mtz, and then on control
plate with chloramphenicol 15J.lg/ml.
8. Growth on the Mtz plate indicated that for these strains, inactivation
of only rdxa gene resulted in resistance.
9. No growth on Mtz plate, inactivation of a second gene (frxA) may
be necessary for these strains to become resistant. This can be
tested with genomic DNA from a strain that contained a kanamycin
resistance gene cassette inserted next to a functional rdxA gene. We
expected that a fraction of Kan" transformants would acquire the
donor strain's rdxA+ and become sensitive whilst others that did not
acquire the functional rdxA will remain resistant.
3.11.3 165 rRNA and rdxA DNA sequencing
To detect changes in 165 rRNA sequences associated with Tet resistance,
165 rRNA genes were amplified by PCRwith primers 165-F (5'-
CGGTTACCTTGTTACGACTTCAC-3') and 165-R (5'-
TATGGAGAGTTTGATCCTGGCTC-3') and the amplified 165 rDNAs were
sequenced as previously described [236].
For detection of mutations associated with Mtz resistance, the rdxA gene
of 51 (33 MtzR and 18 Mtzs) strains was amplified by PCRwith the
68
following primers (rdxAF S'GTTTCGTTAGGGATTTTATTGTATGCTA-3' and
rdxAR S'CACCCCTAAAAGAGCGATTAAAACCATT-3'), PCR products were
sequenced, and the sequences were edited, aligned and analysed using
DNAstar programme (Lasergene, USA, Version 7) and Clustalw2
programme.
3.12 peR amplification for virulent genes (cagA, vacA, iceA)
The extracted DNAs were tested by PCR for the presence of H. pylori
using H. pylori specific 165rRNA primers. The H. pylori positive samples
were further tested for the cagA oncogene, signal (51 and 52 alleles) and
middle regions (m1 and m2 alleles) of the vacA toxin gene, iceA1 and
iceA2 genes as previously described [21]. Typically 2SJ.l1containing 1U of
Taq polymerase (Bioline, UK), 10pmol of each primer per reaction,
0.2SmM (each) of deoxynucleoside triphosphate, and 2mM MgCI2 in
standard PCR buffer and 1J.l1 of DNA were carried out in a PTC 200 DNA
Engine cycler, under the following general cycling conditions: 30 cycles of
94°C for 1 minute, 55°C or 60°C for 1 minute and 72°C for 1 minute.
Positive DNA from previously determined genotypes and template free
controls that contained only the reaction mixture without DNA were
included in each batch as positive and negative controls respectively. The
presence of a particular gene or allele was inferred when a product of the
expected size (table 3.1) was obtained using appropriate primers.
A 100bp DNA ladder (Biolabs, UK) was used as a size marker in all gels.
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Table 3.1 Primers used for virulent gene and RAPD
Region Primer Nucleotide se_g_uence bp reference
cagA eagA-F gat aae agg eaa get ttt gag 9 349 [21]
eagA-R etg eaa aag att gtt tgg eqg a
cag empty site Luni-l aea ttt tgg eta aat aaa ege tg 535 [21]
R5280 ggt tge aeg cat ttt eee tta ate
vacA 51 & Val-F atg gaa ata eaa eaa aca cae 51 259 [21]
vacA 52 Val-R etg ett gaa tge gee aaa e 52289
vacA m1a Va3-F ggt eaa aat geg gte atg 9 290 [21]
Va3-R eea ttg gta eet gta gaa ae
vacA m2 Va4-F gga gee eea gga aae att 9 352 [21]
Va4-R cat aae tag cge ett gea e
iceA1 1048-F get tgt aae gat aag aaa ege eag 297 [21]
1345R at
gga atg age ttg tat tta gag eeg
at
iceA2 ICEA2-F gtt ggg tat ate aea att tat 229 or [21]
ICEA2-R ttr eee tat ttt eta gta ggt 334
H. pylori Hpl etg gag aga eta age eet cc 109 [252]
16sRNA Hp2 att act qac get gat !9_t_ge
RAPD 1254 1254 eegeageeaa [2541
RAPD 1283 1283 gegateeeea 12541
3.13 peR amplification for Randomly Amplified Polymorphic DNA
CRAPO)
PCR for DNA finger printing (RAPD) was carried out with two arbitrary
primers as previously described [254]. 251-11containing 1U of Taq
polymerase (Bioline, UK), 10pmol of one primer per reaction, 0.25mM
(each) of deoxynucleoside triphosphate, and 4mM MgCI2 in standard PCR
buffer and 11-11of DNA were carried out in a PTC 200 DNA Engine cycler,
under the following general cycling conditions: 45 cycles of 94°C for 1
minute, 36°C for 1 minute, and 72°C for 2 minutes. Primer 1283 (5'-
GCGATCCCCA- 3') was used to type the selected isolates to confirm the
results of the first primer 1254 (5'-CCGCAGCCAA- 3').
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3.14 Gel electrophoresis for virulence genes and RAPD
81-11of the amplified genes or fragments were detected by electrophoresis
in a 1.50/0 aqarose gel with ethidium bromide (500ng/ml) after the
addition of 21-11of gel loading solution (Sigma, USA) as described below:
1. 1.50/0 agarose (Sigma, USA. Cat.no. A-9414) gel was prepared by
weighing out 1.5g of pure agarose and suspending in 100mi of lxTBE
buffer in a conical flask, dissolved by boiling in a microwave for 3
minutes and allowed to cool to 56°C in a water bath.
2. 1001-11of ethidium bromide solution was added to a concentration of
500ng/ml; the gel poured into the carrier on a level surface with the
plastic combs already inserted and allowed the gel to set and the combs
removed.
3. Ensuring the power pack was switched off; the gel was transferred to the
electrophoresis tank and covered with lxTBE buffer to about 0.5cm
above the gel.
4. 2,..11of the running dye (loading buffer) was transferred into au-shaped
micro-titre plate. One well was required for each reaction.
5. 8f.l1of PCR product was removed from the PCR tube, mixed with the
running dye by reflux action in the pipette tip and loaded into the gel by
introducing the tip under the surface of the buffer and into the well. (The
density of the glycerol in the dye made the product sink into the well).
6. The gel tank was covered with the lid and checking that the polarity was
correct (DNA moves towards the anode), the voltage was set to 100Vand
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the process ran for 1 hour, For RAPD, the voltage was set at 7SV and-the .
process was allowed to run for 4 hours.
7. When the electrophoresis was complete, the gel was transferred to a
sandwich box and carefully moved onto the UV box. The gel was
positioned and the camera focused.
8. After putting on UV protective glasses, UV light was turned, the gel
examined and a photograph taken using Gel Doc 2000 (Bio-Rad
laboratories, Milan, Italy) and analyzed.
lOObp and lKb DNA ladders (Biolabs, UK) were used as size
markers in all RAPD gels.
3.15 Multi-Locus sequence Typing (MLST) using seven House-
keeping genes
3.15.1 MLST Gene Amplification
MLST was carried out by PCR using seven house-keeping genes loci (atpA,
efp, mutY, ppa, trpC, ure! and yphC) in order to characterize the H. pylori
strains using sequence analysis. The extracted DNA were amplified with
both the forward and reverse primers (amplification primers are listed at
http://pubmlst.org/helicobacter) of each house keeping gene under the
following conditions: 30 cycles of 94°C for 40 seconds, 50°C for 40
seconds and 72°C for 1 minute. The primers used for all PCR
amplifications and sequence reactions for MLST are listed in table 3.2.
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Table 3.2 MLST Primers used for both amplification and
sequencing
Name Gene I Primer sequence Reference
atpA atpA forward ggactagcgttaaacgca~ httg:LLgubmlst.orgLhelicobacter
atpA reverse cttgaaaccgacaagcccac httg:LLgubmlst.orgLhelicobacter
efp eto forward ggcaatttggat9_a_gc_g_a_g_ctc httg:LLgubmlst.orgLhelicobacter
efp reverse cttcaccttttcaagatactc httg:LLgubmlst.orgLhelicobacter
mutY mutY forward gtggttgtagy~ggaaactttacac httg: LLgubmlst.orgLhelicobacter
mutY reverse cttaagcgtgtgtytttctagg httg: LLgu bm Ist.orgLhelicobacter
ppa ppa forward ggagattgcaatgaatttaga httg: LLgubm Ist.orgLhel icobacter
ppa reverse gtggggttaaratcgttaaattg httg:LLgubmlst.orgLhelicobacter
trpC trot; forward tagaatgcaaaaaa_gcat~ccctc httg:LLgubmlst.orgLhelicobacter
trpC reverse taagcccgcacactttattttcgcc httg:LLgubmlst.orgLhelicobacter
ureI ureI forward aggttattcgtaaggtgcg httg :LLgubmlst.orgLhelicobacter
ureI reverse gtttaaatccctta_gatt9_cc httg: LLgubm 1st.orgLhel icobacter
yphC yphC forward cacgcctatttttttgactaaaaac httg: LLgubm Ist.orgLhelicobacter
voht: reverse cattyaccctcccaa~atgc httg: LLgubm Ist.orgLhelicobacter
Tet16S Tet16S cggttaccttgttacgacttcac [236]
rRNA forward
Tet16S reverse tatggagagtttgatcctggctc [2361
3.15.2 DNA purification for MLST
PCR amplification products for each of the seven house-keeping genes
(atpa, etp, mutY, ppa, trpC, ureI, yhpC) were transferred in a sterile
1.Sml eppendorf tube diluted with phosphate buffered saline (PBS) and
the contents were processed using a Qiagen purification kit (Qiagen, UK)
as described below:-
Method:
1. The whole volume of PCR product was transferred in 1.Sml
eppendorf tube and SX volume of PBS was added and mixed
(e.g. 201-11of PCR product + 1001-11of PBS)
2. Content was transferred into a spin column, centrifuged at
13000rpm for 1 minute and flow-through discarded.
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3. O.75ml of PE buffer was added, centrifuged at 13000rpm for 1
minute and flow-through discarded.
4. The spin column was centrifuged again to remove any residual
ethanol from the PE buffer.
5. The column was transferred into fresh 1.5ml eppendorf tube and
DNA eluted with 50~1AE (elution buffer).
6. The tubes were incubated at room temperature for 5 minutes to
increase DNA yield and centrifuged at 6500rpm for 1 minute.
7. The resulting purified DNA was stored at -20°C until used.
3.15.3 Sequencing
Sequencing of 2~1of the purified DNA was performed on both the forward
and reverse DNA strands separately using a BigDye terminator as
described below:
3.15.3.1 Sequencing reaction
2.075JlI
0.500JlI
5.105JlI
0.320JlI
8.000JlI
PCRproducts 2.000JlI
Total 10.000JlI
The reaction was amplified under the following conditions: one cycle of
5X buffer
BigDye
Sterile distilled water
Primer forward or reverse (5JlM)
96°C for 1 minute, followed by 30 cycles of 96°C for 10 seconds, 50°C for
5 seconds and 60°C for 4 minutes.
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3.15.3.2 Clean up procedure for amplified products
The amplified products were cleaned up, denatured and dried before
sequenced using an ABI Prism 3130X DNA sequencer (Applied
Biosystems, USA).
3.15.4 Editing and analysis of the sequences generated
Consensus sequences for each of the samples were generated using
DNAstar programme (Laser gene, USA; Version 7). The sequences
obtained were submitted to the H. pylori MLST data base
(Http://pubmlst.org/Helicobacter) for allele and sequence identification.
The FASTA format of the concatenated sequences of each sample was
aligned and imported into MEGA version 5 (MEGA 5) and computed for
phylogeny.
3.15.4.1 Allele and sequence type identification
Isolates MLST sequences data were queried against the global
Helicobacter MLST database and alleles and sequence type (ST) Profiles
assigned to individual isolates (assigned alleles and ST profiles through
the stated MLST method).
3.15.4.2 Nucleotide analyses
The calculation of the ratio of synonymous to non-synonymous changes
(dn/ds) was done using START2 (Sequence Type Analysis and
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Recombinational Tests Version 2) tool which uses the method of Nei and
Gojobori to estimate parameters [255].
3.15.4.3 Comparative analysis
For comparative analysis, 71 strains from Africa, 33 from Spain and 24
strains from Japan making 128 unique STs were downloaded from
Helicobacter MLST web site (Http://pubmlst.org/Helicobacter).
Concatenated sequences were aligned and imported into MEGA 5 [256].
The evolutionary history was inferred using the Neighbor-joining method.
The percentage of replicate trees in which the associated taxa clustered
together in the bootstrap test (2000 replicates) was shown next to the
branches.
3.15.4.4 Admixture and no-admixture models of H. pylori
populations using STRUCTURE.
To determine the relatedness of the Gambian H. pylori to the previously
studied strains from elsewhere, 170 strains from elsewhere were
randomly selected from the public MLST data base (table 6.5). The non-
admixture and admixture models of the program STRUCTUREV2.3.4
[257] were used to assign concatenated sequences of individual strains to
previously identified bacterial populations. The highest value (K) that
gave consistent clustering between individual runs was 4 (K=4).
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3.16 Comparative statistical methods
3.16.1 Comparison of DNAs from culture and directly from
biopsies
Percentage agreement was calculated to compare H. pylori genotypes
obtained by PCR performed directly on gastric biopsies with the genotypes
obtained by PCR of DNA extracted from bacteria cultured. In addition, the
kappa statistic which allows for chance agreement (kappa=O corresponds
to no agreement beyond that expected by chance and kappa=1
represents perfect agreement) was reported.
3.16.2 Prevalence of H. pylori genotypes in different age groups
The prevalence of genotypes within different age categories was
described. The null hypothesis of no association between prevalence and
age was tested using Fisher's exact test and the differences among
groups were tested using Fisher's exact test.
3.16.3 Prevalence of infection with single or multiple strains
The prevalences of infection with single vs. multiple strains was assessed.
For the cagA gene, for example, the occurrence of cagA positive, cag
empty site and mixed (cagA positive and cagPAI negative) infections was
noted. Prevalences were compared between disease groups and p-values
were determined using Fisher's exact test.
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3.16.4 Antibiotic resistance in males vs females and between age
groups
Comparisons of antimicrobial resistance in strains from children vs adults,
males vs females, and distribution of rdxA nonsense mutations in different
groups of strains were determined using Fisher's exact test; a P-value of
<0.05 was considered significant.
78
Chapter 4 Prevalence of Helicobacter pylori virulent genotypes:
PCR-based genotyping of Helicobacter pylori of Gambian children
and adults directly from biopsy specimens and bacterial cultures
4.1 Introduction
H. pylori, because it is a fastidious micro-aerobic bacterium, it is
technically difficult to grow and maintain for molecular biologic research in
poorly resourced laboratories in Africa. These challenges coupled with the
uniqueness of genotypes of African strains and special features of human
physiology and environment in this continent limit our understanding of
the spectrum of H. pylori-associated diseases and how this is affected by
bacterial genotype in Africa [62,209]. So extensive efforts have been
made to determine an optimum method for peR-based genotyping of H.
pylori [258-261] with various success rates. The methods used thus far to
detect H. pylori infection such as stool antigen [262] and peR restriction
analysis using an RNA polymerase gene (rpo8) [259] were either found to
be inadequate in detecting H. pylori virulent genes or experimentally too
complex for routine purposes. To more effectively investigate prevalence
of H. pylori genotypes and their influence on associated diseases in a
West African setting, this chapter sought to determine an optimum
method for peR-based genotyping of H. pylori in The Gambia, and by
extension determine the prevalence of H. pylori and H. pylori genotypes
associated with the development of gastro-duodenal diseases in The
Gambia, West Africa.
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4.2 Results
A total of 169 biopsy samples from 169 subjects between the ages of 9 to
80 years, and 21 from young children between 18 to 31 months were
investigated for H. pylori infections by both culture and peR of DNA
obtained directly from biopsies (figure 3.1). 89/169 (52.6%) biopsies
cultured were initially identified as H. pylori culture positive. Pure H. pylori
cultures were obtained from only 63 of them, but not the other 26,
primarily because of overgrowth by contaminants despite inclusion of
multiple antibiotics in the culture medium (figure 4.1) or bacterial cells
failing to survive further subculture.
Figure 4.1 H. pylori selective media showing over growth of
contaminants
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4.3 Comparison of PCRand culture to detect H. pylori
The same set of 169 biopsies cultured had DNAs extracted directly from
the biopsy material. Direct PCRfrom these DNAs indicated that 164/169
(97%) were positive for Hp16srRNA (table 4.1).
Table 4.1 Comparison between culture results and direct PCRwith
H. pylori specific 16srRNA primer
Result Culture Direct by PCR
Positive 89 (52.6%) 164 (97.0%)
Negative 80 5
rTotal 169 169
The DNA extracts from the remaining 5 biopsies were H. pylori negative
with Hp16s and did not amplify for any of the genes tested, even though
they were culture positive (figure 4.2).
Figure 4.2 PCR of 5 culture positive samples with H. pylori
16srRNA.
M 1 2 3 4 5 6
Lane M is a lOObp ladder,
lane 1 is a positive control,
lanes 2-6 were H. pylori
culture positive but
negative by Hp16s rRNA
peR.
ioobp
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These five samples were tested for peR inhibitors by addition of DNA from
a known H. pylori positive sample. The samples which now contained H.
pylori positive DI':JAwere also all negative after peR (figure 4.3). This
implies the presence of a potent inhibitor.
Figure 4.3 peR using H. pylori 16srRNA negative samples with H.
pylori positive DNA
M 1 2 3 4 5 6
Lane M is a lOObp
ladder, lane 1 is a
positive control, all 5
samples (2-6) with H.
pylori +ve DNA added
were negative by
Hp16s rRNA peR.100bp
Of the 169 subjects between the ages 9-80 years, 121 biopsies from 121
subjects successfully amplified for virulence genes; among the 21 young
children, 8 were Hp16s positive and pure H. pylori cultures were obtained
successfully from six of them (figure 3.1). Direct peR of the biopsies for
virulent genes from the other 15 children were either negative (n= 10) or
not done (n=5).
Amongst the 80 culture negative adult subjects for whom Hp16s was
positive, amplification of some or all virulence genes was only achieved in
20 cases. It is not yet known if these strains lacked virulence genes, were
divergent in primer binding sequences, or the bacterial density was so low
that amplification was possible only with the most general of primer
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combinations, such as Hp165. The remaining 60 samples did not show
amplification for any of the genes tested despite a positive response to
Hp165.
4.4 Comparison of genotypes between peR on bacterial cultures
and direct PCR on biopsy material
Virulence gene data were obtained by direct PCRfrom both biopsies and
cultures. A comparison of the products that were indicative of cagA, cag
emptysite, vacAs alleles, vacAm alleles, iceA1 and iceA2 between both
methods for detecting H. pylori was summarized for 60 samples for which
sufficient amplified DNA was obtained for the comparisons in table 4.2.
Table 4.2 Comparison of DNA from culture and tissue biopsy
Culture (60) Biopsy (60) Failure to amplify
DNA from biopsy
material
_genotype no 0/0 no 0/0 no 0/0
ca_gA status 7 11.7
ca_gA+ 37 61.7 35 58.3
ca_gA- 14 23.3 13 21.7
cagA+ and 9 15.0 5 8.3
ca_gA-
5 allele 7 11.7
51 39 65.0 39 65.0
52 14 23.3 14 23.3
51 and 52 7 11.7 0 0
m allele 10 16.7
m1 26 43.3 23 38.3
m2 20 33.3 23 38.3
mt and m2 14 23.3 4 6.7
iceA allele 10 16.7
iceA1 8 13.3 6 10
iceA2 46 76.7 14 23.3
iceA1 and 6 10 30 50
iceA2
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4.5 Detection of cagA using biopsy material and culture
The proportion of samples that were cagA+ve (figure 4.4) with DNA from
biopsies and from culture was similar, 58.3% and 61.7% respectively
(table 4.2).
Figure 4.4 peR inferred results of cagA gene
M 1 2 3 4 5
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1.5% gel electrophoresis of H.
pylori genotypes showing PCR
results of cagA. Lane M is a 100bp
ladder (Biolabs, UK); lanes 1, 2, 3
and 5 showed PCR products
(349bp) of cagA genes, lane 4 is
cagA negative
4.6 Detection of cag empty site using biopsy material and culture
For the cag empty site, the proportions of samples that were cag empty
site positive (figure 4.5) with DNA from culture isolates and tissue
material were also similar, 23.3% and 21.7% respectively (table 4.2) but
the presence of strains that were both cagA gene positive and cagA
negative were higher in DNA from culture isolates than from tissue
biopsies, 15% vs 8.3% respectively.
Figure 4.5 peR inferred results of cag emptysite.
M 1 2 3 4 5
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1.5% gel electrophoresis of H.
pylori genotypes showing PCR
results of cag emptysite.
Lane M is a 100bp ladder (Biolabs,
UK), lanes 1, 2 and 4 showed PCR
products of 535bp indicating the
presence of cag emptysite, lanes 3
and 5 were cag emptysite negative
4.7 Detection of signal region alleles (51,52) using DNA from
biopsy material and culture
The presence of 51 and/or 52 allele was inferred when a product of the
expecteo size, (259bp and/or 289bp) was obtained using appropriate
primers (figure 4.6).
Figure 4.6 peR inferred results of signal region of vacA gene.
M 1 2 3 4 5
1.5% gel electrophoresis of
H. pylori genotypes showing
peR results of 51 and 52
allelles of vacA gene. Lane M
is a lOObp ladder (Biolabs,
UK), lanes 1 and 2 showed
the presence of 51 (259bp),
lane 3 is both 51 and 52
positive and lanes 4 and 5
were 52 (289bp) positive.
The success in amplification of vacA51/52 (51 = toxigenic vs 52 = non-
toxigenic) from cultures and corresponding biopsies was similar (table 4.2
and 4.3). The prevalence of both vecas: and vacA52 was 65% and 140/0
respectively. However, multiple alleles of vacA51/52 were found only in
11. 7% of samples from culture isolates and none from tissue biopsies
(table 4.2).
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4.8 Detection of mid region alleles (m1., m2) using biopsy material
and culture
For the vacA middle region (ml and/or m2), their presence were inferred
when a product of the expected size, (290bp and/or 352bp respectively)
were obtained using appropriate primers (figure 4.7).
Figure 4.7 peR inferred results of mid region of vacA gene
M 1 2 3 4 5
1.5% gel electrophoresis of H. pylori
genotypes showing peR results of ml
and m2 allelles of vacA gene. Lane M
is a 100bp ladder (Biolabs, UK), lanes
1, 2 and 3 are ml positive, 290bp;
lanes 4 and 5 showed the presence of
m2 (352bp).
The prevalence of vacAml and vacAm2 was also similar (table 4.2) but
multiple alleles of vacAml/m2 were found in 23.3% of samples from
culture isolates as oppose to 6.7% from tissue biopsies (table 4.2).
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4.9 Detection of iceAl and iceA2 using biopsy material and culture
The iceA gene has two allelic variants that yielded either 297bp (iceAl) or
229bp and 334bp (iceA2) products by peR (figures 4.8 and 4.9).
Figure 4.8 PCR inferred results of iceAl
M 1 234 5
Figure 4.9 PCR inferred results of iceA2
M 1 2 345
1.5% gel electrophoresis
of H. pylori genotypes
showing PCR results of
iceA1 gene. Lane M is a
lOObp ladder (Biolabs,
UK), lanes 1, 2 and 5
showed the presence of
297bp of iceA1, lanes 3
and 4 were iceA1
negative.
1.5% gel electrophoresis
of H. pylori genotypes
showing PCR results of
iceA2. Lane M is a 100bp
ladder (Biolabs, UK),
lanes 1 and 2 showed
the presence of 334bp of
iceA2 and lanes 3 and 4
were iceA2 positive of
229bp, lane 5 was iceA2
negative.
The prevalence of iceAl from culture isolates and corresponding biopsies
was similar; 13.3% and 10% respectively. However, the presence of
iceA2 was abundant in culture isolates (76.7%) as opposed to 23.3% in
88
the corresponding tissue biopsies. Multiple genes (iceA1 and iceA2) were
four times higher in tissue biopsies than the corresponding cultures; 500/0
vs 100/0 (table 4.2).
4.10 Comparison of genotypes detected from culture and biopsy
material
The agreements between genotypes inferred using DNAs directly from
these two sources was good for both cagA and m1, m2 alleles of vacA,
moderate for sl, s2 alleles of vacA, and poor for iceA (table 4.3).
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The poor agreement in the iceA analysis stemmed from the many
classified only as iceA2 by peR from bacterial culture but iceAl and iceA2
by biopsy which could have been due to the fact that certain bacterial
strains in a mixed infection grew much better than others in culture. In
direct peR up to 16.7% of culture positive biopsies failed to amplify DNA
for individual alleles.
The proportion of biopsies that were cagA+, the proportion of vacAsl, and
vacAml, and the proportion of mixed cultures from individual subjects
varied with age.
All peR results, including samples obtained from cultures and from direct
peR on biopsies (127 in total) are summarized in table 4.4.
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Table 4.4 Variation in frequency of alleles with age from samples
obtained by peR directly from biopsies or subcultured H. pylori.
Age cagA+ & Not
_(years) Total cagA+ cagA- ceas: amplified P-value
1.5-2.5 6 1 (16.7) 5 (83.3) o (0) 0(0)
9-29 54 35 (64.8) 10 (18.5) 8 (14.8) 1(1.8)
30-40 31 22 (71.0) 2 (6.5) 6 (19.3) 1(3.2)
41-59 24 15 (62.5) 4(16.7) 4 (16.7) 1(4.2)
>=60 12 2(16.7) 5(41.7) 5(41.7) 0(0) 0.001
Total 127 75 (59) 26 (23) 23 (18.1) 3(2.4 )
Age Not
_(years) Total sl s2 sl&s2 amplified P-value
1.5-2.5 6 1 (16.7) 5 (83.3) o (0) 0(0)
9-29 54 43 (79.6) 9 (16.7) o (0) 2(3.7)
30-40 31 27 (87.1) 3 (9.7) o (0) 1(3.2)
41-59 24 18 (75.0) 5 (20.8) o (0) 1(4.2)
>=60 12 5(41.7) 6 (50.0) 1 (8.3) 0(0) <0.001
Total 127 94 (74) 28 (22) 1 (0.8) 4(3.1)
Age Not
_(years) Total m1 m2 m1&m2 amplified P-value
1.5-2.5 6 1(16.7) 5 (83.3) o (0) o (0)
9-29 54 25(46.3) 17(31.5) 10 (18.5) 2 (3.7)
30-40 31 16(51.6) 8 (25.8) 5 (16.1) 2 (6.5)
41-59 24 12(50.0) 4(16.7) 4(16.7) 4 (16.7)
>=60 12 2( 16.7) 7 (58.3) 3 (25.0) o (0) 0.103
Total 127 56(44) 41 (32.3) 22 (17.3) 8 (6.3)
Age Not
_(years) Total iceA1 iceA2 iceA1&2 amplified P-value
1.5-2.5 6 3 (50.0) 1 (16.7) 2 (33.3) o (0)
9-29 54 3 (5.6) 19 (35.2) 29 (53.7) 3 (5.6)
30-40 31 6 (19.3) 7 (22.6) 15 (48.4) 3 (9.7)
41-59 24 4(16.7) 10(41.7) 7 (29.2) 3 (12.5)
>=60 12 2 (16.7) 6 (50.0) 4 (33.3) o (0) 0.065
Total 127 18 (14.2) 43 (33.9) 57 (44.9) 9 (7.1)
This data (table 4.4) is further illustrated in the bar charts below:
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Figure 4.10 virulent genes in various age groups
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Figure 4.11 Non-virulent genes in various age groups
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Where both culture from biopsy and peR directly from biopsy were
positive, only the results obtained from biopsy were included in this
analysis.
None of the young children had mixed cultures with relation to cagA,
vacas or vacAm alleles as opposed to 14.8% to 53.7% in other age
groups (table 4.4). Young children of 18-31 months also exhibited lower
levels of the toxigenic genes (strains that lacked the cagPAI and the less
toxigenic alleles (52,m2) than any of the adult groups (table 4.4, figures
4.10 and 4.11). This difference was only statistically significant (PSO.02)
when isolates obtained from children were compared with those from
adults aged less than 60 years for cagA and 51 allele of vacA, and when
compared with isolates from adults aged 41-59 years for m1 region of
vacA. However, the sample size in children was small and therefore the
difference between children and adults should be interpreted with caution.
4.11 H. pylori genotypes and age
The prevalence of virulence genes was age-dependent. The virulent cagA
oncogene and the vacA toxigenic alleles of 51 and m1 were more common
among the 30-40 year age group and less common in younger and older
age groups. This association was statistically significant (P<0.05) for cagA
and vacA5 and not for the mid region of vacA gene and iceA alleles
(P>0.05, table 4.4). Only 1 elderly subject (70 years) was found to have
mixed colonization with vacA51/52. The situation with iceA was more
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complicated, with a large number of individuals exhibiting mixed
iceAl/iceA2 colonization.
4.12 Discussion
This chapter describes the prevalence of H. pylori genotypes in The
Gambia and also describes the comparison between results obtained from
direct peR to detect H. pylori from gastric biopsies in West Africa,
compared to peR of bacterial isolates obtained from the same set of
gastric biopsies. The present study establishes the prevalence of H. pylori
infection in dyspeptic patients in The Gambia. The overall prevalence of H.
pylori among the study patients was 97% by direct peR and 53% by
culture, although this varied with age. This prevalence is comparable with
that of other developing countries.
Both peR and culture techniques produced different success rates, as set
out in tables 4.3-4.4, and both failed to detect H. pylori in a significant
proportion of infections. The results presented here agreed with Park et al
[263] in that direct peR can produce inconsistent results, and tend to
underestimate the prevalence of specific virulence factors (table 4.3-4.4).
However, in this study, a good consistency of genotypes was detected
between both techniques consistent with what was reported in a similar
study by Chattopadhyav [258] where 83-97% of paired samples (biopsies
vs cultures) had identical results for the various H. pylori virulent cagA
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and vacA genes [258] but different from another study where only 32.8%
of paired samples had identical results [264].
This data differs in that considerably greater difficulty in obtaining pure
subcultures of H. pylori from gastric biopsies than Park, with a
consequently higher failure rate was experienced. I have been involved in
studies cultivating H. pylori from gastric biopsies from populations
throughout the world, and it is my personal observation that sub-culture
failure is a particular problem amongst West African isolates, as
encountered in the present study. The reasons for this are not
immediately apparent.
As a consequence of this problem, not all biopsies from which virulence
factor DNA was amplified yielded a primary isolation of H. pylori, and
there was a significant loss of isolates at subculture. PCRfrom subcultures
gave higher rates of mixed colonization for cagA and vacA genes than
direct PCRof biopsies, in contrast to the situation reported elsewhere with
higher culture success rates [263]. In Park's study, 27% of cases had
mixed infections with tissue DNA as compared to only g% with bacterial
DNA. In this study, the high numbers of mixed infections observed in
cultures may have been due to artifact, either by enhancement of a minor
strain from within the stomach, or due to modification of genome during
culture as observed in a clinical study where different genotypes in a
patient which may have developed from repeated sub-culturing [265].
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This study showed that direct peR produced more positive results, gave
rise to fewer concerns about the development of artifact, and was more
rapid and convenient.
The data also indicate that there may be peR inhibitors or potent
nucleases in some gastric biopsies. In this case 3% of biopsy samples
were inhibited for H. pylori and also for all virulent genes and up to about
12% for various individual virulent genes (table 4.3). This is consistent
with findings in similar studies [19,260,263]. However, the
underestimation of H. pylori by peR in this study was similar to the 8.4%
reported in a study by Park [263] but less than the 42% reported in
another study [261]. Their occasional presence and the underestimated
prevalence of specific virulence factors by direct peR illustrate that culture
can be a useful complement to direct peR for studies in which complete
ascertainment of H. pylori virulence factor genotypes, including mixed
colonization, is desired.
The study showed a difference in predominant genotype with subjects'
age. In addition to adults of various age groups, this study also
investigated children who were very young (18-31months) and were
therefore closer to the time of colonisation. Young children produced
isolates that were more likely to be cagA-ve, and vacAs2m2, in contrast
to adults who were more likely to harbour cagA+ve vacAslml isolates.
The studies that have so far characterized child isolates (mainly from
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children older than those in this study) have shown marked geographical
differences of genotypes. For example, studies in Brazil, Slovenia, North
America, Korea and Japan [81-85] have shown that between 64-75% of
all child isolates carried the virulent 51 allele of vacA gene. 82% of Korean
isolates [84] carried the m1 allele of vacA gene and 94% of cagA gene
which is similar to figures reported in Japan [81]. Similarly in Brazil [82],
the majority of child isolates were m1 allele positive. In contrast, a
significant number of adults carried the more virulent genes of cagA and
vacA in Portugal [87] than isolates from children. This is similar to figures
reported in Israel [88] where only about 25% of children carried the
virulent cagA gene and 65% of the avirulent vacA alleles of 52m2. In this
study, children were also less likely to have mixed populations of H. pylori
strains, which may relate to children aged 18 to 31 months being
relatively recently colonized by H. pylori, compared to older individuals.
The strains of H. pylori discovered in adult stomachs, at ages when typical
H. pylori associated diseases develop, may be genotypically distinct from
the original strains that first colonized young Gambian children. This could
be due to recombination of the H. pylori genome over the course of
decades [104,266] and/or re-exposure to novel strains, with more
pathogenic strains circulating predominantly amongst adults.
4.13 Conclusion
The prevalence of H. pylori in The Gambia is high and comparable to
figures reported in other developing countries. However, in order to
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detect the range of bacterial genotypes harbored by individual patients,
direct peR proved slightly superior to isolation of H. pylori by biopsy
culture in this study, but the techniques were complementary to each
other, and the use of both together produced the most complete picture.
Despite the lower success rate and greater cost of H. pylori culture
relative to peR directly from biopsies, culturing H. pylori is still important
for antibiotic susceptibility tests that could guide therapy and other
phenotypic tests such as bacterial adherence, cagA and vacA action on
mammalian cells, expression of other colonization and virulence traits for
which peR alone is unsuitable. The use of peR to detect genotypes has
greatly improved on the detection of genotypes in this study. Young
children of 18-31 months exhibited lower levels of the toxigenic genes
(strains that lacked the cagPAI and the less toxigenic alleles (52,m2) than
any of the adult groups (table 4.4).
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Chapter 5 Mixed Infection with cagA Positive and cagA Negative
Strains of Helicobacter pylori Lowers Disease Burden in The
Gambia.
5.1 Introduction
Earlier reports indicated high prevalence of H. pylori colonization, but a
low frequency of H. pylori-associated disease in Africa [62,209,267], a
phenomenon that was called the "African enigma" [62]. DNA sequencing
of housekeeping and virulence genes have shown that different sets of
genotypes predominate in different human populations [160]. Of
particular interests have been H. pylori's cagA oncogene and toxigenic sl
and m1 alleles of its vacA gene, which have been implicated in
gastroduodenal diseases caused by this pathogen both in epidemiologic
[268,269], experimental animal and cell culture infection [270]. This said,
several studies from different world regions have not detected such an
association [79,80,268], an outcome suggesting the possibility of other
virulence-modulating factors.
Individuals can be colonized by either a single or multiple strains of H.
pylori, and even colonization by what is initially a single strain can, over
time, lead to the emergence of multiple H. pylori subpopulations, due
variously to mutation or to genetic recombination either between
duplicate sequences in the single strain's genome or with DNAs from
other transiently colonizing strains [268]. The prevalence of such mixed
infections has been reported to vary (5-68%) [264,271-274], depending
on geographical region, whether in a developed or developing country
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(low and high overall infection risk, respectively), and probably also
methods of analysis. The H. pylori virulence-associated vacuolating
cytotoxin (vacA) and cag pathogenicity island (cagPAI) genes, and also
the cag empty site in strains lacking the cagPAI, are typically found in
only one copy per genome [105,274-276]. Accordingly, detection of both
the cagA gene and the cag empty site, or of both sl and s2 (signal
sequence; at 5' end of gene) or both m1 and m2 (middle region) alleles of
vacA in a biopsy or in pool of H. pylori from a person indicates mixed
infection.
We speculated if having mixed infection might influence the risk of gastric
disease; for example, if strains of different genotypes might occupy a
broader range of niches in the stomach as has been seen during
experimental infection [253] and thereby impact on clinical outcome. In
this chapter, we investigated the genotypes of H. pylori in The Gambia
and the relation of apparently single versus mixed infections to gastro-
duodenal diseases. Biopsy samples used for this study were collected
from only the antrum of subjects. Although our primary aim was to look
at variation within single biopsies, using both antral and body biopsies
would have been more optimal to determine H. pylori strains that colonize
different regions of the stomach. However, some Gambian subjects were
happy to allow research biopsies from different regions of the stomach.
Others consented to a single additional research biopsy, which was taken
from the gastric antrum, the preferential site for H. pylori colonisation
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[62]. As we only had a complete set of antral biopsies, we therefore only
included biopsies collected from the gastric antrum in this chapter.
5.2 Results
5.2.1 Gastroscopy results of all patients referred for endoscopy
Clinical data from the MRC Unit in The Gambia revealed that of 428
patients with gastric complaints investigated by gastric endoscopy
between 2003-2008 (figure 3.1), 8 (1.9%) had gastric carcinoma, 20
(4.7%) and 15 (3.5%) had gastric and duodenal ulcers respectively, and
that the others (89.9%) did not have such overt disease (diagnosed as
non-ulcer dyspepsia (NUD) as shown in table 5.1.
Table 5.1 Endoscopy results of patients
Disease No 0/0
Gastric ulcer 20 4.7
Duodenal ulcer 15 3.5
Gastric erosion 9 2.1
Gastric cancer 8 1.9
Gastritis (endoscopic appearance)* 256 59.8
Normal gastric tract appearance* 93 21.7
Oesophagitis* 20 4.7
Oesophageal ulcer* 4 0.9
Oesophageal cancer* 2 0.5
Duodenal diverticulitis* 1 0.2
Irotal 428 100
=Non-ulcerative gastric diseases (NUD) = gastritis, oesophagitis,
oesophageal ulcer, oesophageal cancer, duodenal diverticulitis or normal
appearance of gastric tract
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5.2.2 Gastroscopy results of study subjects
Endoscopic examination showed that of the 121 study subjects whose
biopsies tested positive for H. pylori (figure 3.1, table 5.2), 11 had gastric
ulcer (GU), 7 had duodenal ulcer (DU), 1 had both gastric and duodenal
ulcers, 7 had gastric erosions (GE), 1 had gastric carcinoma (GC) and all
other subjects (94) who presented with either abdominal pain or
dyspepsia had no evidence or history of gastric or duodenal ulcers.
Table 5.2 Gastroscopy results of 121 patients
Disease Number 0/0
Non-ulcerative disease (NUD) 94 78
Gastric ulcer (GU) 11 9
Duodenal ulcer (DU) 7 6
Gastric erosion (GE) 7 6
Gastric & Duodenal ulcer (G+DU) 1 1
Gastric cancer (GC) 1 1
Total 121 100
Our previous data (Chapter 4) demonstrated that in The Gambia
detection of mixed isolates in individual biopsies was best undertaken by
PCR amplification directly from biopsy material rather than by bacterial
culture (Secka 0 Gut 2011). Consequently, the analyses in this chapter
were based only on DNAs amplified directly from biopsy samples.
5.2.3 Prevalence of H. pylori genotypes
One hundred and twenty one patients of the 169 study participants
(figure 3.1) were inferred to be infected with H. pylori when DNAs
extracted from their biopsies were tested by PCR for the presence of H.
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pylori cagA gene and cag empty site. Seventy four biopsies (61.20/0) were
positive for the cagA gene only, 21 (17.4%) were positive for the cag
empty site only and 23 (19%) were positive for both. In parallel we also
tested for the vacA gene presence and allele types. In all, 93 of 121
(76.9%) were positive only for the vacA51 allele, 23 (19.0%) were
positive only for the vacA52 allele and 1 (0.8%) was positive for both.
Only m1 or only m2 alleles of vacA were detected in SS (45.5%) and 36
(29.8%) of biopsies tested respectively; both m1 and m2 (mixed
infections) were found in 22 (18.2%) biopsies and up to 6.6% of biopsy
DNAs failed to amplify for individual alleles (table 5.3).
Table 5.3 Prevalence of H. pylori genotypes
H. pylori genotypes n %
cagA+ 74 61.2
cagA- 21 17.4
cagA+ & cagA- 23 19.0
No amplification of cagA or cag empty site 3 2.5
51 93 76.9
52 23 19.0
51 &52 1 0.8
no amplification of 51 or 52 4 3.3
m1 55 45.5
m2 36 29.8
m1 &m2 22 18.2
No amplification of m1 or m2 8 6.6
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5.2.4 Association between H. pylori genotypes
Of the 93 H. pylori strains that were positive only for vecasi, 72 (77.40/0)
were cagA positive compared with only 1 (4.3%) cagA positive among the
23 strains that were positive only for vacA52; most (16) of them
contained the cag empty site allele only (table 5.3). Similarly, nearly all
51m1 positive biopsies (92.5%) contained cagA genes, whereas none of
those containing only vacA 52m2 allele were cagA positive (table 5.4).
Table 5.4 Association of vacA with cagA Helicobacter pylori
genotypes
cagA+ cagA- cagA+ & Incomplete
ceaa: cagA
H. pylori n (%) n (%) n (%) n (0/0) Total
genotypes
51m1 49 (92.5) 1 (1.9) 3 (5.7) 0 (0) 53
51m2 9 (SO) 3 (16.7) 5 (27.8) 1 (5.6) 18
52m2 0 (0) 16 (88.9) 2 (11.1) 0 (0) 18
52m1 0 (0) 0 (0) 0 (0) 0 (0) 0
51m1m2 12 (66.7) 0 (0) 6 (33.3) 0 (0) 18
5152m1m2 0 (0) 0 (0) 1 (100) 0 (0) 1
52m1m2 0 (0) 0 (0) 3 (100) 0 (0) 3
Incomplete 4 (40) 1 (10) 3 (30) 2 (20) 10
VacA
Incomplete cagA=cagA and cag empty site were not detected
Incomplete vacA=either vacAs or vacAm regions were not detected (4/10 vacAsl was
detected & vacAm was missing, 2/10 vacAs2 detected and vacAm missing, 2/10 vacAml
detected and vacAs missing and for 2/10 both vacAs and vacAm were missing).
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5.2.5 Association of H. pylori virulence genes with upper gastric
diseases .
cagA positive H. pylori strains were found more frequently among study
participants with gastroduodenal diseases than those with NUD: duodenal
ulcers (6/7; 85.7%), gastric erosions (5/7, 71.4%), gastric ulcers (8/11,
73%); no overt gastric disease (53/94, 56.4%; (tables 5.5 and 5.8).
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5.2.6 vacA alleles and clinical outcome
Toxigenic slml alleles were found in 6 of the 11 (54.5%) patients
diagnosed with gastric ulcer, 42.9%, 42.9% and 42.6% in those with
duodenal ulcers, gastric erosions and NUD, respectively (table 5.6). The
prevalence of vacA alleles were similar in the two groups of patients;
overt disease vs. NUD. That is, no association was found between vacA
alleles and clinical outcome (p=O.94, tables 5.6 and 5.7).
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Table 5.7 Association between vacA genotypes and clinical
outcome
Overt gastric disease NUD
H. pylori genotypes n % n %
51m1 13 48.1 40 42.5
51m2 3 11.1 15 16.0
52m2 5 18.5 13 13.8
51m1m2 4 14.8 14 14.9
5152m1m2 0 0 1 1.1
52m1m2 0 0 3 3.2
§Incomplete vacA 2 7.4 8 8.5
Total 27 100 94 100
§Incomplete vacA=either vacAs or vacAm regions were not detected (4/10 vacAs1 was
detected & vacAm was missing, 2/10 vacAs2 detected and vacAm missing, 2/10 vacAm1
detected and vacAs missing and for 2/10 both vacAs and vacAm were missing).
Overt gastric disease = DU=duodenal ulcer, GC=gastric carcinoma, GE=gastric
erosion, GU=gastric ulcer, GUDU=gastric ulcer and duodenal ulcer
NUD = gastritis, oesophagitis, oesophageal ulcer, oesophageal cancer, duodenal
diverticulitis or normal appearance of gastric tract
5.2.7 cagA status and clinical outcome
In the 27 patients with overt gastric disease, 77.8% were cagA positive
compared to 56.4% of those with NUD (p-value=O.Os, tables 5.5 and
5.8). Mixed colonisation (figure 5.1) was only found in the group of
patients diagnosed with non-ulcerative dyspepsia (NUD).
Table 5.8 cagA and clinical outcome
Overt gastric NUD
disease
cagA status n % n %
cagA+ 21 77.8 53 56.4
cagA- 6 22.2 15 16.0
cagA+& cagA-- 0 0 23 24.5
no amplification 0 0 3 3.2
Total 27 100 94 100
Overt gastric disease = DU=duodenal ulcer, GC=gastnc carcmorna,
GE=gastric erosion, GU=gastric ulcer, GUDU=gastric ulcer and duodenal ulcer
NUD = gastritis, oesophagitis, oesophageal ulcer, oesophageal cancer, duodenal
diverticulitis or normal appearance of gastric tract
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Mixed infections were inferred based on three possible criteria (detecting
both cagA+ and cagA-, detecting both vecas: and 52, or detecting both
vacAm1 and m2). Twenty two or 23 patients had mixed infections,
depending on which gene was analyzed (figure 5.1).
Figure 5.1 H. pylori multiple genotypes
SOObp
M=100bp ladder, H. pylori DNA
from this patient amplified for
all H. pylori genes tested. This
patient carried multiple H. pylori
strains that were cagA+slml
and cagKs2m2.300bp
For cagA gene, 23 patients were considered to have mixed infections
(cagA positive and cagA negative). Of these with cagA mixed infections,
10 were also positive for both m1 and m2 alleles of vacA and only one
individual considered to have mixed infection for cagA gene was positive
for both 5152 alleles.
Conversely, 12 individuals who were considered to have mixed infection
for vacAm1 and m2 alleles were only positive for either cagA or cag
empty site.
All 27 subjects with overt gastric diseases (table 5.8) were of uniform
cagA status (that is, uniquely cagA gene positive or cag empty site
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positive, figures 5.2 and 5.3), whereas only 72.3% (68/94) of NUD were
of uniform status; the other 23 contained mixed (cagA positive, cag
empty site positive) infections (figure 5.1).
Figure 5.2 Single H. pylori strain
that is cagA+slml
Figure 5.3 Single H. pylori strain
that is cagA-s2m2
300bp
500bp500bp
300bp
M=100bp ladder, H. pylori DNA
from this patient amplified for
cagA, sl and m1. This patient
carried a single H. pylori virulent
strain (cagA+s1m1)
M=100bp ladder, H. pylori DNA
from this patient amplified for
cag emptysite, s2 and m2. This
patient carried a single H. pylori
non-virulent strain (cagks2m2).
Three other biopsy samples did not give cagA gene or cag empty site
amplification (table 5.8). This association between uniform cagA status
and overt disease was statistically significant (p=0.002).
5.2.8 Association between age and clinical outcome
Higher prevalence of overt disease was found in those subjects that were
over 40 years of age. Conversely subjects between 30-40 years had less
overt diseases. However, across the entire trend of age distribution, no
significant association was found between age and overt gastric disease
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(24.5% <30 years, 12.5% 30-40 years and 27.8% >40 years; p-
value=0.26, table 5.9).
Table 5.9 Association between age and clinical outcome
Overt disease NUD
Age groups n (0/0) n (0/0) Total
<30 years 13 (24.5) 40 (74.5) 53
30-40 years 4 (12.51 28 187.51 32
>40years 10 (27.8) 26 172.21 36
p-value=0.26
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5.2.9 Association between age and mixed infection
For mixed infections, subjects that were over 40 years were found to
habour strains that were both cagA positive and cagA negative. However,
there was no association between age and frequency of mixed infection
(15.1 % <30 years, 18.8% 30-40 years, 25% >40 years; p-value=0.46,
table 5.10).
Table 5.10 Association between age and mixed infection
Mixed cagA Uniform cagA status
{cagA+ &. cagA-} {cagA+ or cagA-}
Age groups n (%) n (%) Total
<30 years 8 (15.1) 45 (84.9) 53
30-40 years 6 (18.8) 26 (81.2) 32
>40years 9 (25.0) 27 (75.0) 36
p-value=0.46
5.3 Discussion
H: pylori infection is common in dyspeptic adults in The Gambia [19,277],
as is typical of developing countries. The range of H. pylori genotypes
implicated in overt gastroduodenal disease as opposed to benign
colonization or possibly even beneficial carriage [269] had not been
extensively investigated in Sub-Saharan Africa. Here we studied the
distribution of H. pylori's main virulence genes, cagA and toxigenic alleles
of vacA, in The Gambia, and their possible associations with disease
outcome.
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The prevalence of gastroduodenal disease (10%) that we detected
endoscopically is similar to that reported elsewhere in Sub-Saharan Africa
[75] and may be lower than that in Europe and North America. In The
Gambia, gastric carcinoma reported from patients who attended the only
endoscopy unit in the country was 1.9% similar to what was reported in
some sub-Saharan countries such as Ivory Coast (2%) and Cameroon
(30/0) but lower than the 6.6% reported in Kenya [75]. However, these
estimated prevalences should be interpreted with caution as they may not
be representative of the general population, but instead indicate the
prevalence of disease among people with gastric complaints of sufficient
severity to prompt diagnostic endoscopy.
We found that just over half of biopsy DNA (61.2%) carried the cagA
gene (table 5.3) similar to the 61.6% found in Tunisia [278]; and that
mixed infections (both cagA positive and cagPAI negative) were common.
Multiple vacA genotypes (m1 and m2) were also found in 22% of our
study populations similar to the 18% reported in Korea [279] but higher
than the 7% reported in Ethiopia [61]. High prevalences of mixed vacA
genotypes (31 %) were reported in a study in Tunisia [278]. .
We also found toxigenic vacAs1 and m1 alleles to be abundant in this
study, but not universal (76.9% and 45.5%) similar to the 88.5% sl and
57% m1 reported in Ethiopia [269]. In contrast, most H. pylori strains
from Egypt carried vacAs2 and m2 alleles, (57.1% and 85.70/0,
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respectively) [269], whereas some 90% or more of strains in Japan,
coastal China, and India carried vacA51 alleles [21,280,281]. vacAm1
type alleles were also nearly universal in Japanese main island strains,
Whereas vacAm2 strains were predominant in coastal China (81%)
[281,282]. In this study, most of the vacA51 strains (77.4%) were cagA
Positive similar to what was observed in a study in South Africa (90%)
[109].
Up to 6.6% of samples in this study failed to amplify for individual genes
consistent with other findings [109,258,263], perhaps due to PCR
inhibitors or potent nucleases in some gastric biopsies as also suggested
previously [109,263,277].
Thus, our data reinforce conclusions that different H. pylori genotypes,
especially types of genes or alleles implicated in virulent vs. benign
infections, predominate in different human populations. Strains of the
vacA 51m2 type were most common in coastal China (81%), and also
seemed to predominate in Southern Nigeria (74%) [170]; and both 51m2
(200/0) and 52m2 (20%) allele types were abundant in South Africa [109].
This contrasts with the predominance of vacA 51m1 strains found in our
Gambian study participants. This apparent difference between Nigerian
and Gambian strain genotypes could have several explanations, including
the distance separating these two West African countries (>3000 km), or
clima_~icdifferences (high rainfall and humidity in Southern Nigeria vs
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aridity for much of the year in The Gambia). Such explanations would
entail genetic divergence by random genetic drift and selection for
adaptation to local conditions respectively.
Previous reports of a lower than expected prevalence of H. pylori
associated disease in Africa [62,115,209] might in principle reflect the
influence of bacterial and/or human genotypes, environment including
other infections (e.g. parasitic infections that affect host response to H.
pylori), normal gut microbiota, diet (including anti-oxidants, salt, spices)
or likelihood of seriously ill persons being diagnosed and their cases
entered in registries. In accord with this last explanation, have been
suggestions that gastroduodenal disease is actually common in Africa,
that there is no African enigma [79,80]. Until recently, life expectancy in
Africa was relatively short compared to developed countries and because
of this, the prevalence of gastric cancers and other gastroduodenal
diseases which are diseases that develop in later life would be expected to
be low. This coupled with poor maintenance of cancer case registries,
under reporting of cases and limited access to health care facilities for
most of the populations in Africa may have led to the concept of the
"African enigma". As more populations get access to standard medical
care and life expectancy increasing, prevalence rates of gastroduodenal
diseases have been found to be similar to what was reported in
industrialized countries [79].
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The cagA gene and vacAs1 and m1 alleles are often linked to severe
disease, and the vacAs2 and m2 alleles with more benign infections
(gastritis only) in other populations. This is partially reflected in our
results: with respect to cagA we did not find a "Gambian-H. pylori
virulence gene" enigma similar to what was reported in Senegal [283];
disease associations with vacA were less clear cut in accord with reports
from Sweden [284]. The possible effects of bacterial or human genetic
and physiologic differences, food, history of other infections and other
environmental and lifestyle factors, on outcomes of chronic H. pylori
infections in sub-Saharan Africa merit further more detailed analyses.
Most important, was our finding that co-existence of cagA positive and
cagA negative strains was significantly more common amongst patients
with NUD than among those with overt disease, which suggests that
mixed colonization is protective. In principle, protection against
development of overt gastric disease might stem from simple competition
- whereby carriage of a less virulent (cagA-negative) strain diminishes
the vigour of growth of a coexisting virulent strain, thereby reducing its
impact on host tissues. It is also possible that factors in cagA-negative
strains that diminish the impact of virulence proteins such as CagA might
predominate during cagA-positive and cagA-negative mixed infections
[285]. Or, more generally, an increased complexity of immune responses
during chronic infection by multiple divergent H. pylori strains might
effectively diminish the inflammatory action of an individual virulent
118
strain, and thereby resultant pathology in host tissues, as noted with
other infections [286-289]. In accord with this idea, the risk of developing
overt disease seemed higher in subjects apparently colonized only with
cagA negative H. pylori, than in those with mixed cagA positive and
negative strains.
Further, the shift in the dominant strain seen in mixed infection due
mainly to either recombination and/or mutation [186] may also help the
bacteria to evade cellular responses by presenting antigenic variation and
diversity [290].
Conversely, however, the presence of mixed infections might also stem
from increased intrinsic host susceptibility to H. pylori infection and
equally the development of a more severe clinical outcome [291-293].
5.4 Conclusion
This study has revealed frequent gastro-duodenal disease among
Gambians with gastric complaints. Many strains carried cagA+ and 51, m1
alleles of vacA, which are disease associated in many European and North
American populations. Although cagA status was associated with disease
in The Gambia, alleles of vacA were not. Comparison of our data with
those from southern Nigeria pointed to a potentially significant difference
in linkage of signal sequence (51 vs. 52) and middle region (m1 vs. m2)
alleles, which control the potency and tissue specificity of toxin action
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respectively (51m1 most common in The Gambia, vs. 51m2 most common
in Nigeria). The possibility that such differences reflect selection for
optimal genotypes or random genetic drift in these well-separated West
African nations merit further study. We suggest that our most interesting
finding is the significantly lower disease burden in Gambians infected with
a mixture of cag-positive and cag-negative strains, relative to those
containing only cag-positive or only cag-negative strains. The possibility
that repeated exposure to colonisation by H. pylori would be beneficial in
Sub-Saharan Africa and in developing countries more generally needs to
be considered when developing more effective strategies for treating H.
pylori infection and thus altering the risks of gastroduodenal disease
[294].
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Chapter 6 Population Genetic Analyses of Helicobacter pylori
Isolates from Gambian Adults and Children.
6.1 Introduction
H. pylori is a genetically diverse Gram negative micro-aerophilic bacterial
species that chronically infects some half of all humans worldwide, and in
particular, most people in developing countries [295]. It is implicated in
chronic gastritis, gastroduodenal ulcers and gastric cancer [70,296] and
also increased risk of infection by diarrheal pathogens [141], infant
malnutrition and growth faltering [251] in low income societies, although
most infections are benign, and some may be beneficial [162,297]. The
risk of infection resulting in overt disease is likely determined by H. pylori
genotype in combination with other variables such as human genotype
and physiology, nutrition and environmental factors.
H. pylori is usually acquired in childhood [298] and can persist for life
unless eradicated by antibiotics [68]. A prevalence of ~ 80% is typical in
developing countries [19,62,63,299], but has become far lower during the
last century in industrialized countries (around 20%), probably due to
dramatic improvements in hygiene and sanitation [100]. Transmission is
predominantly intrafamilial with a low risk of adult infection in
industrialized countries [89,101], whereas transmission within the local
Community is more frequent in developing countries, and often to adults
as well as children, probably reflecting imperfect sanitation and hygiene in
these societies.
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Independent H. pylori isolates typically differ by some 2% or more in DNA
sequence, allowing different strains to be distinguished readily by
sequencing of one or more housekeeping genes [181]. This pathogen's
great genetic diversity is also readily detected by the arbitrarily primed
peR (RAPD) method, wherein each strain yields a characteristic pattern of
DNA fragments, different from those of nearly all other independent
isolates [300]. In addition, DNA sequencing-based analyses (e.g.
MultiLocus Sequence Typing, MLST) have shown that different sets of
genotypes predominate in different human populations or geographic
regions, such as East Asia and Western Europe [159,160]. This great
diversity within and between populations can be ascribed to H. pylori
having chronically infected humans for many thousands of years, with
transmission being predominantly within families or local communities.
This epidemiologic pattern allows considerable random genetic drift and
selection for locally adapted genotypes. H. pylori's genetic diversity is
further enhanced by frequent mutation and recombination between
strains during mixed infection [301]. MLST of seven housekeeping genes
from strains from many parts of the world had identified seven H. pylori
populations, designated hpEurope, hpEastAsia, hpAsia2, hpSahul,
hpAfrical, hpAfrica2 and hpNEAfrica [159,160,208]. Of particular
importance to the analyses of Gambian H. pylori strains presented here,
MLST analyses readily distinguished African strains (hpAfrical, hpNEAfrica
and hpAfrica2) from those of Europe and Asia and further subdivided
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hpAfrical strains into two subpopulations: hspWAfrica (West) and
hspSAfrica (South), the former also found in South Africa at low
frequency. The distribution of hspWAfrica, hspSAfrica and hpNEAfrica
populations may reflect the expansion of the Bantu people throughout the
African continent over the last 4000 years from an ancestral homeland in
or near present day Nigeria. The Bantu migrations from Central West
Africa (present day Cameroon/Nigeria) structured the hpAfrical
population into West African and South African subpopulations. In
contrast to that, hpNEAfrica has mainly been isolated from Nilo-Saharan
speakers.
The great majority of present Gambians come from indigenous West
Africans, and of the predominant Mandinka, Wollof and Fulani linguistic
groups, which are also abundant in nearby countries of Senegal, Guinea
Bissau, Guinea Conakry and Mali. Most Gambians are Muslims, reflecting
conversion of the resident population by Arab traders who began crossing
the Sahara from North East Africa in the ath century. Given the tendency
of H. pylori's populations to track with human host population, it is also
noteworthy that for several centuries, The Gambia was also a major
SOurce of slaves taken to The Americas and also to Europe until the slave
trade was abolished in la07. This story implies that Gambian H. pylori
strains may well have contributed significantly to H. pylori's gene pool in
The Americas and perhaps Europe as well. Indeed, a suggestion of West
Africa!'" admixture in European H. pylori had emerged in our early study of
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a novel regulatory gene-linked insertion-deletion polymorphism (indel) in
Spanish vs. Gambian H. pylori strains [302].
It is with this background that we carried out MLST of H. pylori strains
from ethnic African adults and children in The Gambia. This H. pylori
population is likely to be broadly representative of strains throughout
much of West Africa, a relatively unstudied population, and as noted a
contributor to the H. pylori gene pool in Europe and The America.
6.2 Patients
The patients selected for this study belonged to the following ethnic
groups: Mandinka (19), Wollof (11), Jola (6), Fulani (5), Sarahule (4)
Serere (1).
6.3 Sample choice for MLST
Samples were chosen simply according to successful subculture of
individual H. pylori colonies. One or more single colonies were isolated
from each of 44 patients and used for these analyses (figure 3.1). The 44
Patients (23 male and 21 female) ranged in age from 18 months to 72
years (mean 32 years) and had the following clinical manifestations:
gastritis (23), normal gastric endoscopic appearances (6), gastric erosions
(6), gastric ulcer (3), and oesophageal ulcer (1). Five of these patients
Were from malnourished children with enteropathy (ages 18-31 months,
mean 19 months). Thirty three patients (75%) were from the Greater
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Banjul (urban) Area (GBA) and 11 (25%) were from rural villages: [(LRR
(6), WCr (4), NBR (1)].
To look for genetic heterogeneity in the same stomach, several single
colonies from each of two patients were tested by MLST. From one
subject (14 years of age) with normal gastroduodenal tract appearance by
endoscopy, seven colonies were analysed (4 antrum and 3 body). From
the other subject (72 years of age), also with normal gastroduodenal tract
appearance by endoscopy, 11 single colonies (6 antrum and 5 body) were
sub-cultured and analysed.
6.4 Results
6.4.1 Allelic frequency and nucleotide analyses
DNAs from H. pylori strains from 44 Gambians (one strain/patient in 43
cases; three strains/patient in one case) yielded 42 unique MLST
sequence types based on concatenated DNA sequences of seven house-
keeping gene loci. There were four pairs of strains that yielded identical
MLSTs. The two members of each pair were also identical by RAPD and
Virulent gene profiles (figure 6.1 and table 6.1). One pair was from
consecutive unrelated patients, whose biopsy samples were taken on the
same day. The other three pairs were from patients who had their biopsy
samples taken between a week and two years apart.
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Figure 6.1: RAPD profiles of samples with same MLST type
RAPD profiles
MAAB.BCCDDP
M=100bp DNA ladder, P= 1kb DNA ladder.
Paired letters indicate RAPDtypes of patients
with same MLST type
Table 6.1 Virulent genes of samples with same MLST types and
RAPD profile
Lab cagA Empty m1 m2 sls2 MLST RAPD
number site type types
Hp42 + - + - 1 2034 A
Hpl12 + - + - 1 2034 A
Hp71 - + - + 2 2035 B
Hp72 - + - + 2 2035 B
Hp250Ap + - + - 1 2062 C
Hp252Bp + - + - 1 2062 C
Hp268Bi + - + - 1 2040 D
Hp260AFi + - + - 1 2040 D
6.4.2 Allelic frequency
These exceptions aside, most alleles from the 46 strains occurred only
once, although identical alleles were found in between 11 to 16 of the
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strains, depending on the gene. Except for the four pairs of strains noted
above, which were identical at all loci, no other pair of strains identical at
one locus was identical at another of the seven loci tested (table 6.2).
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Table 6.2 Alleles and sequence types of H. pylori isolates
House- keepin Q genes and allele t ,pe
Sample atpa efp muty p]!a trpc urel yphC MLST type
1* 1810 1703 1774 1761 1852 1891 1887 2034
2* 1810 1703 1774' 1761 1852 1891 1887 2034
3* 1811 1656 1823 1762 1853 1892 1888 2035
4* 1811 1656 1823 1762 1853 1892 1888 2035
5 1812 1704 1824 1763 1854 1893 1889 2036
6 1813 1705 1825 1764 1855 1894 1890 2037
7 1814 1706 1826 1765 1856 1895 1891 2038
8 1815 1708 1828 1767 1858 1897 1893 2039
9* 1815 1729 1848 1774 1877 1919 1915 2040
10* 1815 1729 1848 1774 1877 1919 1915 2040
11 1816 1709 1829 1768 1859 1898 1894 2041
12 1817 1710 1830 1769 1860 1899 1895 2042
13 1818 1711 1831 1770 1861 1900 1896 2043
14 1818 1728 1847 1788 1876 1918 1914 2044
15 1819 1712 1832 1771 1862 1901 1897 2045
16 1820 1713 1833 1772 1863 1902 1898 2046
17 1820 1723 1774 1800 1888 211 1898 2047
18 1821 1714 1834 1773 1864 1903 1899 2048
19 1822 1715 1835 1774 1865 1904 1900 2049
20 1823 1716 1836 1775 1865 1905 1901 2050
21 1824 1717 1774 1776 1866 1906 1902 2051
22 1825 1703 1837 1777 1867 1907 1903 2052
23 1826 1718 1838 1778 1868 1908 1904 2053
24 1827 1719 1839 1779 1869 1909 1905 2054
25 1828 1720 1840 1780 1870 1910 1906 2055
26 1829 1721 1841 1781 1871 1911 1907 2056
27 1830 1722 1842 1782 1872 1912 1908 2057
28 1831 1723 1774 1783 229 1913 1909 2058
29 1832 1724 1843 1784 1873 1914 1910 2059
30 1832 1732 1850 1791 1880 199 1918 2060
31 1833 1725 1844 1785 1860 1915 1911 2061
- 32* 1834 1726 1845 1786 1874 1916 1912 2062
i-. 33* 1834 1726 1845 1786 1874 1916 1912 2062
i-. 34 1835 1727 1846 1787 1875 1917 1913 2063
35 1836 1730 1849 1789 1878 1912 1916 2064
36 1837 1731 1846 1790 1879 1920 1917 2065
37 1838 1733 1851 368 1881 1921 1898 2066
38 1839 1734 1852 1793 1881 1922 1919 2067
39 1840 1700 1853 1794 1882 1923 1920 2068
40 1841 1736 1854 1795 1883 1924 1921 2069
i- 41 1842 1737 1855 1796 1884 1925 1922 2070
i- 42 1843 1738 1846 1797 1885 1892 1923 2071
..._ 43 1844 1739 1856 1780 1870 1926 1924 2072
44 1845 1740 1823 1798 1886 1910 1925 2073
45 1846 1741 1857 1799 1887 1927 1926 2074
"- 46 1847 1707 1827 1766 1857 1896 1892 2075
*lndlcates four pairs of samples with identical MLST types
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The gene trpC had most samples with identical alleles (16) but allele 1774
of mutY was most frequent with 5 occurrences (10.90/0, table 6.3). No
deletions or insertions were found in this data set for all the analysed
hosekeeping gene fragments.
Table 6.3 Frequency of alleles
Gene allele Frequency 0/0
1810 2 4.3
1811 2 4.3
1815 3 6.5
atpa 1818 2 4.3
1820 2 4.3
1832 2 4.3
1834 2 4.3
1656 2 4.3
1703 3 6.5
efp 1723 2 4.3
1726 2 4.3
1729 2 4.3
1774 5 10.9
1823 3 6.5
mutY 1845 2 4.3
1846 3 6.5
1848 2 4.3
1761 2 4.3
1762 2 4.3ppa 1774 3 6.5
1780 2 4.3
1786 2 4.3
1852 2 4.3
1853 2 4.3
trpC
1860 2 4.3
1865 2 4.3
1870 2 4.3
1874 2 4.3
1877 2 4.3
1881 2 4.3
1891 2 4.3
1892 3 6.5
1910 2 4.3ureJ 1912 2 4.3
1916 2 4.3
1919 2 4.3
1887 2 4.3
1888 2 4.3
yphC 1898 3 6.5
1912 2 4.3
1915 2 4.3
129
6.4.3 Analyses of selection
Mutation by nucleotide substitution in the coding region may result in no
change in protein sequence (synonymous) or an amino acid change (non-
synonymous). Estimating the diversity between Gambian isolates, we
used the average number of synonymous and non-synonymous changes
per site (ds, dn) of the 7 loci (table 6.4). The ratio of these two types in a
population reflects genetic drift and selection operating on individual
genes. Since all dn/ds, values were close to zero; this indicates a high
degree of selection to maintain amino acid sequence and function of the
encoded protein. This is as expected for genes whose encoded proteins
act within bacterial cells and provide important housekeeping functions.
The most diverse gene was trpC (mean nucleotide level diversity 4.6%)
and the least diverse was ureI (1.20/0, table 6.4).
Table 6.4 Diversity between Gambian isolates
Locus dn ds dn/ds Diversity
(0/0)
atpA 0.0006 0.1009 0.006 2.3
efp 0.0005 0.1059 0.0046 2.2
mutY 0.0098 0.1822 0.0536 4.5
ppa 0.0116 0.042 0.2761 2.1
trpC 0.0187 0.1513 0.1238 4.6
ureI 0.0052 0.0365 0.1428 1.2
yphC 0.0092 0.0924 0.0995 3.4
overall 0.0079 0.1016 0.1009 2.9
ds and dn: the average number of synonymous substitutions per synonymous
site and non-synonymous substitutions per non-synonymous site, respectively.
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6.4.4 Phylogenetic analysis
A phylogenetic tree formed using concatenated sequences of the seven
housekeeping genes we used for MLST (figure 6.2) reflects a mean
nucleotide level diversity of 2.9% (table 6.4).
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Figure 6.2 Evolutionary relationships of H. pylori strains from The
Gambia
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The evolutionary history was inferred for 46 nucleotide sequences using
the Neighbor-Joining method. The analyses were conducted in MEGAS.
The five strains from young children are identified with green balls.
There was one subject with three different MLST types shown in red
squares.
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There was no evidence of association of particular clusters of strains in
this tree (clades) with variables such as age of participant at time of
endoscopy, endoscopic diagnosis, sex, tribe or district of residence within
the Gambia (figures 6.3-6.6). However, cagA+ strains seemed to cluster
separately from cagA- (figures 6.7 and 6.8).
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Figure 6.3 Distribution of diseases vs MLST types
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Distribution of diseases was inferred for 46 nucleotide sequences using
the Neighbor-Joining method. The analyses were conducted in MEGAS.
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Figure 6.4 Distribution of sex vs MLST types
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Distribution of sexes was inferred for 46 nucleotide sequences using the
Neighbor-Joining method. The analyses were conducted in MEGAS.
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Figure 6.5 Ethnicity and MLST types
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Ethnicity was inferred for 46 nucleotide sequences using the Neighbor-
Joining method. The analyses were conducted in MEGAS.
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Figure 6.6 Place of residence in The Gambia vs MLST types
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Place of residence was inferred for 46 nucleotide sequences using the
Neighbor-Joining method. The analyses were conducted in MEGA5.
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Figure 6.7 cagA distribution of strains
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CagA distribution was inferred for 46 nucleotide sequences using the
Neighbor-Joining method. The analyses were conducted in MEGAS.
The percentage of replicate trees in which the associated taxa clustered
together in the bootstrap test (2000 replicates) are shown next to the
branches.
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6.4.5 Cluster analysis of strains from other countries
The Gambian strain data were compared with data from H. pylori strains
selected randomly from other informative human populations (African,
European and Asian, table 6.5) using neighbor joining and cluster analysis
with both the admixture and no-admixture models of STRUCTURE.
Table 6.5 Selected H. pylori populations from MLST data base
Country hpAfrica1 hpNEAfrica hpEurope hpEAsia hpAfrica2 hpSahul hpAsia2
Burkina Faso 11 a a a a a a
Senegal 5 a a a a a a
Nigeria a 8 a a a a a
Algeria 1 1 2 a a a a
Egypt a a 3 a a a a
Ethiopia a 7 a a a a a
Morocco 5 a 2 a a a a
Somalia a 2 a a a a a
Spain a a 33 a a a a
South Africa 8 a a a 16 a a
Japan a a a 24 a a a
Finland a a 9 a a a a
Estonia a a 11 a a a a
Kazakhstan a a a a a a 1
I-Malaysia a a a a a a 1
Philippines a a a a a a 3
Thailand a a a a a a 4
Papua a a a a a 7 a
~ewGuinea
Australia a a a a a 5 a
Netherlands a a a a a a 1
Jotal 3a 18 6a 24 16 12 la
The Gambian H. pylori strains were closely related to but not intermingled
With 14 strains from Burkina Faso, about 1600Km to the East of the
Gambia, and also to the five available isolates from Senegal which
borders The Gambia in all but its ocean side (figures 6.8 and 6.9).
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Figure 6.8 Evolutionary relationship of global strains showing
country of origin
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The Neighbor Joining tree was calculated from concatenated sequences of
seven housekeeping genes (3406 bp) from 128 isolates of H. pylori
downloaded from mist website (Http://pubmlst.orq/Helicobacter) plus 46
isolates from this study. The strains were colour-coded according to
country of origins.
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Figure 6.9 Evolutionary relationship of global strains showing
population
•
o
• =Gambian cagA+
o =Gambian cagA-
• =hspWAfrica
o = hspSAfrica
• =hpNEAfrica
6 =hpEurope
• =hpEAsia
... = hpAfrica2
0.01
The Neighbor Joining tree was calculated from concatenated sequences of
seven housekeeping genes (3406 bp) from 128 isolates of H. pylori
downloaded from mist website (Http://pubmlst.org/Helicobacter) plus 46
isolates from this study. The strains were colour-coded according to
Populations.
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With the no-admixture model, almost all Gambian isolates formed a
homogeneous group that belonqed to hpAfrica 1 (figure 6.10A) essentially
with no traces of European or North African ancestry despite Gambia's
history of invasion and colonisation by peoples from these regions during
the last millennium. With the admixture model, the proportion of other
ancestral nucleotides in Gambian strains was lower than the hpAfrica1
group (hspWAfrica and hspSAfrica, figure 6.10B). Most Gambian strains
Were clearly distinct from (although related to) strains of the hspSAfrica
and hpNEAfrica populations (figures 6.10A and 6.10B) and also to other
hspWAfrica strains from North Africa (figure 6.10B). We only found one
isolate with significant evidence of European ancestry in a 57 year old
female (figure 6.10B).
Figure 6.10 No-admixture model (6.10A) and admixture model
(6.10B) of Gambian isolates compared with previously assigned
populations.
A
Noadmixture
model; k==4
B
Admixture
model; k==4
~igure 6.10A: Noadmixture model of seven populations and Gambian isolates. Each
Isolate is represented by a thin line that is colour coded according to the population
assignment.
Figure 6.10B: Admixture model of seven assigned popultions and Gambian isolates.
Each isolate is represeneted by a thin line that indicates the estimated amount of
ancestry from each of the seven ancestral populations.
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Further STRUCTUREanalysis of Gambian with hspWAfrica and hspSAfrican
strains showed that with the admixture model, Gambian strains were
closely related to hspWAfri,ca and less closely related to strains from more
distant African regions (figure 6.11).
Figure 6.11 Admixture model of Gambian isolates compared with
hspWAfrica and hspSAfrica.
Admixture model of Gambian isolates compared with previously assigned populations
(hspWAfrica and hspSAfrica). Each line represents an isolate colour coded according to
the assigned populations and indicates the estimated amount of ancestry from each of
the known ancestral populations.
6.4.6 Phenotypic Heterogeneity of H. pylori in a single host
Colonies that differed markedly in morphology were seen among H. pylori
cultured from two persons, and were used to test for DNA level
heterogeneity of H. pylori in individual hosts, perhaps equivalent to that
seen previously in a European with a mixed cagA+ and cagA- [186]. From
one person (14 years) with normal gastroduodenal tract appearance by
endoscopy, 7 colonies were analysed (4 antrum, 3 body). From the other
perS'on (72 years), also with normal gastroduodenal tract by endoscopy,
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11 single colonies were sub-cultured and analysed (6 antrum and 5
body). Three different RAPD profiles and MLST types were identified
among the seven isolates from the 14 year old, represented by MLST
types 2040 from antrum, and 2047 and 2064 from body; figure 6.11)
which were different in all seven gene loci tested. The four colonies from
the antrum were identical to one another and different from the two MLST
types found among three colonies from the body. In the second patient
(72 years), all colonies 6 antrum and 5 body were identical to one
another. Similar RAPD results were observed with both primers (1254 and
1283; figure 6.12). However, the different colony morphologies that first
encouraged analysis of multiple isolates from these two patients did not
correspond to different MLST types.
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Figure 6.12 RAPD-PCR profiles (primer 1254) of strains isolated
from two individuals.
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 P
M= molecular markers (100bp); P = molecular marker (lkb);
Lanes 1 - 7 = strains from 14 year old (1-4 from antrum, 5-7 from body);
lanes 8-18 from 72 year old (8-13) from antrum, (14-18) from body.
6.5 Discussion
Most detailed studies and analyses of H. pylori populations to date have
used strains from non-African countries, despite the great importance of
events in Africa for the emergence and evolution of humans, and of
diverse infective agents, probably including H. pylori. Here we used MLST
to analyse strains from The Gambia, the most detailed study to date of an
H. pylori population from West Africa. These Gambian strains exhibited
the high degree of nucleotide sequence diversity described in other
145
groups of isolates from defined geographic regions strains [181,303] with
no obvious clustering of MLST types in particular age or disease groups.
We have shown that the strains of H. pylori found amongst Gambian
residents are typical of hpAfrica1, and their inclusion within this
population allowed us to define and describe the population with more
precision. Comparison with the handful of sequences available from
Burkina Faso, which is inland and to the East of The Gambia, suggests
some geographic differentiation even within West Africa. This divergence
could be due to isolation by geographic distance and/or linguistic or ethnic
differences and/or human population history, each of which could foster
random genetic drift and selection for locally adapted lineages.
STRUCTURE analysis indicated that the contribution of ancestral strains
from other populations to strains circulating in The Gambia was < 10/0.
Gambian strains were closely related to each other and form part of the
hspWAfrica subpopulation of strains (figures 6.10). The high "purity" of
Gambian H. pylori despite the country's significant exposure to North
Africans and Europeans throughout its history, contrasts interestingly with
Patterns found in strains from Amerindian and Mestizo Latin Americans
[210]: many of these Latin American strains seem to be mosaic, with
significant and complex European, African and/or Amerind ancestries
[95,210].
Different H. pylori populations were also not observed in strains from
neighbouring Senegal or from Burkina Faso. This contrasts with H. pylori
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diverse populations found in rural South Africa [89]. A set of Northern
Nigerian strains were hpNEAfrica [160]. Although not necessarily
expected, it is not surprising as these strains were isolated from Borno
state in Northern Nigeria, which is populated by the Kanuri people who
Were pastoral berbers with roots in Yemen, migrating and settling in
North Africa during twelfth century. During the height of the trans-
Saharan trade, the Kanuris moved south via Libya before settling in the
Lake Chad region including Borno [304].
6.5.1 Identical MLST types
Four pairs of strains of identical MLST types were found in this study. One
pair of was from consecutive unrelated patients, who had biopsies taken
on the same day. However, we think that this occurrence is not likely to
be due to cross contamination during endoscopy or sample processing in
the laboratory as standard endoscopy procedures (SOP-CLS-001) were
fOllowed; using clean endoscopes sterilized with Cidex (Johnson and
Johnson Co) and rinsed with clean water between cases, according to
standard care at MRC Unit, The Gambia.
The other three pairs were from people who had their biopsies taken a
Week to two years apart and also processed in the laboratory on different
dates. No strain pairs with identical MLSTs were from persons from the
same village or with same family names. Further study will be needed to
learn if the people carrying these matched strains had ever lived in the
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same extended family compound, village or district, or had some other
connection, vs. if such identical MLST types reflect some other factor such
as The Gambia's small size and easy hospitality to strangers.
Given the lack of obvious connection between these paired strains,
genome-wide analyses of their patterns of micro-sequence divergence vs.
conservation could also be highly informative.
6.5.2 Heterogeneity of H pylori strains within one stomach
In two patients tested for possible heterogeneity, all colonies from one
patient were identical by MLST whilst the other had three distinct MLST
types consistent with other findings [89,101,186]. The sequence types of
these three strains were different in all seven of the gene loci scored,
thereby suggesting intriguing co-infection among unrelated strains
[253,277].
6.6 Conclusion
This study indicated that Gambian H. pylori are not particularly clonal, in
accord with patterns seen in other non-African populations. Since the
MLST types of the strains obtained from young children were intermingled
with those of adults, we suggest that there may not be any special strain
type uniquely able to initiate infection in naive infant stomachs. We also
note that our strains from the far Western part of Africa showed more
genetic similarity with strains from Senegal and Burkina Faso than from
elsewhere, reflecting again geographic partitioning of H. pylori. The
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relative paucity of admixture of DNA sequences of European and North
African origin in Gambian H. pylori strains in contrast to that seen in Latin
American populations, despite the historical importance of foreigners in
The Gambia suggests to us that hspWAfrica H. pylori strains might be as
or more fit than their European and North African competitors. If correct
this inference would have implications for H. pylori colonisation and
disease in the African diaspora-among people with African ancestry
minorities in the Americas and Europe, as well as zones of contact
between northern and sub-Saharan peoples in the African continent. The
strain collection and database generated in this study should be useful for
further examination of issues such as strain virulence which normally
would spread to colonise new areas with the African diaspora or host
genetics with the colonising strain staying more or less in those of African
descent.
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Chapter 7 Antimicrobial susceptibility and resistance patterns
among Helicobacter pylori strains from The Gambia, West Africa
7.1 Introduction
Helicobacter pylori chronically infects most people in developing countries
[102,305], typically starting in infancy [19,102,103] and lasting for life. It
also remains a significant pathogen in industrialized countries, infecting
some 10-40% of adults in many societies. Chronic H. pylori infection is a
major cause of gastric (stomach) and duodenal ulcers and gastric cancer
[69,71,73]. It also increases the risk of infection by other gastrointestinal
pathogens, iron deficiency anaemia, and infant malnutrition and growth
faltering, especially among the very poor [141,251]. These latter
conditions are of particular concern in The Gambia, a small developing
country on the West Coast of Africa. Fortunately many H. pylori-
associated illnesses can be prevented or cured by timely eradication of
the bacterium, which typically entails one-two weeks treatment variously
with metronidazole (Mtz), amoxicillin (Amo), clarithromycin (Cia), when
affordable, and/or tetracycline (Tet), in combination with a proton pump
inhibitor such as omeprazole, and/or bismuth where allowed by local
regulations [215]. H. pylori transmission tends to be highly localized and
preferentially intrafamilial [89,101] in industrialized societies, and often
also between households in the local community in developing country
settings [306]. Given relatively localized transmission, successful
eradication from many members of a household or community might
markedly diminish the risk of new infections, especially of newborns, and
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thereby contribute importantly to public health.
Resistance to useful antimicrobials, especially Mtz and Cia, has been a
major problem in some societies, even among people not previously
treated for their H. pylori infections. Such resistance is generally
attributable to inadvertent H. pylori exposure during treatment for other
conditions [226]. Mtz itself is an innocuous pro-drug that is activated by
chemical reduction to hydroxylamine type compounds, which are
bactericidal to H. pylori [225]. In the strains studied to date, mostly from
industrialized societies, a modest level of Mtz resistance (e.g. to 8 or
161-1gMtz/ml) was usually associated with inactivation of the gene rdxA,
which encodes a non-essential oxygen-insensitive NAPDH nitroreductase
that chemically reduces Mtz in vitro [222]. Higher level resistance in rdxA
mutant strains, e.g. to 321-1gMtz/ml and above, resulted from inactivation
of frxA, a related but generally less strongly transcribed nitroreductase
gene; yet higher level resistance can result from mutations in any of
several additional genes that likely also affect intracellular redox potential
[222-224]. The hydroxylamine-type derivatives of Mtz that RdxA protein
generates are mutagenic, such that exposure to sub-lethal Mtz
concentrations [225] induces as well as selects for mutations to Mtz
resistance.
No commonly used anti-H. pylori drugs other than Mtz are known to
require activation to render them bactericidal, nor to be so highly
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mutagenic. Additionally, the several resistances to these other drugs
identified to date involve specific mutational changes that alter the
target's function. In particular, resistance to the related macrolides
erythromycin (Ery) and clarithromycin (Cia), which are used in anti-H.
pylori therapy, is usually achieved by point mutations at either of two
adjacent sites in 235 rRNA [230,307] that diminish macrolide binding to
the ribosome. Cia resistance seems to be rare in many societies, but
common (more than one-fourth of strains) in others [216,308]. The
observed prevalence probably reflects a combination of the very few rRNA
sites in which sequence changes can confer resistance and are not too
deleterious for the bacterium, a need to incorporate any resistance
mutation in both 235 rRNA genes to achieve a resistance phenotype, and
the intensity of macrolide use for other infections and thereby inadvertent
exposure of resident H. pylori strains.
Tet resistance is much rarer than Mtz or Cia resistance [233,236],
although several bona fide resistant strains have been identified and
analyzed. In the best described case, modest resistance resulted from
three contiguous changes in the Tet binding pocket in 165 rRNA (positions
965-967) [236,237]. Lower level resistance was achieved by mutation at
one or two of these positions and/or by mutations in genes in other
chromosomal locations that have not yet been identified, but are
suspected to affect bacterial permeability or efflux [236]. Amo resistance
is also very rare, but where found has been ascribed to mutation in a
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penicillin-binding protein involved in cell wall metabolism [235,309-312].
The present study of drug susceptibility and resistance in Gambian H.
pylori strains was motivated in part by considering that H. pylori is a
genetically very diverse species, with different genotypes predominating
in different well separated geographic regions, even in different parts of
Africa [160]; and that most studies of drug susceptibility and resistance
have focused on strains from Europe, The Americas, or Asia. As with
many infection-related topics, there have been far fewer critical studies of
antimicrobial resistance and susceptibility of H. pylori strains from Africa,
especially those from West Africa - the ancestral home of most people of
African ethnicity in The Americas. Given H. pylori transmission
preferentially within families and local communities [89,101,306], West
African strains may well have contributed to H. pylori gene pools in The
Americas.
Bearing in mind H. pylori's impact on public health worldwide, The
Gambia included, and the distinctiveness of African strains, here we
assessed the frequencies of resistance to Amo, Cia, Ery, Mtz and Tet in a
set of 64 strains from Gambian citizens. We tested the importance of rdxA
status for Mtz susceptibility and resistance by transformation and DNA
sequence analysis, and interpreted amino acid sequence differences in
RdxA protein in terms of its recently determined structure [313]. We also
tested by DNA sequencing whether 165 rRNA gene mutations could be
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responsible for the very few Tet resistant isolates found as minority
components of mixed H. pylori populations from several patient biopsies.
7.3 Results
7.3.1 Metronidazole susceptibility and resistance
Of the 64 strains tested for Mtz susceptibility, 20 (31.20/0) were sensitive
(single cells unable to form colonies) on media with Mtz at 8J.1g/mland 44
(68.80/0) were resistant. All six strains from young children (18-31
months) were sensitive to this modest level of Mtz, whereas only 14
(24%) of 58 strains from adults were sensitive (P=0.0031; table 7.1).
Table 7.1 Minimum Inhibitory Concentration (MIC) for Mtz against
H. pylori isolated from males vs females
Range of MIC for Mtz (lJg/ml)
Aqe croup Sex <8 8 16 32 64 128 Total
Adult Male 8 2 8 12 1 0 31Female 6 1 5 14 1 0 27
Infant Male 4 0 0 0 0 0 4Female 2 0 0 0 0 0 2
Total 20 3 13 26 2 0 64
The prevalence of Mtz resistance in males vs. females was 66% vs. 720/0
respectively but the difference was not statistically different (P > 0.05;
table 7.1 and figure 7.1).
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Figure 7.1 Prevalence of antibiotic resistant isolates in males and
females
80
All but three of the 44 strains that were resistant to 8j.JgMtz/ml also grew
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well on medium with 16j.JgMtz/ml. Additionally, 28 of these strains also
grew on medium with 32j.Jgof Mtz/ml; and two of the 28 grew on medium
with 64j.JgMtz/ml. None of our 44 strains grew on medium with 128j.Jg
Mtz/ml (figure 7.2).
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Figure 7.2 Number of isolates growing on metronidazole medium
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The numbers of isolates that formed colonies on different levels of metronidazole
medium were determined and graphed.
In further tests of strains that did not grow with 8~g Mtz/ml, two of the
six from infants (18-31 months), and two of fourteen representative
strains from adults grew on medium with only 4~g of Mtz/ml.
7.3.1.1 rdxA (nitroreductase) gene analysis
A transformation test was used to learn if MtzS strains were distinct
metabolically from most susceptible reference strains, in requiring more
than just rdxA-inactivation to achieve Mtz resistance [222-224]. Eleven
Mtz sensitive strains were transformed with genomic DNA from a
derivative of strain 26695 whose rdxA gene had been replaced with a
chloramphenicol-resistant (Cam") cassette (IlrdxA-cat). Each of the 10-20
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earn" transformant colonies tested from each of the 11 strain
transformations grew well on agar with 8IJg Mtz/ml. This outcome
indicates that most or all MtzS Gambian H. pylori strains are just one
mutational (rdxA inactivation) step away from becoming resistant. In a
converse experiment, we tested if mutation in rdxA was important for the
resistance of MtzRGambian strains. This entailed transforming 12
representative MtzRstrains with genomic DNA from an H. pylori strain
containing a kanamycin-resistant (Kan") cassette inserted next to a
functional rdxA gene. We expected that a fraction of KanRtransformants
would acquire the donor strain's rdxA+ (functional) allele [314], even
though most might retain the recipient rdxA mutant allele because H.
pylori transformation tends to involve mostly short DNA fragments [315].
At least two of the 20-30 KanRtransformants scored from each of 12 MtzR
recipient strains were found to be MtzS on agar with 8IJg Mtz/ml, even
though most KanRtransformants remained MtzR.We infer that these few
KanRMtzS transformants had gained the donor's functional rdxA allele,
and thereby conclude that rdxA inactivation is needed for most or all MtzS
Gambian H. pylori strains if they are to become MtzR.
7.3.1.2 Sequence comparison of rdxA from MtzR and MtzS strains.
The rdxA gene was PCRamplified and sequenced from 33 MtzR(MIC
range 8-32IJg/ml) and 18 MtzS Gambian strains (MIC <8IJg/ml). Average
rdxA sequence diversities were 3.6 % in MtzRand 3.4% MtzS strains
(overall, 3.50/0), which is within the range of diversities among Gambian
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strain housekeeping genes (range, 1.2 - 4.6% mean, 2.9%), and whose
protein products also act internally in these Gambian strains (observation
made during experimental work for chapter 6).
Of the 33 MtzRstrains characterized, 15 (45.50/0) contained nonsense
(translation stop) codons within the rdxA orf, including 13 of the 19
resistant to 32 ~g Mtz/ml; in contrast only two of the 14 isolates with
lower level resistance (8-16~g/ml) contained nonsense mutations in rdxA
(p=O.004, table 7.2).
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Table 7.2 rdxA nonsense and frameshift mutations a
Strain !.I9/ml Frame Mutation description (base Mutation (codon #, base
shift position) posltlon)"
MtzR
71R 32 0 CSubstitution (523) Cor G -> T Stop codon (175, 523)
83R 32 +1 Insertion (576) Stop codon (205, 613)
93R 32 0 Substitution (415) C -> T Stop codon (139, 415)
100R 32 0 CSubstitution (523) Cor G -> T Stop codon (175, 523)
114R 32 0 Substitution (19) G -> T Stop codon (7, 19)
115R 32 -1 Deletion (496) Stop codon (167,499)
121R 16 +2 Insertion (6,7) Stop codon (14, 40)
123R 32 +1 Insertion (23) Stop codon (23, 67)
205R 32 +1 Insertion (595) Stop codon (205, 613)
239R 8 +1 Insertion (313) Stop codon (110, 328)
244R 32 -7 Deletion x7 (179) Stop codon (74, 220)
249R 32 +5 Insertion x5 (178) Stop codon (64, 190)
263R 32 +1 Insertion (193) Stop codon (73, 217)
269R 32 -1 Deletion (191) Stop codon (76, 226)
270R 32 +1 Insertion (193) Stop codon (74, 220)
MtzS
JS114S <8 +4 Insertion x4 (300) Stop codon (111, 331)
JS124S <8 +4 Insertion x4 (300) Stop codon (111, 331)
frameshift +4
1015 <8 -1 Deletion (86) Stop codon (33, 97)
a Not listed in this table are other MtzRstrains that contained a 3 nucleotide deletion at
codon 191, a 21 nucleotide (7 codon) deletion starting at codon 18, or the many
missense mutations that resulted in amino acid differences in the encoded protein
relative to rdxA of reference strain 26695. These amino acid replacements are shown in
figure 7.3.
b Complete RdxA protein is 210 amino acids long
c 17 isolates have a "C" and 14 "Gil at position 523 (figure 7.4)
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Figure 7.3 Amino acid sequences of metronidazole resistant
isolates showing "stop codons" (X)
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Multialignment of amino acids showing changes in rdxA gene of metronidazole resistant
H. pylori isolates. H. pylori 26995 whose RdxA structure was determined was chosen as
a reference strain. Multi-alignment was performed using Sea View Version 4.
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Figure 7.4 Multi-alignment of nucleotides of MtzR isolates
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~..a CGCCMGClCI fACAIlCACCClIC AtGCCATl I JGlt;A1CCT1ACCAAf---flll(lilli' ffAAMOOfl MIlTlC(n&tACRtAr.{IAITI InR'GllACACMtAnMMGCGCntA mM!
?f;O&JI rl.l1:IltI .. I[1 I rr"IIr.lll:Olllil:t:n II.£H II I IIillillll.lilIIt:OIH.----flIHiliHI I IHHIIIIJItH-[HIIIIIII;rm;r.ftClK:ItI.r IIII I I IHallolllUiIIlilllGIII IIIItIIRI~:Iit:llr.Hlit1il11Ul1
?&I_I 1I.t1:HHlititl IHlIIlDtl:llllt.rJ:JI II ... " I I IIClliHililillll:[HIII---Hllhl.HIIIHHIIIHlIII .IIIUllllotlll;r."I:tIl")II~;IIU II IIIRlldIIU,HIiHIr.KIIHltIIHI.:r.C-lltlll .. "I 1l1li1
48J1 ILCt:Hllotlf.I IHlIUI(:KtJ)fllllll"~iOII I I ICllililldinHtlItHI---flIIf.r.n1 "H_WIll-4:IIHIIIII~:lItitr.r:JUlll~.IHI II fIIHlloIIHI..tIIIllIGHIIII111lHI~:Iir.1II:fil:tfillllAl
~5l-~ rro .r-iIiI".tltltlll »lIOft .. 1ir.C1.IiIt.r.tllll I IIill.Hfl~.1 IHt[Hill- WorJll1 fHIIlI".1II ·I1MI lI.t1lt.aI:Hl:lli~.flll I IIUUIlJilII,RliHfCAI IIIIliIHIUiC I I illJIIII
'" -" C6CCftAr.tTClTfiGIlIlCOCCOlGCtATGr.tRlTTI61GPTr.cnrICTfIIlT-·-AAGGATTlRflAIlflflR MATIOCill'''GCflOl{".cTAnnMt6ft/1(i1l(j~l'MTMAAc(GctTCRG,,;nIlllT
97 JI (r.cutfIG(lCllfiGllfICflCCCII tftTGGCRlTTTGT!ifll1im TACIMf --AflfiGAtTrAMllflAA MIlrrr.tIlOCGtl1UlGC TArTflftAffAlltiftGIIlLllT1I1M1lfj(;Gt I tCIIGC1Hfll(IT
7LR CGCtnnGC1ClTACnncnc n ATr,(,(mmCTGllTGrnnefMT---IIntGRlTTMMIlflA-eflllftllr.tnOCGC",JlGCTIIlllCnR1GMCnGnlCnlTOMnr.cCCnCnr.cr,1TfIflT
;o~JI CtC(flAC(ICllflCnACOC n CATcc.cnm IGmnr~tlflCTM"---IIllGGnl rTnI1MMR-eMATlr.cnGTC(OCOC.nnmCnntalllGAGATGIlTTOMIIGCGCfTCnr.cr;ITnm
1:7 JI CGCCnnGCTCnOCnllCne ft C"IGGCnl n IcrGnTGGflncCIVII---Il1lGGll1 TTnllMlllln- IlMllGCnGCCcocnr,crnll1 Innrr.MCIIGnTGIlTTnllMGCGCTltnGCCTTOOT
Z4'lJl (CCCMGr I cnncnncncecA nlGr.tRlT ncrOOTGGnnel Alll----flnCCnn TlIllMlllln-Cnntll IGCllCCccncAGCmn nnnlGllflGllGnJCnlTMflnGCGC ne en MT
:>ClJl CGCCMGClCnACMCACOOIA ~IGr.tAlT I ICICAICClll1C rAAT---IIAGCRI TlAIIIIIIMAACAMTTGCnr.cACAtAG(TRlTTTnIlTGMCAGAlt;AlmMRGCGC I Ie Cl TAAI
lo3_R U.rr.""~ I~I I ... HIII;1tIrolJlliluII~£I1IIII"'I.tIII;r.IIOCtNtl---flHf~.HII ICHiilIHltG-IHIIIIIII;tH ..tfil.lIIlII~:lInllllllitl""".HhHlliilflIlllllHIiNUl ICIII;r:10111lA1
99_R n:r.nllu·ICI IIt"Uftill CI:HIII:IOlloiLHlI1 IIill~III~;t"ICIHHI---flHGGAI nIllIlllIHfIlUl·IIIIIIIII~.IIi\Cr.tlll)tl~;III1IIlUAII.iflMllifIlCIIIIHIIfIFII~.I.I;IICill;(:fillllAl
!'1l!o_R l.Iit)JIIU ICI Itt Hllfll'C.I.ll1II1.HlllitHII IILII,"II~.II .. :1HIII---flH'diHII IHHf_H-CllHHfll~ HI.rr.r.IItIII~:IHI I 11IIHllilllvdlliHlrJlIIHltfjIiI~·IiClI(fllil:la IANI
t 14_R ChU Hlld·,tl rIlIlIllJI.IiI;RCI.I AII;r.'iiTlI IhllJlHilil I.. CItIIl--tlllldiHIIIIIIIIIIlI.,HoI-1lHH1 fliflll£Gl.IltlM·,HI I I IH"".iflIi.AI.BIGHI HI"14HI~I.CIICfll~;IiI1AHI
11U CGCTMGCTCITflClIIICIlC ",GCCAlf1"'(jI!fGlllfACTMI--IIAGGATITAMAMIl MIlTl&tIl!lt:AtOCfW:fAlI11MlfIARGMAIGM1AMnr.umCIIGCGllMf
llLR CCtt reITACIlfICIl(CCII AIGCCnTl m IWlr.c nOCCAIII---IlntGnl ITlIOMMR-CflMUr.tAGCGtocnr.c TAl II IMIGIlIltllr.nl,nn IlMIICCr.t IlCcr.cCI Ioor
2I;,JI CGtCIllU Ttl JntI1AC1lCCOlGCtATGr.tlllll Ie IGlllr.cT lOC1MI---flIlGGAlllIlJIMUn-CMiIlIGtI!GC"OCfIGC 1m" IIlftlGlllItIIGIll&RI IllfIflIItcGC I ICIlr.tCllllllT
If)(JI tGCtflAC( ICI1OCllllCfl( on ftlGGCflll1 ItIGlllr.clI11(TflllI---ImGGnll IlIIlIlItIlfln-ellnIlTTGtnGCAtncnr.r 1m tTlnOIGlllltnGOI&BI IIIfIflOGC&t1rcnr.cCITMT
lZ'JI CGCCMCClCI locnneccncWllr.ccn I I I JCI GIlrGGl TnelM t---nncool TTMIVIIlIIR-CMnr IGCRGCGCAtIlGtTmTICRAlf.MCIIGIIICAITMflnCTGC mllCCel 1III!I
:!SOJI CACTMGrTCI TACRIICIKCCARCCAIGr.tRTTIIC1GllfGllT TnerMI---AnCCAI TlAflMMA· MIlT TCCntCCCACIIr.t'TAlTlCn8IGMGftGA1CATTMRR&tGCfl CACCGIICJlT
!1_H CftctIltlOCICI1H1:H ItCUlH[CHIIAlCHII I IGlt.HlloUIIIl:IIlI"--lm~b"' 118111111IHIH-C_1IlitflGCRtHtJltl("I "I t'l11I"'t.tIRt;AIiHIGHI IHltlllWtGtIICtiGCGIIIIIl,
""4. tGCI:RIII~.I t I I 1I::f11ltllCl'.r.llf.r.UIIAiOIllllI.II;t1l1i1i I III:Cltllt ---flHld'" I I IfIHfIIIItIlfH::HItIlIIIJ flCotilCIlOU:I Ht I I ",nll.ln,ftr.nlCH II H"""fi': ... I I(",.clil IIlill
IP!')! [r.IDIIIi;Cltl fllllll!1ltttllr.fI HIIAiCIlll I II.I ..lIlIil1l lIf(fltIIl--AIIfJalIIIRJV.'llfII-4:"VIIII~]IiJ.AI~lrJil'rJAIIIIIIlIIIiIlIII",,",Ili!IllIlHIltll;cr.tIICIlIiI:r.IIAHI
nl_R Clor.t:fIfI"~Ir.I 11I1I1ICIICCtlIr.ttRII~£'H11 I ICII;nllllil Ill:fHHI _IIIJiRl J1HIIIIIHlIA-ClIIIlIlloI.ilrotAOlCII'A:IHI IIC1lRII.iflKdlliIIIGBIIIUIIAtIT.cl I tJIIitC I 111111
"0_1 CGCCIIfIf'.nCllACAfII'.IlCCOIr.r. .rr.roClllTllr.Tf.flT .. TlftCtMT_Ar"A11T_ IIIlflTrr.l.Ar.c.r..flCllroHAlllcAA'follflCjJrJlTLAl1flM a:r.cnCAr.c .I1I1AT
24'JI C~ct lCI TACAIIUlC ActArr.c.cAT TTIG1G1ltGeflACTAAIC1ARIAnGGRI nflMllMA IlMTTr.cnt.cGtI1UlGCTAITTCflftT6MGftGR1GRllIlllflIKiCGC ITCGOCGIl flAT
L)OJl C(;CtIVfGCTCTTflCIIIICIlCGClIGCCRTcr.cnm 1&rcnTGGnnerMI --flllliGAnmflflnflfln fIflIlnr.cnr.cnCll(OCCl nfTllOQtGIIflGIlGflltATTlIfIflIIr.t&t ncnr.c& 1100 I
l00Jl C&tCnnr.cTC' TflCAfICIf( ~ CRrcc.cnnl IGfGnTr.clTAC[fIflr ---RnCCRI ITI1fIIIflIlfIn-ennnrrtClIGCnCnellGCTnt HCnATf.llll!iftGnT&BTTMftnOCf.t Trcnr.cc !TMT
115J1 tGCcnnr.tlCnOCnllCAC A CftTGGCnlTI IG1WI'CCTlnerOOf---nnGGni I '"MAnon MIlTTGCnGCncnenccTnnTTflftIGllllGnGnt&nnllllllnGC&tllCnGCGITMT
Z44..a CGCCMGCTCIIntllllCllCCCII c~IGGC"n TlGTWl'CCnnerooT-----A1lMM1IIlf1Vlll TTGCnGIccncnccm'TTTflAIGftnGltG"'Cnr TRIVIAGCGCI lcnGCC I rOOT
117 _R CGCtM'.C1CHArRlICRCctftCCCRTcc.cm I ICIGllmGTrllC TMf ---AflGGRTTrRRIlflMA-tJlllATTGC. ACRrflGCTATrnORlt:llACRGRlCATTAAAAGCCCTTCC&tCI TAAT
Con.on.ul el. I 1IIIt~ I .1 IIttlllltHt"tllAIl "Ii~.t"lll II.II ... "iIH !fIUltHi HHt~iAIItIUllIlt"'lH.rHllllfll~·flfit:fICIItlII~ IHlIltll"lf.tltk"'I.~II.~1 IIIIIIIRi.,I.ClltAr.r.tillfIHi
PGI P70 l'8O 1'911 300 llO 3:>0 :1:10 340 :IM :tlill 3;>C) 3jfl) 1911
1---..- • -.-.---·_.,.__···.,._.__·-...- ··----·-·--..-·-·- ...··-.......--·-.----I
RdHIU"S5 GGTGGTRTt.cICIfTMGIICCtfIGCGIl6TTGTTOCCIltOCGGC fI1tArGCIWIACCrr·TRIGC ilGTCTrRTiIM IT mIlfCCtGTtIITTlC1CMAlc.cmGCGfIillGATTCAIICCA
4lJl u. IU. Tmce" I I TlWlIW:tlnr.tGllGTfGT locCWlmcccnnOCnTttllllflflIC IC- TlITCt1ltllCTt TIftl nnnGlTllGftC TGIlrCCCC1CTnc&CTtMIITGCTTGC(GlCIlGIllTCAlltcn
2Wl>JI r.c I",mlr.t1C I ITIWlIW:CTnr.t~ 1m OCtCCnrnr.ctllT rntl1TUnnnnrCTt- TATctllQI(;rCllR1IlflnGI rllGftCTGIlIctCCT CI rrCtCTtflftflTr.tnGGC"GIlGIlTTCMCCn
3LR tt T(;I;m lACICI I lllflllfl(CTnccGntl I nm:C&CfITflfLCftT IACnI tCllIlflftmc· TnTtCJlGIl(iI(I I nlMIJ&l TIDGlmlCCC(T[ n rCC(fCflnllltCT lecce ICIlGIlTTCOOCcn
.aJl CCIGllT"lGCltl I IIIIWICCT GIlC1 TCnneCIOCIICAGC rnenlGCllMIlCcrC-Iftlccccncm rnllWlCl TIII'.AGltnlCcccrC-I mccrcnMT&tTTGGCcrCllGlllTClVleCn
13J1 CCIGIlTATGCleI I fllAAllCCTACCCllClItTl ACCCCIICAGCCAnOCIIIGClIfIIlnlCIC- lA ICCGllIICICl I~IMnGl TIIGIIGrGllTCCCCTCII TCllCTCMIIIGt TTGGCCICIlCIlTTtmecR
mJl GGlIoIoI",G(Ie, IIItiIItIICCIIllitIiHGII~1 Httr IlCIU.tI:HI IIl(HIOCRHllflCC"IC-'HICC m;ICII"'ItH"bltllliftGI~HltCct leI I IC1lel tltflHlIOCI IGGtelGItCIIIlCltl4[CH
51J1 liIliGLIRIr.tlrl I IlIlIIfllCtIOOJ:&lIIlIlI;JlI£CWlIf"WJlfll.HlliIlII"'ICI:IC'·IRltIJ'Mnlrllal""'lIll II. .11i11ICCCliltl I Ir.litlfll"~lIl:1 IGrnlh,.."" IIlItIXH
11_R Iililtd.IHILtltl I ''''''8: IHliI:IiJII. I If,. IIn:&f'IlCIUiCl1H IRCHllitlllllltr.I;1C-IRlu:JMr.ICI '" IIIIIHl ICHI.ftGIIJlfI'O:t lei I I ltiCltHllllII";I IllIiI~.III1"oHI 10111111
mJl LIllt"'IHI..t1 1111IIIflACC11II.. 1oIIJ1lfil IAtI:liCllIIII.c1:H111II:H,,;CHlllAttltH1HICCI~"It.ICIIHlliIlI"ilr:NliA""~"tCIXIC'I I "~lr.ICHAAILtl IGri;,aliItr.1I "~,,~;,,
It7J1 Cl4lr"IAIOCICII1_UAr.tfilllilTmrRCC5r.llfHroUAtrACAlr£llMfllCIt-IR1CCfofilltllUIlITfWlIiltIltlAr.Tr.alcr:CCTCIIII6CTCMItIOClt6f.r.r.rr.oc.nlff.llfltCA
Z4!iJl GGTliliTATGCTCTTTIIIIIW:tTftOC6llliTlmACtiCATllIittAT TlICftlt.cnRftfICCTe· THItCOOIIGIt TlAlflIlfl61 CRGAliTliRTlCC6It ITlCftCI CRlIIl1liCTIGOCGf6llCillTTCAI1CCA
2fOlJl r.cr"I"IUIt I I lAMllCCtnocGntT1C1TOCc""rnr.ccnTl OCIliOCIlllMTClt- rnTtCr.cnc-TCTI nTMIICTCIl6tOCTGIIltcCCTCT"TTCnCrCMnrGCIl'CC"GIlGAT ICMCcn
10JJI GGlGGrnn.crCTIlIlllllfltClIIGCGntlTGHlUGCACflGWlTrflCflrGCIIfIflfI((TI-TRTCl:GGIl!iTeTTRTIVIIlIiTCflGIIGTGII1C(CCTCllTfliCrCMflTr.tnGr.tGTGIlIiIlH[fIfl(Cn
"JI GGIG£","lGCICfIlIIIVIIICCTAGCGlICl fliHnetcCllTlllltCI1T TIICfITCCJ1MOCCrC- rnlCUGnGlCT1IITIVIIIGrellGllG1GIITCCCCTCmCGCTCnOOlGClTCGCGTMGllTrClVlCCft
ZM..a GGTllGrnlGCTCfIlMlll:C1nCCGIIG1TGTTflCCGCllffHiCcnTTocnrnrIllVlllCCTC-TnTCCOOOO1CTTftTMnGTtIlliGGTrollrccCCTcmCGCTcnnnrGCTTGGCcr1illGflTTCmCCn
114J1 ~ reCTA rGClt I I IMftIICCTflGCGl!GITGT1AtCWlTAGCCATTACfliGCMMCClT - TRICCCGfl(jTCl IflTRMGTC GltAnCCG TCmCGCTCAAIITGCnGGCClGftGIlTTCllACtA
IIOJl t.llIr.t.I"IGI II I I 11IHII11:f."t{~·'iIIIilW1HIrCCtllClN tIIl1l11:1lllotIlllAHtCIC·1Mlcer ••I•• ,f.I IlIllilllH.I IIlhllrolldlt Iwml IICltClrIlflKIr.t;llGlil;r,IfoflIilllltlllltl II
IPI _R 1~.1f"'IHI" 1&111_1 IU IJII.I 1101III CIlI.lr:llmu IHI'IlI iii HHIIfM:rlt-1HII.I~~~M.It.I IMIlIIIIH.ICHlillGlloIlli. CCltll I tIlC I(·'IIIR1I,c I Ihl~,I,'6IlfiII111:Hf1J;f.H
!'1O!JI M.I(j(,IHII.tlfl I IAfIIllIlXHliflillJ I 161I1HGtHIiMoCI'lH IflIJllliClllIlIIf.CIC-1HII twl.ilCIIMilIflIJljIIlIJllfiI1~"LtCCI II I~'Il II Hfllur.a;1 IGI~ GI141.HIICIIlrtH
104J1 ""'''IiIHIhl:ICI I IIIIIIfII'.cllll~.LIII,1 IG11HI.f IlI:SHHI;t'I'ln fHl:HIIII.IIIIIlHCr;1C·lHlr;crof.nuli. I '"'AHl,r.IlHloAr.IIlII'ff.I1lltl I I lOC'ltltH"'1lC1 llil~ 1i1f~".1I11.HH1~H
lZlJl CWIIiliTHlr.cTCTIIIIIWICCTIlGCIillliTlr.cTOCtWTflGCtflTTIICfITr.cflRftACCI.C·Tftl"66MICITATIlIlIlIiTT GTliRrcctGfeTlTTGCICIUIIITt.cn6OCGIIiIlIiIITTCMCCA
250JI "I" IRlr.t ICTTlIIIVw:GTnr.tGntTf rOCCCtflTflGTCIlTlOCftlr.tIlllflOCCTC- In1"r.cfIGTe nRTIlflnGT TIl!iAI01G11TCttGIt.11 I 1~ntllMTC;Cn'r.tCIGIlGIllTCMCCO
'lJI U.lr.c TATr.trc I II CTnr.tlOllGrrcc: I flCtWlTflGTCATlOCllTUilIlflIlCCfC- T9TCCGGfl(;ICTTRTllflnGlTlUlOTtnTtCCGT CImu TClIIIIlTr.tmCCGTCIlGIlTlCflfltco
34J1 rli J(;I;rn Ir.tlCI I llOft:ClIf(;(GIlGT I mACtliCllTIIGCCIIT IACRItCOMACe I.C- TftTeCGQK;T(I IftTfWl(;lT IGIlIC((CI en nr.t TCftAIlTr.cInr.cliTGIlIiIl TTmne(fl
1ZZ..R GIll GGTAlGCTCTI I flMllCClnr.tGllGTl CTTOCCCCIIlootCIITrocm GCJ1MntCTC- Tn Iceccnom rnrMlMlTCIlliftGTf.nrCCCCTCI I lcnCI CflftRlliC TTGGCGIGIlClOlICMecn
231Jl GIlICGTftlGCltl n... IICCCII(jTlCl IACtWlIAGCCflTTIICIIIGCIIflAACCIC-TRTte ICT Iftl RMCITIlG1IG1GAICCeGICI IlCCCTCMlI1CCITGGCGIGIlGIITTCAnCCR
210Jl GGTGGTftlr.c ItT I TMRIICtTlTGCGI!GI TGITACCGCAtIlGCCRTTACRIGCIlRARltIC-1 RICCGGftGTtT I aTlWIIIrTlIIllIGlGArCtttTC I IlCGtl tMIITGC11GGCGIGIlGIITTCIWlCCft
743J1 loIllhlil"lr~:ILllllIIIHIICtlHl.iU;II'" IIilIlH&J;ltrHlUHI IHI. ""iLHHHIIt[IC-l"'a;I~~llIill.I 1""III«jl 1111 lIo1ll(C~liltlllCI!tliJlllflln:I mlif;"".,IiIH IOIltl II
I ll!_R IlLtbf.IHII;Clrlll_:tllu;Jilllll Jr.I IIl!:Caw;IHliltfll IJrJl""'HlIltOCtIC-IHI(r;tifillhlr.IIRlliIlI~ICHlillr."."~tC~ICI1ll6CICIIHBIr.r;1 "a~.6". allll;mrl H
lOO_R hGllililNlr.clCI I llIIIIIII:t:tllGf.Glljl Jr.lll caw;tt.I;COO I lOll r.tllHHfIt[l f'IHltr:rol!~Ir.IIH'HH,.ijIIHl!"lill,"";C~I:'CI 11~CI~In:' "!'~:r."illiHI I {:HffCtH
I I~JI .... lliIHflI~I ICII IIIIHII.PHl~.li!Ill IIiClfI.L1i£HIHlitlXIIOIIWlI"HICIC.IRlctlililll.iIU INIItHm.I IHlIHGI(jllII,[t6ICII ItNtltMRlllliI, I ''''i1:UHiIIIiHl IIlIiteR
Z+UI 66T" TA1(iCItTt TIIIIII1CCTfIOCGMil16TI ACtKIITfIGCCIlTTACAlr.tMIIflC( IT· TftIctGflllGTCl1l1 ftIIIIIi re ~lliRlt~CG Tt n ItGe 1CAflAlliCnijt.c"6IlCiIITT CIlftCCft
117 JI U. ru. TnIr.tl (TCTJIIlflIICtTlIGC£IlIiI rGnOCtwlrnr.tCIIl men IOCOflflftltT t- TAIttGGOOT~I IftTIlflnGTCIl!iA~IGArtttCTt TITTACTtflAllTr.t H'~lG IGIlIiIlTrtllllttA
Con.et1IU. CWlliGTmr.tTnn IWlIW: nr.tlilllill r.tTOCc~nr.cCl TACnrr.cRllfllkClc lftTCCJGII&TCTffti flfIflGTlI GTallen, Tt ITI etCl CIlMTr.t 116r.cGlGllClOlTCMeCn
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I "'ii "lid II1II Ilm1IUIlIl~,'HI"'IIIHlJIt~ ""lIitl"1 "'['~ lIilhhr~,111f1II11n~./tIl.lil~.rillilU.lIIH1II1,"h"1 lI~illIIH,llIdJlII HI lIi1ilUihCII IhllIl.U IllIlUllllill;r~.r:
!:IlIiI H"ilIIIIIIIIIIIRf,""lIliCIHIHIIIIIiCN~ "R"iCIIIIHIr;la:lli1blir~,n'"'"llIir"l(jlir.rr."iIllIClll1lflhr.iIHmiftlllfil II .. Hllltl IIi1allinll,Cf"'lrtlllijIIllHliIIiW,C
rRlilHHillllllllllllIliIIlIU IHIHIIII6Iilll~ltRIfi( IfllAICIiCllillilililil AHAlllm~Hllili'it:lilliINiI:lllIllliliGHIII~iR"Mi6Im:HIIHllr~ij!lililll[liIIlU;1111 HIfMillifihC
rNljfRIl;r"RHIIIIIRlilIIlIlf~'IHIHIIII6liIll~·HRlliI'IHIHI[li[llillilifilirIlRIH I Ililltllilir,rrillil"it:l IlIlllirv.HllliliIIlllIil IIil'HllltI HiliIlIilHIltliIIlrrlll ~1lIIIIlill.dir
CAIiCRTliClIfItlflfll TIIGfIIIIGCTATftI TTT6GIIUCIIATIiClftTftTCIiCT~T66(jfitIlRATlI6CftTG66tli llilHiCI lI11116fNll TTfJ6ll1 ,lHill6tfll Tftl TliGftliGTTlCIifIIC( TITAnnRlilliGfit
,,,(;Conium IlfmlllGClOCOI rnWWl"Himm]CIiCTG1GGliGUlIlIllIIC.CMr.liIiCGIGIlGCIIIlllHjlilillIf(jWH1(jll~tRlI", Hi(jIlCiGCHHilllttl m!lllfl~IGIiIit
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Multialignment of nucleotides showing changes in rdxA gene of metronidazole
resistant H. pylori isolates. H, pylori 26995 whose RdxA structure was
determined was chosen as a reference strain. Multi-alignment was performed
using Multiple sequence alignment with hierarchical clustering [316]
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This difference in distribution is in accord with nonsense mutations
causing protein truncation and thus, complete loss of RdxA function.
Some missense mutations diminish but do not entirely eliminate an
encoded protein's activity, and thus would confer only leaky phenotypes
(lower level Mtz resistance in the case of rdxA), whereas many others
would be well tolerated and have little if any effect on activity of the
encoded protein.
Three of 33 MtzR (9.00/0) strains had insertions of one or two nucleotide
and thereby rdxA frameshift mutations, which would result in new amino
acid sequences distal to the mutant site and thereby loss of rdxA function.
In addition, two strains contained in-frame deletions of three and 21
nucleotides, which do not cause changes in RdxA protein sequences distal
to the mutant sites (table 7.3).
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Table 7.3 Identification of proteins with frame shifting mutations
or with large in frame deletions of MtzR strains (excluding those
already detected as non functional in table 7.2)
Lab MIC Mutation Mutational effect
No J,lg/ml description
1 nucleotide Loss of function not reflected in
99R 16 insertion at translated sequence
nucleotide 201
1 nucleotide Massive mutation from residue 199.
264R 16 insertion at Probable loss of FMN binding
nucleotide 607 capacity
2 nucleotides Massive mutation from residue 192.
231R 8 insertion at Loss of FMN binding capacity
nucleotide 586
3 nucleotide Massive structural mutation due to
122R 32 deletion at loss of residue 191. Loss of FMN
nucleotide 580 (in binding capacity
frame)
117R
large in frame Protein residues 18-24 missing.
16 deletion (1 Not compatible with proper folding
nucleotide, 7
codon deletion)
Thirteen of 33 (39%) MtzR strains had neither translation stop nor indel
mutations in rdxA, but their rdxA alleles differed from those in MtzS
strains by numerous substitutions (table 7.4).
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Table 7.5 Mutations found in only MtzR or MtzS isolates
Mutations Number of Mutations Number of
only in MtzR occurrences only in MtzS occurrences
isolates isolates
H25R 1 S30G 2
S43L 2 T31A 1
P44L 2 A67V 2
A80I 1 A68V 1
A80T 1 Q197R 1
C87Y 1
H97T 1
E133K 1
E194K 1
S158R 1
G163D 2
G170S 1
G189C 1
D205A 1
A206T 1
The basis of Mtz resistance in two strains (127R and 104R, MIC
32I-lg/ml) is not clear from RdxA structure considerations. Their 210
residue RdxA proteins differ at many positions (6, 133, 170 and 194;
figure 7.5) from the RdxA protein whose structure was determined
(Hp0954 of reference strain 26695).
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Figure 7.5 Multi-alignment of strains 104R and 127R
1 10 20 30 40 50 DO 70 00 90 100 110 120 130
1-----+----+------+------+-----+-----+-----+-----+-----+----+-----+------+-----1
RdxR.2D&95 H<fLDQEKRRll_LNrn1SCKMFIlSHYITSSmEEIAEIARL~SSYHTQP~HrvHVTDKDLKKQlAAhSYFNEEMIKSAS{lLMWCSLWSELLPHQ1Y~tl YPESYKVRVIPSfAQK_GIJRFtf1'3!IQ
104 R H<fLnHEKRRQLLNrn1SCKMFIlSHYITSSTELEEIAEIARL~SSYHTQP~HrvMVTNKnLKKQlAAhSYfNEEMIKS{lS{lLMVVCSLKPSELLPH~YPIJI'l YPESYKVRVIPSfA()lGIJRFtf1'3!IQ
127 =R H<fLDQE~QLLNrnlSCKMFIlSHYITSSTILEEIAEIARL~SSYHTQP~HrvHVTNKDLKKQll¥ihSYFNEEMIKS{lS{lLMVVCSLKPSELLPH~YPIJtl YP[SYKVRVIPSfA[)lGIJRFttlSMQ
Coosensus H<fLDqEKRRQLLNrn1SCKMFIlSHYrrssmEEIAEIARL~SSYHTQP~HrvMVnKDLKKQIl¥lhSYFNEIMIKSASALMVVCSLkPSELLPHsHY~tl YP[SYKVRVIPSfAI)lGIJRFttlSMQ
131 140 150 160 170 100 190 200 210
1-----+----+------+------+-----+-----+-----+-----1
RdxA_2D&95 IUSYIL[OCYIAVGQICHGVSLHGLDSCIIGGHfLKVGEVLEERltiKPKIACLIALGKRVAEASIJ(~K~vnAITVl
104_R KLKSYIL[OCYIAVGQICHGVSLHGLDSCIIGGf[J'LKV5ElLE~ItiKPKIVCLIALGKRVAKASKKSRK~IDAITVl
127 _R KLESYILEOCYIAVGQICHGVSLHGLDSCIIGGf£fLKVGIILEERltiKPKIVCLIALGKRVAEASKKSRKSKIDAITWL
Coosensus kLeSYILEOCYIAVGQICHGV5LHGLDSCIIGGf[J'LKVgE! LEIRItiKPKI vCLIALGKRVAeASkKSRKSKIDAITVl
Multialignment of amino acids showing changes in rdxA gene of 104 and 127
metronidazole resistant H. pylori isolates. H. pylori 26995 whose RdxA structure was
determined was chosen as a reference strain. Multi-alignment was performed using
Multiple sequence alignment with hierarchical clustering [316].
However, all the differences present in strain 127R (D59N, R90K,
G98S, R131K, V172I, A183V, Q197K, V204I) and most (Q6H, D59N,
R90K, G98S, R131K, E133K, G170S, V172I, E175Q, A183V, E194K,
Q197K, V204I) in 104R were also present in many other resistant and
susceptible strains and thus may not perturb function (table 7.4). We
interpret that most of those differences simply reflected neutral
mutations in accord with H. pylori's great genetic diversity. None of
the three mutations that are specific to 104R (E133K, G170S, and
E194K) is expected to affect RdxA function because they appeared on
the protein surface far from the FMN binding site. Thus, why strains
127R and 104R were resistant is not obvious: possibly their particular
combinations of changes in RdxA diminished function (conferred
resistance); or these strains might have polar mutations in the
upstream DNA that was not sequenced.
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Among the 18 rdxA sequences from MtzS strains, three (17%) had
internal stop codons (table 7.2) and three others had point mutations
that also might lead to rdxA inactivation: R16H (in one strain) because
it should decrease RdxA affinity for FMN's negatively charged
phosphate; and A67V (in two strains), because it entails replacement
of small alanine by bulky valine in the protein core, although direct
tests will be needed to learn how severely this replacement affects
protein stability and function. If these mutations do indeed cause rdxA
inactivation, the MtzS phenotypes might stem from high-level frxA
expression [222,224]; the possibility of nonsense suppressor mutant
tRNAs in certain strains also merits consideration. The nonsense
mutations between MtzS and MtzRstrains to 321-1gMtz/ml was
significant (p=O.002s, table 7.2), however, overall, the nonsense
mutations between MtzS and MtzRstrains was not (P=O.06S, table 7.2).
Fifteen substitutions were found only in MtzR isolates (H2sR, S43L,
P44L,A80I,A80T,C87Y, H97T, E133K, Sls8R,G163D,G170S,
G189C, E194K D20sA and A206T; table 7.5), which suggests that
some of them might decrease RdxA function. Conversely, five were
only found in MtzS isolates (S30G, T31A, A67V, A68V and Q197R;
table 7.5) and thus might be neutral (of these five, only A67V is
suspected of decreasing RdxA function, as noted above).
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7.3.2 Susceptibility of Gambian strains to other antibiotics.
All 64 of our Gambian H. pylori cultures grown directly from gastric
biopsies were found to be highly sensitive to the closely related
macrolides Cia and Ery. All cultures were also Tet and Amo sensitive
(table 7.6), although one and four of them contained rare Amo and Tet
resistant cells able to grow on medium with 21-1gof Amo or Tet/rnl,
respectively (frequencies of 10-3-10-4).
Table 7.6 Susceptibility of Gambian H. pylori strains to .
amoxicillin, clarithromycin, erythromycin and tetracycline
MIC (!-IQ/m!) Amo Cia Ery Tet
<2 64 64 64 64
2 0 0 0 0
8* - - - -
16* - - - -
32* - - - -
64* - - - -
128* - - - -
* Strains sensitive at 2lJg/ml were not tested at higher concentrations (8-
128IJg/ml).
Further tests of one TetR colony from each of these unusual TetR
subclone-containing cultures showed that their MICs ranged from 2-
41-1gTet/rnl and that each was indistinguishable by RAPD-DNA
fingerprinting from the predominant TetS strains from the same biopsy
(figure 7.6).
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Figure 7.6 RAPD profiles of four strains with TetR colonies
M 835 83R 2495 249R 2505 250R 2525 252R
Lane M is a kb DNA ladder (Biolabs, UK), "5" = Tet
sensitive cells; "R" = Tet resistant cells
These four sets of strains were not closely related to one another, as
expected, since they came from different persons. We found that PCR-
amplified 165 rDNA of each TetR strain was identical in sequence to
that of its TetS sibling from the same biopsy (figure 7.7). We conclude
that in each of these four cases, Tet resistance is due to mutation in a
gene distinct from that for 165 rRNA.
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Figure 7.7 Multiple sequence alignment of tetracycline
resistant and sensitive siblings
1 10 20 30 40 50 60 70 80 90 100 110 lZO 130
I--------+---------------------+---------+-----+_----+-----+_------.---------+----_-- 1
249_ Tet.R AGCCnATTTAGCATCCTGACTTAfUiGCIlRACACflAC T(C[ATG6TGTGACGG(jCGGTGAGTOCRAGACCCGGGRflC6TllnCACCGCRflCI1TGr.cTGATTTGCGnTTACTAGCGATTCCAGCTTCATGr.n
249_1 et.S IIGC(AATll AGCRTC("TGRC TTOOGGCflfWICflCflOCTCCCATGtiTtiTGRCGGGCGGTGAliTflCIIUiRCCC6G1iAlICGTRTTcncrtiCAIlCnHiGCTGRTTT GCGAJ lACTflGCURTT(CRIiC Tl cnrscn
83_ Tet.R RGeCRRl J I AGeATle TGRC11 flfUiIiCflHHCHCHft( nCCRl G6 T6 T6ACGGGCG61 GAGl RCfflGHCCC6Ii6Rf1C6' arr CRCCliCflHCH fllGC' GRTTTGCGA I TACT ftGCGHTTC(RG£ Tl CH rGCH
83_Tel.S AGCCAATTTAIiCATCCTGOCTIAfUiGCIlAACACAACTCc.cRTG6TGTGACGGGCGGTGAGTRCAAGACCC6GGRAC6TATT[.Flccr.cAACAT6GCTGRTTTGCGATTACTAGCGATTCCRGtTTCAT6CA
250_' eLI": AGCTAGTlI AGCRJa::TGOC T1 rIlGr.(]1RflCRUlOC fCa:AT(iliT6TGRCGGG[GG I GAG' OCfllGACCCliGliAlICIi fAT T(]1CCGCfll-lCI11 GGCl GATTTGCGnl TACTIlGCGIIT1[CRG£:ll CRTliCJ1
250_1 et.S AGCT AGlI TRGCRTCC fGIl: T1OOGGCIl'lJICflcnoc recent Gfi re TGRCGGG[GGTGAGI OCftflGflCCCGGGRlll"1iTflTTCRCCOCHl1C"TGGCI GAT I TGCGAI TACTIIGCGIIT T(CUti( fl mTCC"
252_ TeLR ItGCT AGl T TAGCA' CC TGf£TTRftIi6CARftCHCARl: TCCCATG6T1iT6ACGGGCGG TGAG TOCHAGRCCC6G6RHCGTflTT CACCfil::HftCA 16GC lliATTTIiCGRT TRCI RGCGRT TCCAIi(TTcn TGCH
252_ 1 el.S AGC TAG TTTAGCRTCCTGOC nf"lfHifiCflf1nCRCflOC TCCCATGliT6 TGACG6ijC(i6T6A6TOCFllGncccr.GGAIlCflTHTTCflCCGl:OOCRTliOCTIiATTTGCGATTACTnGCGRTTtCAro£. TTCATGCII
Consensus AliCeRa 11 TnGCATCCTGf':; nnnGliCflnnmcnocnCCAlGti I G rGACGGli[GGT GAG IOCIlUiflCCUiGliRIICliTflTl CRCCGCOOCIITGGCT GATTT GCGA' fRC1I1JC(iRTTCCRr.c. Tl cnrccn
131 140 150 1&0 170 180 190 200 210 220 230 240 250 2&0
1--------+--------------------- ...---------+---------------------- ...---------+-----.-----1
GliCGRGT I GCRGIX TACAAI Ct:GfUJ( HillliAGGCGT TTTGFWlGnTl GGCTCCA(TTCGCAGTATTGC' TCI CTTTGTGCflCC'CCA nGT AGCnClilGTGTR(ie(r I flGGCGI flAGGGCCII TGATGfICTHi
GGCGAG1 TGCHGCCTACRATCt:GfUICT6RGR6liCGT TT TGARGR n GGC' CCACTT CGCflG rATTGCTTCTcTTHiTIiCRCCCCATTGTRGCftC61GTIiTHGCCCT RGGCGlflAGGGCCfl TGATGflCT ra
6GCGRGTTGCRGCCTACARTUGfUICT6A6A6GCGTTTT6AAGATTG6CTCCRCTTCGCRGTATTGCnCTCTTTGTGCOCCCCATTGlRGCAC6T6T6TRGCCCTAGliCGTAAr.c.Gf_CRTGATGRCTTR
GGCGAGTTGCAGCCTACAfH[(GAOCT(jf'MjAGr.cGTTTT6nRGATT(j(jCTCCACTTCGCAGTATTGCTTCTCTTTGTGCOCCCCflTTGTAGCflCfiTGTGTAGCCCTnGGCGTAAGGOCCflTGATGRCTTfI
GGCGAG1 I GCIIGCC TAeARI CCGIIOC Hi";";OCGTTTTGOOGATl GGCTCCACTTCGCAGTAT' GC fTCICT TTGlliCOCCCCfHTGl eecncarut IiI nGCCCTAGGCGTRAGGOCCnTGATGflCT fG
GGCGAGll GCAGCC TA[AATC[Gftfl(T6R6F16IiCGTT TTtiAllGftTTG6[TCCAI: r r [6CAG TA lTGCTTCTI:TTlIiTGCfI([([ATTGTAG[A(6 rGTGTAGeC[1 RGG[GTfIFIGGOC[lHGAl Gft[lHi
GGCGRGTTGCRGCCTACAATtrGAACT6A6A6GCGTTTTGAAGATTG6CTCCACTTCGCAGTATTr.cnCTCTTTGTr.tOCCCCATTGTAGCRC6TGTGTAGCCCTAGr.CGTAAGGGCCAT6ATGACTTI6
r.GCGRG T I GC'IGCC TRcnnTCCGflOCTllAliflr.GCGl TT HiFWIGIH 1 GlJC TCCACT 1 CGCAGTATTGCTTCTCT TTGTGCnr.CCCnn Gl FM;CflCGTGTIiTnGI:CC TAGGr.LiTFWlr.GliCOHGRTGlICT Hi
GGCGAGTT GtRGCC 1nrnn I [((ifJOCHifIGflGIiCIiTTTTGfIlGATTGGCTCCACTTCGCnGTATlliC I-I C I C I n u f lil:1n.:Cl:CH 1 Tu 1nt.iClictiTGTGTAGCCC' AGGCGTOOGGGCCn rem GflC1 T.
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1--------+---------------------+---------+-----------------------+---------+---- 1
RCGI CGTCCCCACCnC1:TCCTCC TlRCG6A6OCftGTATCCTTAGftGTIC TCAGCRTGACCTGn RGCflFICTRAliRflA6liGliIi fTGCIiC ICGT IIiCGGIiACTTAHCCCHRCRT CTCACIiACflCliR6Cl GH
RC6TCGTCCCCACCTTCCTCCTC(TIACG6AGGCA6TRTCCTIRGAGTTCTCA6CATGACCTGTTRGCAACTAAr.AARGGI6r.GTTr.cGCTCGTT6CGGGACTTAACCCAACRTCTCRCGRCIIC6RGCTGA
ACGTCGTCCCCACCTTc.tTCCTCCTTOCGGfWiIiCAfiTATCCTTAGI1GTTCTCAGCATGACCTGTTAr.f..flOCTAAf,RARfir,c,GliTTr.cr.cTCGTTGCGGGRCTTAnCCCAACATCTCOCfoflCACGRGCTGA
IICGT eGT cCCCAcenC1:TCCICC TT ACGGAGGCR61RTCCT THmGT I CTCAIiCHTGACC fG n '''(.'1lOCntllGRflR6Ei6G1iTl GCGCTCGTT GCGGGRCTTAnCCCHnCATC rCOCGllCACGIIGCTGn
RCG rCG I (CtCAceTI CC rccr ITn flCG6A6IiCA6 rRTCC1IRGftGIICTCA6CflI6ACCTGTl ft6CflOCTRfI6RflA6G6G1iTTOCGC rest T6CGGiiAC I TAACCCHACA rCTCACGRCAC6ftGCTGA
ACGTCGTCCCCACCTTcrTCCTC£TTACGGAlGGCAIGTATCCTTAGAGTTCTCAIiCATGACCTGTTAGCAACTAAGAAAGr.,r;r.6TTGCGCTCGTTGUiGGACTTAACCCARCATCTCOCGRCAC6R6CTGA
RCGTCGTCCCCAa:TTCCTCCT[('TTACGliA(iOCA6TATCCTTnGAGTTCTCA(jcnTGACCTGTTAGCflOCTAA6fVUlIiG6G6TTGCGCTCGTTGCGGGACTTAnCCCARCATCTCOCGl1CACfiRfiCTr.tl
ACG rCGlCCCCflCCn cc TCCl ITTTOCGtiR6GCA61RTCCT TAGIlGT lCTCAGCR I GRCCTGTIIlGCnOCTnAGOORGGliGG TT Gt:GC I CGTlGCGGGACTlAIlCCCnACATCTCOCGnCRCCAGC"l GR
R[GT [6 1 [[[[ACC rr rcrccr C( nfl(66FtGGCF16 rRTC[TTAGHGT re I CA6[AT6RI:[ 1Gn RG[ROC TRH6Rf1tftiIiliIiliTTOCGCTCG-116CGGGACl TAACC[AACATClCOCGHCACtiRGCl Gf\
- - - - ~ - ~ ~ - ~ - - = =1--------...---------------------+------- -+-----------+-------+-------+------ --+----- 1
CGRCAG[CGTGCAGCACCTGnnCRA6GT(TRGCHRGCCAGACOCTCCACTATTTCTAIiCGGATTCTCTCAAT6TCRAGCCTAGGTRAGI6TTCTTC6TGTATCTTC6AATTRAACCACRTGCTCCOCC6
CGRCIIG(CGTGCAGCACCTGnncnAGGTCTnGCflAGCCAGACACTCCACTATTTCTRr.CGGATTCTCTCRRT6TCOOGCCTflGGTAfl(j{jnCTTCGTGTATCTTCGRATTAAOCCACATGCTCCOCt6
CGflCRGCCGT GCflGCHCCTG 11 TTCflIl(iGTClIIGCflfIGCTrJ:iACACTCCAClA1 T TClAGCfJ:iAI TCTCTtFWI TGTCRflGCCl RGGT ftflG6TTCl TCGTGTAGCRTCGnflTl IW'IOCCnOITGCTa:OCCG
CGACAGCCG fGCRGCACC TGT1 TT CRA6GTCTftGCflAliCTRliACAC I CCACIA' T lCTAGCflGATTCTCTCflft IGTCflftGCCTilGGl AAG6TTCT Tcut GIHGCATCGAAl TAARCI:ACflTIiCl CCOC[6
GGRCAGCCGTGCAGCACCTGnnCAfMjGTCTfWiCAA6CTAGATACTCCACTRTTTCTAIiCGGRTTCTCTtARTGJ[RRGCCTA6GTAAG6TTCTTCGTGTR6CTTCGRATTRRRCCAt.ATGCTCCOCC.G
CGACRGCCGTGCAGCACCTGnnCflAGGTCTFWiCIIAliCTAGFllOCTCCACTATTTCTAGCGGATTCTCTCOOTGTtRflGCCTflGGTOOGliTTCTTCGTGTA6CTTCGAATTAflRCCACATGCTCCOCCG
CGRCAGCCG I GCFlGCACC TG nTTCflIJ(iGI Cl fIIiCfllJ(iCTAGATFIC n:CRCTRl TIC I AGCIiGAT TCTCTCIIfITGTC"'lGCCTFlGGTOOGliTl ClTeGTG TAGCTTCGflATTflAlICCnCRTGCTCCOCCG
I:GACRGCCGTGCAGCACCTGTTTl CAfRjliTCTIIGCHAliCTAtiRlOCTCCR[l ATll C lAGCtiGAT TI: rr TCf.HG TCMGCCT R6GTflHG6nCl TCG TGTR6CllCGARTTAAttCCflCATGCl CCR(C6
C(iRCRGCCGTGCRGCACC TGnnCAR6GTCTflGCflA6Ct.AfiAcAClCCRCTRTTTCTAGCgGATTC TCTCAAHi TCARr.cClRGGTAAG6TTCTTCGTG TRtCt. TCGRATTRRACUICflTGCTCCACC.G- - - ~ - - - ~ - ~ - - ~ ~1---- ---+-- --------------- -- ...---------...----+------- ---------+---------+-- --+--- 1
CTTGTGCGGGTCCCCGTCTATTa:TTHiA(jTTTTAflTCTTGc:GI1CCGTACTCCCCAGGCGGGATGCnnRTGCGTTAGCT6CRTTACT6GAGAGflCTAnGCCCTCCAACAOCTAGCnTCCATCGTTTAGr.er TGTGCGGGICCI:CIiTC TA no: TT ftAli TT THin rcnGCmCCGI AeI CCCr::A~~C~GGA TGCT TARTGCGTTnGr.TGCAnOCTIiGllGfUiElCTARGCCC TccnncnOCTAGCIIlCCATCGT1 fAG6
CT 161 GCGGGTCCCCG TC lAll ccrr T6fllilT TTRIITCTl OCGRCCGTAC TCCCCH(j6C6GGA TGCT THAl GCliTTAIiCTGCflTl OCTGGHGftGltClAAGCCCTCCAACAOCTAGCRTCCAI C1iTT rsss
CTTGTG[GGGTCCCCGTCTAnC(TTT6A6nTTfWll(TTGCGACCGTACJ(CCCAGGC6GGATGCTTflRTGCGTTflGCTGCATTACT6GAGAGACTAAGCCCTCCAACAACTAC.cRTCCRTC6TTTRG6
CTTGTGCGGGTCcccc.TCTAncrnTtAliTTTTAATCTTGCGACtGTACTCc[CAGGCGGGATGCTTnnTGCGTTnr.c:TGCAnOCT6C,fIGI1GHCTRAGCCCTCCAAcnOCTRGCATCCATCGTTTRr.c
(TTGTGCGGGTCCCCGTCTATT[(nn;fMiTTTTfIfITCTTGCGnCCGTACTCCCCRG~CGGGATGCTTnRTG(GTTRGCTCCATTAC~GGftGflGflCTRnGeCCTCCnR(AOCTnGCnTtCATctlnTnGG
C1161 GCtiGGICCCC1iTCTR T Icern 6f16TT rt RIll (TT GCGACC61 AC I tCCCRGliCGGGATGCI fAATOCGl fflOCT6CflTl RCI GGHGHGlfClAAGCCe I rCAACAR[TAOCRl CCAlC6ITTHli6
[TTGTGCGGGTCCCCGTCTRTTCl:TTT6RGTTTTAATCTTGCGflCCGTACTCC(CIIGGC6GGflTGCTTAATGCGTTAr.r.:TGCIITTACTCGflGflGRCTARGtCCTCCRACAACTAGCRTCCATC6TTTRG6
CTTGTGCGGGTCCCCGTcmna:.TTTGAGTTTTOOTtTTGCGACCGTACTCCCCAG6CliGGATGt.TTAATGCGTTAGCTtCATTOCTGGflGROOCTAAGCCCTCCRACAACTAGCRTCCATCGTTTA(I(i
- ~ ~ - ~ - ~ = ~ - - - = -I--------+----------- ---------+---- ----+----------------------+-- ------+----_-- 1
GCGT tGACTRCCIIJGli TATC TRR1 C[TliTTrGCTa:ccocGC nn:GCGCRA TCRGCtl CRG rfllTGTTCCfIGCflG6TCGCCT rCGCnttTr.flG ImlCCTCTlGn rCTCTOCGGlI1 TT mcrccrnrncc
GCG fGGRCTACCRGGGTATCTflRTCC Hi TT IGCTCCCCOCGCTTTCGCGCAATCAGCGTCAGTHflTGTTtcA6Cfllili lCGCCTTCCCAUTGf1GTnTlC(lCTT GRTC I C I OCGGATT1TIICCCCT ACACC
6CG166AC l'ACCItiGG fA rr TAHTCCT6TTT6CTUCCOCGCTT TCGCGCAA I I:AGCGT CAGT RAT6TT[CR6CAG6TCGC[T TCGCRHT6FIG TATI ccrcr r 6R ICTCTOCGGHT TTTflCCCC rumcc
GCGT6GACTACCOCiGGTATCTAATCCT(jTTT6CTcctrOCGCnTCGCGCAATCAGCGHAGTAATGTTCCAGCOG6TCGCCTTCGCAAT6AGTflTTCCTCTTGATCTCTFlCGGATTTTACCCCTACACC
~~~!~~=~~=~~:~i~ig==~~~~~~·~~~~~~~~g~~~~~~=}~=~~~~~=~}:~~~~~::g:~~g~g~~~=~~:i!:~ig~n~~~~~·~!-~~~~~gr:~~~:~-::~
GC6TGGRCTACCflGGGTRTCTAATC(T6TTT6CTCCCCACGCTTTCGCGCARTCAGCtT[AGTRATGTTCCRGCflr.GTCGCCTTCGCAATCRGTRTTCCTCTTGRTCTCTACGGATnTACC[CTACACC
GCGTGGACTACCAGGGTATCTAATccnTTT6CTCCtcACGCTTTCGCGCnRTCAGCGTCAGTMTGTTCtAGCIlG6TCGCtlTf.GCOOTGAGTATTCCTCTTGATCTCTACr.GnTTITACCCCTACflC.C
GCIiTGGnCl ACCfJJGG rAT(TRRTCt:HiTTTGCTCCtc,ICGCTl TCGCGCAR ICAGCGTCAGTIIATGTTCCRGC1IGGTtGCtl TCGCFWlHiFl(iIHTTCC' CTTGA ICl CTOCGGnTll TRCCCCTflcnCC- - - - ~ ~ - ~ - ~ ~ ~ - ~~~~~~~~~~~cc~crTC~~ococ~r;GfiFif~rn~nc;;oo~c~Gi~r;~;~G~;;;~CA;;~ffinC;;cn~~~~OCrnKCCGCC;~CGCGClcli;ocGCcr;;~~f[UiiRiT~
HA6AR l '([ACe fRIXltTC((OCft( TC TAGftRTA6TA(iT TTCAfIt 16CA6T ,I:1AT6G1 'AAG(CATRfi6R I T1 [R(flCC f6F1( I lift( 'AT(CCGC[TA[6(GCTI: TTl ACGCCCRG TGRTTCCGRGTR
AAGRATTCCACCTACCTCTC[(OCOCJ(TAGAfHRGTAGTTTCIIARTGCAGTTCTATGGTTnAGCCATAGGATncncnCCTr.OCTliOCTArcCCGCCTRCGCGCTtTTTocr.cCCnGTGATTCCGf'ljTA
~~~=~1i~~~~~~=~i~~~g~~~~i:~~i:~:~~1~g:=}~~=~~!~~=~~~i~=~g:~:~=~gg:g:~r~~~·~~!:~~~~~~1~~~~g~H~}{~~~~ig~ii~~:r:
RR6ARTTCCA(CTACCTCTC[(ACA(TCTAGAATAI6TAGTTTCflAATI6CRGTTCTRTGGTTAAGCCRTA~ATTTCACACCTGACTGACTATCCC6CCTACGCGCTCTTTOCGCCCJI6TGATTCCGA6TA
AAGRATTctRCCTACCTCTCCCRCOCTCTAGfUlTfWiTAGlTTCAFVtTGCflGTTCTATGGTTAAGCCATnr,(lATTTcncnr..cTGOCTGOCTflTCCCGCCTnC6CGCTCTTTocr.c:rs.oc,TGATTCCfiIlGTn
nAGAR I rCCACCTACCTCTCCt:OCOC I CTfIGflRTA6TnGT 11CflFWlI GCHGT IClA' ~Gr1fI'lliCCAlnGliAl Tl cncacc rGRCTGOCIAlCCCGCCTACGeGC rCT 1TACGCCCRGTtiAT rcccscm
RA6AR IICCACC TAeeTCTCCCRCfI(J( THGflRTflliTAGT I T CHAIl T6tAG r TC lATGGT TfIFIGCCA rRGGATT TCHCACCT6OCHiOCTflTCCCGCCTAC6C6CTCl TTOCGCCCfIGfGHTTCC6flliT R
~ _ _ ~ ~ - - ~ ~ ,- ~ ~ ~ -
AC6cTlficA~(crrCG~y;occ;C6f.(r;UG6CH[6;;GllHiiC66~G[lTR1T[G~jHGRTocC6~mTHrrn~u;;a;;;;;GAGijiR[~AT(CT~A~A~crITRTU~[RC6C6r.cG{
AC6CTTGCACCCTCCGTATTOCCGCGGCTGCTr.GCflCliGAGTTAGCC6GTGCTTATTf.GTTAGATACCGTCATTATCTTCTCTAACRAAA6GAGTTTACAATCCTAAAACCTTCRTUTCCAr.6C6r.cGT
ACGCTTGCACCCTCCGTFlTTOCCl6C16GCTliCTr.6C11tGGRGTTAGCCGGTGCTTRTTCGTTRGRTRCC6TCATTATCTTCTClfVlCfUVlf1(;GAGTTTRCAnTCCTAnOflCCTTCATC(TCCflUr.IiGCGT
RCIiClIGCRCCCTCCGTAHflCctiC1iGC TGCTCGCActiGflGT TRGCC1iGIG(1 rat TCGl I_HGRTRCctlTCATI flTCTTCl(T RRCHfV-IAliGRGT TlACOR I CClARARCCI TCATCCrccnCGctiGCGT~~~~~~~~~~~~~~~~~:~~~~~g~g:~~=~~~:~~~~~~~i:~~~~i~::~~~~~~~~~=~~g~:;g::~=:~g~~~~~~~~~~t~~~~~~}~~~t~t~~~~~~g~
~~~g~~~g=g~g~g~~=~~~~~~~~g~g:~~~~~=:i:i~~g~~~=~r~gi;~~~~~~~=~~:~gggg=~::::::g~~~~g~:!~g~~~~~gg~~~=!~1·~~g:~~~~~
RCGCTTGCRCCCTCCGTATTACC6CI6GCT6CTG6CAC6roAGTTAGCC66TGCTTATTCGTTAGRTRCC6TCRTTATCTTCTCTAACAAARGGftGTTTACAATCCTAAAACCTTCATtCTCCAC6C6GCGT
~~~~--:~~~----~~---~~---~~---~~~------~:~~---~~~--~~~----~~~---~~~~------:~~~---~~---~~~
TGCT&CTTCAGGGTTTCCCCCIITTGAGCAATRTTCCCTOCTI6CTGCCTCCCGTRGGRGTtTGGRCCGT6TCTCA6nttfWiT6HifCCI6TTCACCC.TCTCRGGCCGGATACCCGTCRTAI6CCTTGliTAfWi
rg~~~g~~=~gg~i!~~ggr=:~=~:g~g~~~g~g~g~~~~=gg~~n~~~~~~~g~~::~~::i~~~i~~g~~g:~gg~=~~ggg~=r=~~T~~;~~g~~~=
~~~~~g~~=~~~n~ff~~g:::i=i:g:~g~~:g:i~H~~~~:~~=~~n~~~i~i~~~=gg::f~f:~~~~n~~gg~:~~~~~~~i=~~~~:i::~g:i::
~g~~~~i}~~~~}}~~~g:g~~=i:r}gg~}~g~~~~~~~~=g~~~~~}~~~~~~~~g:g~~~~i~~~~}_~g:~~~gig:gg~~2~~1=~~ig~~~~i~~}:::
1GCT6C 11 CRGliGTTTCCCCCATl GAGCAfI fATTCCCTOC 16CTGCCTCCCGT =~~~~~~~GGACC1iTIi fCTCAGn COts T6n; TCCliT1CflCCCTCl CAGliCC66Al ACCCG TCRIRliCC TlliliTRfIIi
TGCTGCTTCRCJGGTTTCCCCCflTTGAr.cAATATTCCCTOCT6CTGCCTCCCIIT J GGACCGTGTtTCAGTTCCAGTGrr.TCClinCIICCCTCTCflGGCtGGATACCCGTCRTACCCTTGliTRR6
~~ ~ ~ ~ - ~ ~ ~ ~ ~ ~ ~ ~
~CR;T~[CT;RCCA~Mr1T6MA6~;;mr.Gcrr.;~Tcn;;C6A~~AA~~~~~g~~CCcc-GTnG~;mrrnGl:r~R1cnITr,nccAnT~~~;~T~c~A;;~CT;;;;~~CATGocCTn+
CCA rmccrr RCCAOCJllGC"lGRT";GllCATRIi6Cl GIIT(TCI fAliCliflTAAA .• GIIIGGliRliTnTCTGCTR1TRRTCATCGTnCCRHTGGC Inr CCCARRCTOOGflGGCAcnTGOCCTHT
CCfI rlRCCTT ACCRRCIWtliCT6AI fIIiliflCflTHIi6CTlifITCTCTl A6C6A TAH:i~iiiU~~GTRGli6ft6TATC1GGl HI TRRlCftTCGIT T[("RAT6GCTHT [(CARflCl RRGAIi6CACATGRCCTRT
~~=g=~~~~~g::i=~~::i=:~i:~~i:~~~~~:~=i:~ATCTTTCCCCCg~:::~:i~~~g~:i~:~ig:i~~~g~=:i~~~~:i~~~=:~~~::~~~~~~g~:;
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7.4 Discussion
H. pylori infection contributes importantly to several human diseases
in both developing and industrialized countries, and directly impacts on
health care systems worldwide. Its public health impact is of particular
concern in developing countries because the prevalence of infection is
so very high [102,305].
Here we scored susceptibility and resistance to clinically relevant anti-
H. pylori agents using a test of efficiency of colony formation by single
cells. This test is especially useful for scoring susceptibility toMtz
because Mtz can be mutagenic as well as bactericidal; it both induces
and selects for resistance mutations [222,224,225]. We found that
more than two-thirds of Gambian H. pylori strains were Mtz resistant.
This high prevalence can be explained by the relative low-cost and
easy availability of Mtz in The Gambia, as is typical of developing
countries worldwide. Our results are in accord with other reports of
many Mtz resistant strains elsewhere in Africa
[109,169,221,228,317,318], India and Latin America [21,319].
Typically somewhat less than half of H. pylori strains from Europe and
North America have been found to be MtzR[216], likely reflecting the
tighter control of Mtz usage in industrialized than in developing
countries. Our observation that all six strains from infants (18-31
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months of age) were sensitive to 8IJg of Mtz/ml, in contrast to 24% of
those from older people (~14 years) (P = 0.003) also merits further
examination, especially on the possibility that rdxA function might
contribute to fitness during establishment of infection.
Prior studies with other sets of strains had shown that Mtz resistance
typically involves inactivation of rdxA, which encodes a nitroreductase
that converts Mtz from prodrug to bactericidal agent by chemical
reduction. However, H. pylori strains also contain a related gene, frxA,
which also confers Mtz susceptibility if highly expressed, independent
of rdxA status [222,229]. DNA transformation studies performed in
this study indicated that each of 11 MtzS Gambian strains tested
required only rdxA inactivation to gain a MtzRphenotype, and
conversely, that resistance involved rdxA inactivation in each of the 12
MtzRstrains tested.
Sequence analysis of rdxA genes from study strains identified loss of
function mutations that should cause Mtz resistance similar to those
found in previous studies [222,224,320]. In particular, rdxA nonsense
(stop codon) mutations were more common in strains with moderate
level resistance (32IJg/ml) than in strains with lower level resistance
(8-16IJg/ml), in agreement with other findings [222,224,320].
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However, three of 18 MtzS strains had rdxA-nuli nonsense mutations
and three others had point mutations that also possibly might result in
inactive RdxA proteins. These observations are consistent with other
reports [222,224,321,322] that rdxA inactivation need not always lead
to Mtz resistance, and can be explained by postulating higher level
expression of the related frxA nitroreductase gene [222,224].
We also found that most MtzRstrains had mutations scattered across
the rdxA gene that are not likely to contribute to their resistant
phenotype. This is in accord with H. pylori's well known great sequence
diversity, here seen in the rdxA gene.
Increasingly frequent Cia resistance, up to one-fourth or more of H.
pylori strains has been reported in Europe and North America
[216,308]. High prevalence, where encountered, has been attributed
to use of macrolides to treat respiratory infections [216,323-325]. In
The Gambia, Ery is now routinely used to treat lower respiratory tract
and skin infections. However, there was no evidence of resistance to
Cia or Ery in the 64 H. pylori we tested in accord with results reported
in a nearby country (Senegal) where only 1% of isolates were resistant
to Cia [317].
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Tet and Amo are also much used. Tet, especially, is cheap and readily
available in local drug stores in The Gambia, often without
prescription. However, its easy availability did not result in much
resistance in Gambian H. pylori strains: TetR strains were recovered
from pooled cultures from only four patients, and then only as very
rare cells in the population. This outcome is in accord with the rarity of
Tet resistance in H. pylori from other parts of the world
[216,317,326]. None of the four TetR strains had mutational changes
in the several allowed positions in the 16s rRNA Tet binding pocket
that can result in modest Tet resistance [236,237]. Thus, by default,
their resistances are likely to stem from mutations in other loci - a
class of mutations previously interpreted as more easily achieved, but
also likely to diminish H. pylori fitness [236]. We propose that the low
probability of mutation at just a few specific rRNA sites and low fitness
conferred by Tet resistance mutations in other genes explains the
rarity of TetR H. pylori, despite considerable exposure, in The Gambia.
Resistance to Amo was also very rare in Gambian strains, much as has
been reported for other geographic regions [216,326].
7.5 Conclusion
The increased prevalence of resistance to antibiotics used against H.
pylori is of great concern especially in developing countries where the
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costs of even the least expensive first line drugs are a burden to
average citizens. This contributes to the urgency of monitoring
antibiotic resistant strain frequencies to help clinicians effectively
manage patients and their antibiotic regimens, and effectively deal
with treatment failure. The rich repertoire of rdxA mutations found in
our many Gambian H. pylori strains should be useful for future studies
of RdxA structure and function, of how RdxA and its FrxA homolog
make H. pylori susceptible to prodrugs such as Mtz, and the roles of
these two nitroreductase enzymes in H. pylori's central metabolic
networks.
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Chapter 8 Discussion of hypotheses, aims and objectives
The primary aims of this study which was to characterise and evaluate
the putative virulent H. pylori genotypes in The Gambia in relation to
clinical outcome have been fulfilled.
8.1 Putative virulent factors such as cagA and vacA influence
disease outcome in The Gambia.
The association of H. pylori virulent genes such as cagA and vacA and
gastric pathologies (gastric cancer, duodenal and gastric ulcers) have
been well established in some studies [268-270]. However, several
studies from different world regions have not detected such an
association [21,79,80,93,268,327-329], an outcome suggesting the
possibility of other virulence-modulating factors.
In The Gambia, virulence genes were indeed common similar to results
in Western countries where gastric cancer is high [330]. The cagA
oncogene and the vacAslml toxigenic alleles are often linked to
severe gastric pathologies. In this study, it was found that cagA was
significantly associated with gastro-duodenal disease but vacA was
not. Therefore, this hypothesis was accepted only in respect to cagA.
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8.2 Mixed colonization with different genotypes influences the
development of gastroduodenal disease.
Most important of our novel finding was that the co-existence of cagA+
and cagA- strains was significantly more common in patients with NUD
than those with severe gastric diseases; however there was no
association between mixed vacA alleles and gastroduodenal disease.
The study indicated that the coexistence of both cagA+ and cagA-
strains in a single host was protective against the development of
gastroduodenal disease. Therefore, this hypothesis was accepted in
respect to cagA status.
8.3 Children and adults in the Gambia are colonized by different
strains of H. pylori, which therefore circulate amongst different
age groups
The transition from childhood colonization to adult disease state is
affected by multiple factors including evolution of genotypes of
colonizing H. pylori strains themselves, driven in part by the host
response to infection. The chronically infected adults are likely to have
reached a "steady state" of adaptation between host and pathogen
after a period of many years. Phylogenetic analyses of strains found
that the MLST types found in children who have been recently
colonised completely intermingled with MLST types of adults from the
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same population suggesting that strains from both groups of study
subjects were similar in conserved genes. Children and adult strains
had both genotypic and phenotypic differences in relation to virulence
genes and antibiotic susceptibility to Mtz respectively. Young children
significantly carried less virulent strains than any of the adult groups
and we also found that all children strains were sensitive to Mtz. The
difference in Mtz sensitivity between adults and children isolates is an
indication that Mtz resistance might have developed from intensity of
use over time for the treatment of other infections (parasitic and
vaginosis) which are common in our environment. During the course of
this thesis, we have seen no evidence that different strains circulate in
different age groups, but evidence to suggest that strains may evolve
into new genotypes within individual host. Therefore, this hypothesis
was not accepted.
8.4 Gambian isolates of H. pylori form a distinct phylogenetic
family within the grouping of African derived strains.
The population structure of H. pylori from West Africa has previously
been barely determined, albeit a few strains in the MLST data base
despite the high levels of prevalence. This data set presented in this
thesis reported the largest sample to date from West Africa
determined by MLST. MLST of seven housekeeping genes showed that
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H. pylori followed human migration out of Africa and identified seven
H. pylori populations. We found the strains from this previously
unstudied far West African population do form a distinct phylogenetic
family within the grouping of African derived strains but show genetic
similarity with hpAfrical particularly hspWAfrica which shows their
possible common genetic origin and therefore this hypothesis was
accepted.
8.5 Study objectives
8.5.1 Genetic relatedness and phylogenetic of isolates in a
single stomach
In a European study, differences in colony morphology reflected
genotypic characteristics in relation to cagA+ and cagA- infection [186].
In this study, when we looked at different looking colonies from two
individual stomachs, all colonies from one individual were identical by
RAPDand MLST in accord in what was observed in Colombia [117].
The other individual had three distinct RAPDprofiles and also three
distinct MLST types consistent with other findings [89,101,186]. The
sequence types of these three strains were different in all gene loci
showing that one can have different strains of H. pylori colonising one
or more sites of an individual stomach. Further, in the subject with
multiple MLST types, it was believed to be a case of re-exposure to
novel strains colonizing the individual rather than recombination of the
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H. pylori. This shows that true mixed infections may have been due to
repeat colonisation events and not to recombination, at least in this
subject.
8.5.2 Prevalence of antibiotic susceptibility and resistance to
amoxicillin, clarithromycin, metronidazole, erythromycin and
tetracycline
The treatment of H. pylori and its eradication continue to be a
challenge especially in developing countries despite being sensitive to
many antibiotics [29,216,226,323]. The factors associated with the
cure of H. pylori includes increase in resistance to commonly used
drugs, high rates of re-infections [226] and poor compliance [219].
Studies in India and Peru have reported 73% and 43% [226]
recurrence of H. pylori infection within the first year respectively in
patients whose initial infection was successfully eradicated.
Several regimes have been evaluated and currently used for treating
H. pylori infections but the optimal therapy has not yet being defined,
more so in developing countries where this is dictated by availability
and affordability. The choice of antibiotics for the treatment of
diseases is usually driven by antibiotic susceptibility tests but this is
rarely done in H. pylori infections. With the increase in antibiotic
resistance, this may contribute to treatment failures.
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In this study, we found that all Gambian H. pylori cultures were highly
sensitive to Cia, Ery, Amo & Tet but resistance to Mtz was high and
were only seen in adults especially in females. All strains from young
children were sensitive to Mtz. We also found rdxA, an established
locus that harbours mutation in many Mtz resistant isolates was
responsible for most of the resistance in Gambian H. pylori isolates in
accord with other findings.
In The Gambia, erythromycin routinely used to treat ALRI especially in
children and more recently clarithromycin in some clinics is a cause for
concern as current treatment regimes for H. pylori are often beyond
the reach of most Gambians.
8.5.3 The usefulness of peR in the diagnosis of H. pylori in The
Gambia.
Presently, there is no universally accepted "gold standard" for the
detection of H. pylori. Culture based techniques for bacteria are
generally cost effective and relatively easy to perform and reproducible
for most clinically relevant bacteria. However, the culture and isolation
of H. pylori, a fastidious organism, is both challenging and technically
difficult to perform. Gastric biopsies are often contaminated with gut
and upper respiratory tract microbiota and so it requires a selective
medium with various antibiotics and an antifungal [253] for its
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successful isolation in the laboratory. Further, H. pylori is a micro-
aerophile and requires micro-aerobic gaseous environment provided by
either Gaspaks or micro-aerobic incubators. All these requirements
make the culture and isolation of H. pylori expensive and technically
challenging especially in resource poor countries.
Thus, various DNA based methods have been evaluated to determine
an optimum method for the detection of H. pylori in biological
specimens. The use of peR was found to be slightly superior in our
hands with a higher diagnostic suitability, faster and technically easier
to perform.
However culturing H. pylori is still important for antibiotic susceptibility
tests that could guide therapy especially in cases of persistent infection
where the isolation of the organism is important [331,332]. The choice
therefore of test for the detecton of H. pylori from clinical samples
largely depends on the clinical situation, resources and the local
expertise available.
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Chapter 9 Concluding remarks
9.1 Limitations of the study
9.1.1 Sampling bias
Due to invasiveness of endoscopy, most H. pylori studies including this
one, has a sampling bias in that only symptomatic patient with
suspected gastric diseases significant enough to warrant upper gastric
endoscopy were selected and investigated. In addition, samples were
taken only from a small part of the stomach. In this study most of the
samples were collected from the gastric antrum because although
some of the study subjects allowed research biopsies from different
regions of the stomach; but most consented only to a single biopsy
which was taken from the antrum. Although the antrum is the most
colonised area of the stomach as far as H. pylori is concerned, it is
possible for a different strain or strains to colonise other parts of the
stomach such as corpus and/or fundus. This has potentially affected
our aim to look at variation within single host in great detail.
9.1.2 Sample size
Over 400 subjects were routinely investigated for possible gastric
disease during the course of this study but only a third consented to
joln the study. Increasing the sample size could have been more
representative, but due to limited resources and invasiveness of
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technique, this was not possible. Advances in less invasive techniques
such as the use of string test, gastric washings which reflects the
whole stomach, and stool antigen test [29] may allow increase in
sampling and provide opportunity for large epidemiological studies to
study the dynamics of H. pylori infection and its transmission by
looking at asymptomatic individuals and parents whose children are
colonised.
9.1.3 Children strains
We have seen in this study that children carried mainly less virulent
strains but the numbers investigated were small which limits our
ability to make any significant conclusion. Increased sample size would
have provided us the opportunity to evaluate the specific features that
contribute to the success (from H. pylori's perspective) of initial
colonization, and subsequent evolutionary changes that lead to
adaptation, and potentially gastro-duodenal disease after many years
of chronic colonization. This limitation was due to lack of adequate
resources and the need for an experienced paediatric endoscopist and
the related patient care associated with such patients.
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9.1.4 Lack of histological assessment
Gastric diseases were mostly diagnosed by macroscopic examination
of the stomach only and the classification of diseases may have been
inaccurate without histological assessment. In a study to investigate
gastric intestinal metaplasia, about 8% with normal gastroduodenal
tract appearance by endoscopy may have had premalignant gastric
lesions [333]. Thus, histological examination of gastric biopsies could
have increased the accuracy of gastro duodenal disease classification.
9.1.5 Culture and mixed infections
H. pylori is a fastidious organism and biopsies are often contaminated
with gastric and upper respiratory tract microbiota. Only 53% of
gastric biopsies cultured were successfully isolated and purified. This
was mainly due to either failure to survive subculture or contamination
despite the use of a selective media. In addition, the repeated
passaging of cultures to obtain a confluent growth for storage and
analyses may have contributed to over enhancement of minority
strains and also influence changes in the bacterial genotype due to
recombination/mutation thereby over representing the presence of
mixed infections in culture as indicated in chapter 5.
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9.1.6 Data
The only endoscopy unit in The Gambia is found in MRC, Fajara where
the study was conducted. A bias may have arisen on the prevalence of
gastric diseases and geographic locality of patients as only select
patients are seen in this unit; those who can afford the travel distance
and those lucky to obtain endoscopy as only a limited number of
endoscopies are undertaken each day. Most patients from other
regions outside of GSA stayed with relatives on the coast during the
course of investigations and treatment and gave these locations as
their addresses instead of where they actually come from. A robust
demographic information system and a good follow up will in future be
necessary to provide insights into the prevalence of gastric diseases in
the different regions and also relatedness of strains and possible
sources of infections.
9.1.7 Genotypes and gastric diseases
Several studies have identified many genes that were implicated in the
development of gastric diseases [334,335]. At least in Western
countries [335], the presence of homA, homB, sabA were also found to
be associated with the development of gastric diseases. In a study of
Colombian subjects [329] using micro-array, Jhp0045 and Jhp0046
were shown to be associated with gastric carcinoma in cagA positive
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cases. Thus, the detection of only cagA and vacA in this study is
limited in the information that they provide.
9.1.8 Phylogeny of H. pylori
MLST is often regarded as the "gold standard" method to determine
the genetic relatedness of H. pylori. The test produces data that is
highly unambiguous, reproducible, and portable and can discriminate
between many sequence types and can be used to investigate
evolutionary relationships among bacteria. However, a limitation of
MLST is the need for DNA sequencing, which is restricted to few
institutions. Further, due to the sequence conservation in
housekeeping genes, MLST sometimes lacks the discriminatory power
to differentiate bacterial strains, which may limit its use in
epidemiological investigations. To improve the discriminatory power of
MLST, a multi-virulence-Iocus sequence typing (MVLST) approach has
been developed using Listeria monocytogenes [336]. MVLST broadens
the benefits of MLST but targets virulence genes, which may be more
polymorphic than housekeeping genes.
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9.2 Future studies
1. Given that more genes than those examined here are implicated in
the development of gastric diseases [334,335], it would be useful
to investigate the presence of other genes in this largely unstudied
population and their relationship with gastro-duodenal diseases.
2. H. pylori share their gastric niche with numerous other strains and
bacterial species (and some protozoan species) and given that H.
pylori engages in DNA exchange with other strains and bacterial
species, metagenomic analysis would provide us the opportunity to
study the composition of the stomach microbiome in relation to
presence or absence of H. pylori and genes encoded in the
different species.
3. DNA sequencing used in this study only looked at highly conserved
housekeeping genes; the rest of the genome may be different.
About 60 of our strains have been deposited at the genome centre
in Washington University, St. Louis, USA for whole genome
sequencing.
4. The use of a minimally invasive technique such as the string test to
look at asymptomatic subjects, children and parents whose
children are colonised could allow us further to evaluate the
prevalence of H. pylori in The Gambia and possible transmission
routes.
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9.3 Closing remarks
Despite these limitations, this study provides a detailed initial
description 'of a set of H. pylori isolates directly related to a
geographically defined West African population. This has answered
some relevant questions on H. pylori virulent genes in association with
gastro-duodenal diseases in this population that may have contributed
to the gene pool of H. pylori in Europe and the Americas, and
described susceptibility and resistance to clinically relevant anti-H.
pylori agents that are commonly used in The Gambia and reported the
molecular basis of their anti-H. pylori activities. All of the clinical and
virtually the entire laboratory procedures were conducted in The
Gambia, providing a comprehensive basis for future studies into areas
that need to be explored further and in greater detail.
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Chapter 11 Appendix A - Study approvals
DMID IRS Approval Certification
Purpose A completed and signed IRS Approval Certification form certifies that the documents
listed in section III were submitted and approved by the IRS listed In section II and does not
replace a valid IRS approval letter or stamped informed consent form.
COMPLETION INSTRUCTIONS
i 1 Provide information requested In sections I, II and III.
: 2 The Srte Prindpal Investigator must review, hand sign and date the completed form.
'3 Please read carefully. If any information is incorrect, please contact the PPD-CTM Essential
Documents group at email address: dmidregdoc.distribution@wilm.ppdl.com.
'4 "ax the completed, signed and dated form to FAX (919) 654-4665 or send as an attachment to
th~.~~.~~I._a.~_~:~.S..s~_.d.mi.ct.Ee8~"'E.<1.Is~r.i~~tic>n..@~ill!,l.PP.ct.I. .c?m •....
I. GENERAL INFORMATION:
DMID Protocol Number:
Full Protocol Title:
06-0053
Genotypes of Helicobacter pylori in West African Children and
Adults:
Part 1: The Development and Evaluation of Minimally Invasive
Techniques for Obtaining H. pylon'lsolates from Adults and Children
in The Gambia
Site Principal Investigator. Prof Richard A Adegbola
II. IRSI1EC INFORMATION: Please complete one form for each IRS/IEC, if applicable.
IRSIIEC Name· The Gambian GovernmenVMRC Elhics Committee
III. DOCUMENT INFORMATION: Provide a complete list of the IRS appnoved documents, including
version number andlor date with corresponding approval date. Examples of document types:
protocol, protocol amendments and 'protocol-associated' documents, such as the informed
consent form. study advertisements, or written information given to study subjects.
Document(s) Submitted I Version Number
andlor Version Date
_1, 1.9 March 2007
1. 19 March 2007
1, 19 March 2007
IRS/IEC
Approval Date
April 27'" 2007
April 27" 2007
April 27" 2007
Pnotocol Number 06-0053
Information sheet and Conse_r:!!_forrn (Adults)_ __ ._
Information sheet and Consent form (Children)
PI Signature Date
Richard A Adegbola
PI Name (please print)
DMIO IRS Approval Certification Form vs 0 dated 09-Apr-08
Page 1 of 1
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.;\~;..,.,""""1' ,.. )..: , . Medical:.
<M'l:" [), Research. "C Council',
4.:,·,"\ ,. '''<I,f
Scientific Coordinating Committee
Medical Research Council Laboratories Fajnra
Tel (220) 4494564/4496715 FAX (220) 44965 J 3/4494498
Email: scc@mrc.gm
Website (intranet): \\open.mrc.gmlscclhome.asp
J z" April 2007
Dr Richard Adegbola
MRC
Fajara
Dear Richard
RE: L2007.23· 19" March Z007. Genotypes of Helicebacter pylori in West African children and
adults (Ref sec 988vZ): Protocols version I of 06·0004 and 06-0053 dated 12" MArch 2007 and
19" March 2007 respectively.
Thank you for your letter which was considered at the recent SCC meeting on April 7'". As the
sce was happy to approve the current versions of your protocol. namely version I (l3'h March
2007) of DMID protocol number 06·0004 and version I (l3'h March 2007) of DMlD protocol
number 06-0053. as outlined in your letter. It was also noted that Dr Robert Walton is now
performing most of the endoscopies in the hospital and may therefore be added to the list of
investigators.
With best wishes
Yours sincerely
Prof. Sarah Rowland-Jones
Chair. Scientific Coordinating Committee
222
,I
Medical
MRC ResearchCouncil ..:
Scientific Coordinaung Cornminee
Medica I Research Council Laboratories Fajara
Tel (220) 4494 ~64/44967 J 5 FAX (220) 4496513/4494498
Email: scc@mfc.gm
Website (Intranet): IloPeI'l.mrc.gm\scclhome.asp
24th April 2007
Dr Richard Adegbola
MRC
Fajara
Dear Richard
RE: L2007.13 - 19th March 2007. Genotypes of lJelicobacter pylori In West African children lind
adults (Ref se 988v2): Protocols version 1 of 06·0()04 And 06-0053 dated 12"bMarch 2007 and
19'b March 2007 respectively.
Thank you for your lerter which was considered at the recent SCC meeting on April 7111• In
addition to my letter dated 12'h April 2007, I am happy to note that the protocol is consistent with
the grant.
With best wishes
Yours sincerely
Prof. Sarah Rowland-Jones
Chair, Scientific Coordinating Committee
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The Gambia Govemment I MRC laboratories JoInt
ETHICS COMMITTEE
clo MRC laboratories Fajara
P. O. Box 273, Banjul
The Gambia, West Africa
Fax; "'220 -449449B or 4496 513
Tel: "'220 - 4494 073-9 ext.409
30'h April 2007
Dr Richard Adegbola
Head of Bacterial Diseases Programme
MRC Fajara
Dear Dr. Adegbola
RE: L2007.23 - t9'b March 2007. Genotypes of Helicobacter pylori in West African
children and adults (Ref SCC 988\'2): Protocols version 1 of 06-0004 and 06-0053 dated
12'b Marth 2007 and 19'h March 2007 respectively.
Thank you for submitting the proposal documents for the above study. These and your
covering letter and the sce's letter were discussed during the Gambia OovernmentIMRC
.Joint Ethics Committee meeting on April 27'h 2007.
Your proposal was approved based on the following submitted documents:
Protocol Number 06-0004 Version I, 12 March 2007
• Protocol Number 06-0053 Version 1, 19 March 2007
• Appendix Number 06·0004 Version I. 12 March 2007
Appendix Number 06-0053 Version I, 19 March 2007
We also note that Dr Michael Walther is the Safety Monitor for this project. Concern was
raised about performing endoscopy ill ill malnourished children but it was clarified that this is
mostly clinically indicated as an investigation for those with slow recovery after initiation of
nutritional rehabilitation.
We would like to review for annual renewal of approval in twelve calendar months.
Best wishes
Yours Sincerely
"1' 'l , I, •••."'-
Mr. Malcolm Clarke
Chairman, Gambia GovemmentIMRC Joint Ethics Committee
The Gambl" GoVf!mment I MRC L«boratorfea Joint Btbica Com.mittee:
M'Mu/coim Clar"'. Cbosrman
Mrs Kathy HIli, Secretary
M,. NOfWOhAI~ 1'" St.c;retary
Pmftuor (haman Nyu". Scientific Adviso«
Mr rxr..da Jagne
Mr., 8",,,,, MbQg~
Mr. ModlJJJ Pholl
Pr(l/'.uor ruman/ CrJn'tJh
Pro/eos"" lfilt(Jlt Whltt/,
Dr Sr"III.n Howi«
Dr MarlmlJU Jatlo»
Dr. /.altl/n Sidfb.h
Mr. Ma/amln $onko
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Chapter 12 Appendix B - Information sheets and consent forms
Bi -Adult information sheet
DMID Protocol 06-0053 (Part 1) Appendix A: Information Sheets
Version 1.0 19 March 2007
Medical Research Council Laboratories
Genotypes of Helicobacter pylori in West African children and
adults
Research study information sheet for adults
Your illness is suggestive of a disease that is caused by infection with a
bacterial germ called Helicobacter pylori. This infection results in
damage to the lining of your gut and this leads to the pain that you
are experiencing. Your doctor will like to examine the lining of your gut
to investigate the cause of your illness by passing a scope into your
gut in order to decide which is the appropriate treatment for your
illness. This test is called an endoscopy. In addition to your doctor's
examination, we would like to study this problem in a research study
to help us to develop better ways of caring for people who are infected
and are sick. This research project will be studying a germ called
Helicobacter pylori. The results of our findings will be available for the
use of your doctor at the MRCward.
Infection with this germ can be treated. If you are found to have this
infection and signs of disease, you will be given antibiotic treatment
that normally kills the germ.
When you have your endoscopy test, the doctor will take some tiny
pieces of tissue (about 10 to 14 mg), called biopsies, from your
stomach to see if this germ is present. If the germ is detected, the
doctor will arrange for you to have appropriate treatment. We will also
squirt a small amount of liquid (2-5 mL or a teaspoonful) down the
endoscope, with a syringe and suck this back with a syringe to look for
the germ. This process will not cause you any extra health risk.
We hope that up to 75 adults and 20 children who have endoscopy
tests here at the MRCward will join this study this year. All
information collected as part of this study will remain confidential and
can only be seen by scientists and doctors working on the study, the
ethical review board and by representatives of the study sponsor.
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If we detect the germ in your stomach, then we will store samples for
future studies in The Gambia and overseas.
You should-not participate in this study if you have a history of serious
organ disease or have a history of bleeding problems.
You are free to decide whether or not you will participate in this study
or not. If you decide not to participate in this study, this will not affect
the standard of clinical care that you would normally receive. Your
attending physician will continue to treat you even if you decide not to
participate in this study. There will be no compensation for you for
participating in the study and it will be done at no extra costs to you.
If the results of the study are written up for publication your identity
will remain confidential.
This study is sponsored by USA National Institute of Allergy and
Infectious Diseases (NIAID).
The Joint Gambia Government and MRC Ethics Review Board can
review the subject records whenever required.
You may ask any questions that you have. Further information can be
sought from Dr. Corrah (who is also a member of the Ethics Review
Board, and can answer any questions you might have about your
rights and the way in which this study is being conducted) and Sr.
Vivat Thomas. We hope that you will agree to participate in this study
and thank you very much for your cooperation.
I further agree that specimens obtained from me for research
purposes may be kept for further study of bacterial infections at some
future date.
Do you have any questions?
Contact for further information:
Dr. Tumani Corrah
MRC Laboratories, Fajara
Banjul, The Gambia
Phone (+220) 4495442
Email: tcorrah@mrc.gm
Dr. Richard A. Adegbola
MRC Laboratories, Fajara
Banjul, The Gambia
Phone (+220) 4494491
Email: radegbola@mrc.gm
Sr. Vivat Thomas
MRCWards, Fajara
POBox 273, The Gambia, Phone (+220) 4497114
226
Bii - Adult consent form
Medical Research Council Laboratories
Genotypes of Helicobacter pylori in West African children and
adults
Consent Form for Adults
The information sheet has been explained to me and I understand it or
I have read and understood the information sheet.
I understand what participation in this study means to me.
I understand the information regarding me in the course of this study
will remain confidential.
I understand that laboratory tests will be done tissues and fluid that I
will provide and that, parts of these will be stored for further tests at
Fajara and abroad.
I understand that I am free to take part in this study or refuse and
that I can withdraw from the study at any time. If I decide to withdraw
from the study I understand that this will not in any way affect the
standard of clinical care I would normally receive.
I have asked all the questions that I wanted to ask and they have
been answered to my satisfaction.
I further agree that specimens may be kept for further study at some
future date
I agree to take part in the study.
Signature or thumbprint of participant: -----------------------------------
This form has been read by/I have read and explain the form to (write
name of participant) in a language that s/he understands. I believe
that s/he has understood what I explained and that s/he has freely
agreed to participate in the study.
Signature of field worker: --------------------------------------------------
Name and code of field worker---------------------------------------------
Date: 1_1_1/1_1_111_1_1_1_1
I have witnessed that this form has been read and explained to (write
name of participant) in a language that s/he understands. I believe
that s/he has understood what has been explained and that s/he has
freely agreed to participate in the study.
Signatu re of witness: -------------------------------------------------------
Name of witness------------------------------------------------------------
Date: 1_1_111_1_1/1_1_1_1_1
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Biii - Children information sheet
DMID Protocol 06-0053 (Part 1) Appendix A: Information SheetsVersion 1.0
19 March 2007
Medical Research Council Laboratories
Genotypes of Helicobacter pylori in West African children and
adults
Study participant information sheet
Your child has severe malnutrition and is not growing well as other
children. An important cause of this problem is bacterial infections that
cause damage to the gut. This causes the child to be sick and not
absorb food well. We would like to study this problem to help us
develop special treatments that may be necessary to heal the gut and
help the child to grow better.
To know this we will need to examine your child's gut for infections. To
do this we will look at the gut with a special camera and also take fluid
and very small pieces of tissue from the gut lining. Your child will be
asleep throughout this examination. This has been done many times
before to other children with severe malnutrition and there have been
no problems with the procedure.
If your child gets sick at any time, your child can receive medical
treatment at the MRC Fajara Ward and the Royal Victoria Teaching
Hospital.
You are free to decide whether or not your child will participate in this
study. You may ask any questions that you have. Further information
can be sought from Dr. Corrah and Sr. Vivat Thomas. We hope that
you will agree that your child will participate in this study and thank
you very much for your cooperation.
Do you have any questions?
Contact for further information:
Dr. Tumani Corrah Dr. Richard A. Adegbola
MRC Laboratories, Fajara MRC Laboratories, Fajara
Banjul, The Gambia Banjul, The Gambia
Phone (+220) 4495442 Phone (+220) 4494491
Email: tcorrah@mrc.gm Email: radegbola@mrc.gm
Sr. Vivat Thomas
MRCWards, Fajara
POBox 273, The Gambia Phone (+220) 4497114
228
Biv - Children consent form
Medical Research Council Laboratories
Genotypes of Helicobacter pylori in West African children and
adults
Consent Form for Parents
The information sheet has been explained to me and I understand it or
I have read and understood the information sheet.
I understand what participation in this study means to me and my
child.
I understand the information regarding me in the course of this study
will remain confidential.
I understand that laboratory tests will be done on tissues and fluid that
my child will provide and that, parts of these will be stored for further
tests at Fajara and abroad.
I understand that we are free to take part in this study or refuse and
that I can withdraw from the study at any time. If I decide to withdraw
from the study I understand that this will not in any way affect the
standard of clinical care that my child would normally receive.
I have asked all the questions that I wanted to ask and they have
been answered to my satisfaction.
I further agree that specimens may be kept for further study at some
future date
I agree my child taking part in the study. Name of Child: ---------
Signature or thumbprint of parent: ---------------------------------------
This form has been read by/I have read and explain the form to (write
name of parent) in a language that s/he understands. I believe that
s/he has understood what I explained and that s/he has freely agreed
for his/her child to participate in the study.
Signature of field worker: --------------------------------------------------
Name and code of field worker---------------------------------------------
Date: 1_1_1/1_1_1/1_1_1_1_1
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I have witnessed that this form has been read and explained to (write
name of parent) in a language that s/he understands. I believe that
s/he has understood what has been explained and that s/he has freely
agreed for his/her child to participate in the study.
Signature of witness: -------------------------------------------------------
Name of witness------------------------------------------------------------
Date: 1_1_1/1_1_1/1_1_1_1_1
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\Completion Certificate
·1hi, i, to certify that
Julian Thomas
has completed the Human Participnnts Protection Education for Research Teams
online course. sponsored by the National Institutes of Health (NIH). on 0712912004.
This course included the following:
key historical events and current issues that impact guidelines and legislation
on human participant protection in research.
ethical principles and guidelines that should assist in resolving the ethical
issues inherent in the conduct of research with human participants.
the usc of key ethical principles and federal regulations to protect human
participants at various stages in the research process.
a description of guidelines for the protection of special populations in
research.
a definition of informed consent lind c.OI11Pnents necessary for a valid
consent.
a description of the role of the IRB in the research process.
the roles, responsibilities. and interactions of red era I agencies. institutions, and
researchers in conducting research with human participants.
National Institutes of Health
b11p:illl WI, .nih.l2o\'
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\Completion Certificate
----,_,-- -------,
This i> to certify that
Juli:1II Thomas
ha_ completed the Human Partlclpants Protection Eductnion for Research TI!~HI1S
online course, sponsored by the National Institutes of Health (NTH), on 07/2912004,
This cours in luded the following:
key historical vents lind current issues that impact guidelines and legislat.ion
on human pantclpamprotectlon in research.
• ethical principles and guidelines that hould assist in resolving tbcethical
issues inherent in the conduct of research with human participants.
• the use of key ethical principl and federal regulations to protect human
participants at various stages ill the research process,
n description of guidelines for the protection of'speetal POPUI,ltiOl1f> in
research.
• a definition of informed consent lind components ne .essary for a ,'slid
con cm.
• a descript ion of the role of the IRS in the research process,
the roles, responsiblliries, andinteractions of federa! agencies, institutions. and
researcher in conducting research with human participants.
National Institutes or Health
ht' !\\,w\\.nill._gru;
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OIlSR Page 1 of 1
Certificate of Completion
The NIH Office of Clinical Research Training and Medical Education certifies
that Ousman Secka completed the computer-based Clinical Research
Training course.
Completion Date: 10/15/2007
http://\v\,w.nihtraining.com/CI1pub _508/certify.hunJ?kiUycache=854352&userlD=seck74... J 5/1 012007
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TRAINING ON THE PROTECTION OF HUMAN SUBJECTS IN CLINICAL
RESEARCH: DMID/PPD- Essential Documents Collection and Submission
Process CD package
Protocol Number: 06-0053
Protocol title: Genotypes of Helicobacter pylori in West African children and adults:
PanI: The development and evaluation of a minimally invasive technique for obtaining
H pylori isolates from adults and children in The Gambia
Topics:
~History and Ethics of Clinical Research
• Investigator Responsibilities
• Informed Consent
• Ethics committees
This is to confirm that I have received training on the above topics.
No Name
1 Or. Ma
2
3 Ousman Secka
4 Recard Richards
5 Buba Camara Nurse
6 Estina Luc Thomas Nurse
7 Kutub Hydara Laboratory Technician
Signature PJ. ..~~[~ Date: .. .!7!~tJ.'lo.P~.
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Chapter 14 Appendix D - Media preparations
Di - Preparations of antibiotic stock solutions
1. Trimethoprim*
(Sllg/ml = SOOOllg/1000ml = Smg/L)
To make 20ml stock solution
i. SX20 000 = 100 0001lg/20ml = 100mg/20mls
ii. Therefore lml = 100 000 X 1 = SOOOllg/ml= Srnq/rnl of stock
20
iii. lml of stock to 1000ml = Sllg/ml
2. Vancomycin
(6Ilg/ml = 6000llg/1000ml = 6mg/L)
To make 20ml stock solution
i. 6X20 000 = 120 0001lg/20ml = 120mg/20mls
ii. Therefore lml = 120 000 X 1 = 6000llg/ml = 6mg/ml of stock
20
iii. lml of stock to 1000ml = 6llg/ml
3. Polymixin B
(lOllg/ml = 100001lg/1000ml = 10mg/L)
To make 20ml stock solution
i. 10X20 000 = 200 0001lg/20ml = 200mg/20mls
ii. Therefore lml = 200 000 X 1 = 10 OOOllg/ml = 10mg/ml of stock
20
iii. lml of stock to 1000ml = lOllg/ml
238
To make' 20ml stock solution
4. Bacitracin
(200llg/ml = 200 0001lg/1000ml = 200mg/L)
i. 200X20 000 = 4000 0001lg/20ml = 4000mg/20mls = 4g/20ml
ii. Therefore lml = 4000000 X 1 =200 OOOllg/ml= 200mg/ml of
stock
20
iii. lml of stock to 1000ml = 200llg/ml
5. Nalidixic acid
(lOllg/ml = 100001l9/1000ml = 10mg/L)
To make 20ml stock solution
i. 10X20 000 = 200 0001lg/20ml = 200mg/20mls
ii. Therefore lml = 200 000 X 1 = 10 OOOllg/ml= 10mg/ml of stock
20
iii. lml of stock to 1000ml = lOllg/ml
6. Amphotericin B
(8Ilg/ml = 80001l9/1000ml = 8mg/L)
To make 20ml stock solution
i. 8X20 000 = 160 0001lg/20ml = 160mg/20mls
ii. Therefore lml = 160 000 X 1 = 80001lg/ml = 8mg/ml of stock
20
iii. lml of stock to 1000ml = 8llg/ml
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7. Amoxicillin, Clarithromycin, Erythromycin and
Tetracycline
(2Ilg/ml.= 20001l9/1000ml = 2mg/L
To make 20m I stock solution
iv. 2X20 000 = 40 0001lg/20ml = 40mg/20mls
v. Therefore 1ml = 40 000 X 1 = 2000llg/ml = 2mg/ml of stock
20
vi. 1ml of stock to 1000ml = 2llg/ml
8. Metronidazole
(8Ilg/ml = 80001lg/1000ml = 8mg/L)
To make 20ml stock solution
vii. 8X20 000 = 160 0001lg/20ml = 160mg/20mls
viii. Therefore 1ml = 160 000 X 1 = 8000llg/ml = 8mg/ml of
stock
20
ix. 1ml of stock to 1000ml = 8llg/ml
*NB: Trimethroprim is first dissolved in Ethanol
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Dii - Ordinary H. pylori media for subculturing & antibiotic
susceptibility
1. Weigh '39g of Columbia agar (Unipath; Cat no CM331B) powder
2. Suspend in 900mls of distilled water and mix gently to dissolve.
3. Sterilize by autoclaving at 121°C for lSmins
4. Cool to 55°C in cooling water bath
S. Add 20mls of 2% vitox (Unipath; Cat no SR090A) and mix
6. Add 100ml Laked Horse blood (Unipath; cat No SR0048C) and
mix.
7. Pour 20mls of media in single compartment petridish and allow
to set.
8. Flame, label and store in plastic bag at +4°C until use.
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Diii - Selective Columbia blood agar media
1. Weigh 39g of Columbia agar (Unipath; Cat no CM331B) powder
2. Suspend in 900mls of distilled water and mix gently to dissolve.
3. Sterilize by autoclaving at 121°C for 15mins
4. Cool to 55°C in cooling water bath
5. Add 20mls of 2% vitox (Unipath; Cat no SR090A) and mix
6. Add 1ml of the following antibiotics: Trimethoprim (5/-lg/ml),
Vancomycin (6/-lg/ml), Polymixin B (10/-lg/ml), Bacitracin
(200/-lg/ml), Nalidixic acid (10/-lg/ml), Amphotericin B (8/-lg/ml).
7. Add 100ml Laked Horse blood (Unipath; cat No SR0048C) and
mix.
8. Pour 20mls of media in single compartment petri-dish and allow
to set.
9. Flame, label and store in plastic bag at +8°C until use.
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Div- Semi-Selective Columbia blood agar media
1. Weigh 39g of Columbia agar (Unipath; Cat no CM331B) powder
2. Suspend in 900mls of distilled water and mix gently to dissolve.
3. Sterilize by autoclaving at 121°C for 15mins
4. Cool to 55°C in cooling water bath
5. Add 20mls of 2% vitox (Unipath; Cat no SR090A) and mix
6. Add Iml of the following antibiotics: Trimethoprim (5J.lg/ml),
Vancomycin (6J.lg/ml), Amphotericin B (8J.lg/ml).
7. Add 100ml Laked Horse blood (Unipath; cat No SR0048C) and
mix.
8. Pour 20mls of media in single compartment petri-dish and allow
to set.
9. Flame, label and store in plastic bag at +8°C until use.
NB. This media with trimethroprim, vancomycin and amphotericin that
do not act against H. pylori as described by Akada [253] suppresses
possible contaminating bacteria and moulds.
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Dv - Glycerol broth (200/0)
Procedure
1. Prepare Brain Heart Infusion broth as described.
2. Weigh 47 g of Brain Heart Infusion broth (Unipath; Cat No.
CM022SB)
3. Add 1000ml of Distilled water
To prepare 100ml of glycerol broth
1. Brain Heart Infusion Broth...................... 80ml
2. Glycerol (Sigma; Cat No. G8773)............. 20ml
3. Mix well and distribute in Smls amounts in screw-cap tubes or
bottles
4. Sterilise by autoclaving at 115°C for 20 minutes
5. This medium should be within the range pH 7.2 - 7.6 at room
temperature.
6. Put in the fridge for longer storage.
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Dvi - Urea (O.03M solution)
1. Weigh 0.18g of urea (Sigma; cat. No. U6504)
2. Dissolve in lOOmis of distilled water
3. Add a small amount of phenol red
4. Sterilize by filtration
5. Aliquot in eppendorf tubes
Store at +4 to +8°C. Solution is stable for 4 weeks.
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